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Abstract
High density lipoprotein (HDL) plays an important role in the prevention of 
cardiovascular disease. Apolipoprotein A-I (apoA-ï), the major apolipoprotein of 
HDL is mainly secreted by the liver. Once secreted, apoA-I acquires lipid to form 
nascent discoidal prepHDL which by further acquisition of lipid are converted into 
spherical aH DL particles (HDLz and HDL3). Cunent understanding of HDL 
metabolism is limited due to technical difficulties in measuring the kinetics of HDL 
subclasses. Traditionally, HDL is separated by ultracentrifiigation (1.063<d<1.21 
g/ml), however, this process may damage the integrity of certain HDL particles 
leading to the dissociation of apoA-I. The aim of this study was to develop methods 
to separate and deteiinine the kinetics of aH DL and prepHDL using stable isotopic 
techniques. Separation of HDL% and HDL3 by sequential ultracentrifugation aimed to 
investigate the kinetic difference between HDL2 and HDL3 .
A two dimensional electiophoresis technique was developed and optimised to 
separate apoA-I from aH D L and prepHDL. Using this methodology apoA-I kinetics 
were measured in healthy subjects. Subjects (3F+1M) were given a primed constant 
infusion of 1-^^C-leucine to label apoA-I. Plasma was separated by agarose gel 
electrophoresis in the first dimension. aHDL and prepHDL bands were removed and 
apolipoproteins were exti'acted and separated by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis in second dimension. The isotopic enrichment of 
apoA-I in HDL subclasses was measured by gas chromatography mass specti'ometiy.
The results indicate this protocol can be used to separate and measure the kinetics of 
aH D L and prepHDL. The fractional secretion rate (FSR) of apoA-I from aHD L and 
prepHDL was 0.15±0.017 pools/day and 0.19±0.022 pools/day respectively 
( f  =0.039). HDL2 and HDL3 FSR was 0.16±0.018 pools/day and 0.14±0.017 
pools/day respectively ( f =0.003) and their production rates were 4.07±0.61 and 
2.82±0.37 mg/kg/day respectively.
This novel technique allows the measurement of prepHDL and aHDL apoA-I 
kinetics.
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Chapter 1 Introduction
1.1 Lipoproteins
1.1.1 structure and composition of plasma lipoproteins
Plasma lipoproteins are approximately spherical particles, which are soluble 
aggregates of lipids and proteins that deliver hydrophobic, water-insoluble lipids 
such as triglyceride (TG) and cholesteiyl ester (CE) from the liver and intestine to 
other peripheral tissues. The proteins are referred to as apolipoproteins. ‘A typical 
lipoprotein particle consists of a core of TG and CE with an outer sur face monolayer 
of phospholipid and free cholesterol’ (Frayn 2003). The lipid core is particularly 
hydrophobic while the outer siuface is relatively hydrophilic and contains specific 
apolipoproteins (Frayn 2003) (Figure 1). Apolipoproteins are amphipathic proteins, 
ie they have both hydrophobic and hydrophilic domains. The hydrophobic domains 
of the protein are anchored to the lipoprotein particles by dipping into its core, while 
the hydrophilic domains, are exposed on the outer surface of the particles in the 
aqueous environment (Frayn 2003). The apolipoproteins identified in lipoproteins 
include apolipoprotein A (apoA-I, apoA-II, apoA-IV, apoA-V), apolipoprotein B 
(apoB-48 and apoB-100), apolipoprotein C (apoC-I, apoC-II, apoC-III, apoC-IV), 
apolipoprotein D, apolipoprotein E, apolipoprotein H, apolipoprotein L (apoL-I, 
apoL-II, apoL-III, apoL-IV, apoL-VI), apolipoprotein M, apolipoprotein F and 
apolipoprotein J. The general functions of specific apolipoproteins include the 
mediation of the recognition between specific lipoproteins and cell surface 
lipoprotein receptors, which are involved in redistiibution lipids between specific 
cells and tissues and to act as cofactors for enzymes o f lipid metabolism. For 
example, apoA-I is the main activator of lecithin:cholesterol acyltransferase (LCAT).
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Other apolipoproteins including A-II, C-I, C-II, C-III and A-IV also possess some 
degree of cofactor activity (Mahley et al. 1984). Another specific function for 
apolipoproteins involves their role in the maintenance of lipoprotein structure. 
Various apolipoproteins. e.g. apoB. A-I and E, appear to stabilize the cellular 
structure of lipoproteins in cooperation with the phospholipid monolayer on the 
surface of the particle (Mahley et al. 1984).
Free cholesterol _
Triglyceride
Phospholipid
Hydrophilic surface
Hydrophobic core
Apolipoprotein Cholesteryl ester
Figure 1 Typical structure o f lipoproteins
A typical lipoprotein consists o f a highly hydrophobic core and a relatively hydrophilic surface 
(modified from (Kostner 2 0 0 2 )).
Lipoproteins are heterogeneous particles, which vary in size, density, structure, lipid 
and protein compositions. They have traditionally been isolated and classified into 
groups based on either their electrophoretic mobility or flotation in an ultracentrifuge. 
The latter is a more popular classification system (Frayn 2003). Lipoproteins are 
usually divided into five major classes based on density. These classes of 
lipoproteins include chylomicrons (CMs), very low density lipoproteins (VLDL), 
intermediate density lipoproteins (IDL), low density lipoproteins (LDL) and high 
density lipoproteins (HDL). HDL can be further subdivided into HDLi, HDL] and
14
HDL]. Based on apolipoprotein composition, lipoproteins can also be divided into 
two series. One is apoA containing lipoproteins including HDL and the other is apoB 
(apoB-100 and apoB-48) containing lipoproteins which include LDL, IDL, VLDL 
and CMs (Figure 2). Based on lipid composition, lipoproteins can also be classified 
into TG rich and CE rich lipoproteins.
0.95
3  1 .006
5 10 20 40 60  80 1000
D ia m e t« ' (nm )
Figure 2 Two sets o f lipoproteins
Lipoproteins can be divided into two groups. One is apoA containing lipoprotein and the other is 
apoB containing lipoprotein (Garza 2009).
1.1.2 General metabolic pathways of lipoproteins and their physiological 
function
CMs are the largest TG-rich lipoprotein particles with the lowest density, since they 
have the highest percentage of TG (Table 1). They are secreted by the intestinal cells 
and their main function is to transport dietary TGs and cholesterol from the intestine 
to other cells in the peripheral tissues (Mahley et al. 1984). This metabolic pathway 
is often described as the exogenous pathway because it transports the fat derived 
from outside of the body (Figure 3).
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L ip op rotein
class
D en sity
(g/m l)
D iam eter
(nm )
P rotein
(% w /w )
PL
(% w /w )
C E
(% w /w )
U C
(% w /w )
TG
(% w /w )
HDL 1.063 1.21 5 12 32 70 20 30 0 23 3 8 1 2
LDL 1.019 1.063 18 25 25 20 25 42 9 5 15
IDL 1.006 1.019 25 35 18 15 25 23 7 20 50
V LD L 0.95 1.006 30 80 10 10 20 14 6 55 80
C hylom icrons < 0 .9 5 75 1200 1 2 3 9 <I <1 80 95
Table 1 Physical and chemical characteristics o f the major lipoprotein classes
PL: phospholipids, CE: cholesterol ester, UC: unesterified cholesterol, TG: triglyceride (Vance 1996; 
Betteridge 1999)
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ApoE \ J
action
.Muscle y  LPL
^ ^ c t io n  ^  Adipose 
y.FAk %» Tissue
' O
Remnants uptake by the liver
/
Chylomicron
remnants
Figure 3 The exogenous pathway of lipoprotein metabolism— chylomicron metabolism.
HDL: high density lipoprotein; ApoC-II, apolipoprotein C-II; ApoA-I: apolipoprotein A-I; ApoA-IV: 
apolipoprotein A-IV; FA, fatty acids; LPL, lipoprotein lipase (Frayn 2003).
After TG and cholesterol are absorbed and re-esterified in the cells of the intestinal 
wall, CMs are secreted and enter the circulation via the lymphatics. The newly 
synthesized CM particles have a core of CE and TG, with a surface of unesterified
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cholesterol and phospholipid, in conjunction with apoB-48 and minor amounts of 
apoA-I and apoA-IV located on the particles (Frayn 2003). Each CM particle 
contains one molecule of apoB-48 (Frayn 2003).
In contrast, VLDL and LDL particles transfer triglycerides and cholesterol derive 
from the liver for redistribution to other tissues. This metabolic pathway is referred 
to as the endogenous pathway (Figure 4).
Liver 
®^VLDL receptor
^  Mediate the re-uptake of some VLDL particles \ N V
ApoC-II '  VLDL particles
^  ApoA-I 
H D L ^ Q  ApoA-IV 
ApoE
O  O  y -----------s \
1LPL actiod/ AdiposeTissue
LDL particles
LDL receptor
Other Tissues
0
/y
Figure 4 The endogenous pathway o f lipoprotein metabolism— VLDL metabolism
Particles may undergo several cycles o f  hydrolysis by lipoprotein lipase (LPL) in capillary beds 
(dashed lines), forming smaller particles which may be taken up directly by receptors in the liver; 
others remain in the circulation as low-density-lipoprotein (LDL) particles. These are eventually 
removed by uptake into tissues via the LDL receptor (Frayn 2003).
VLDL particles are synthesized in hepatic cells with newly secreted VLDL particles 
containing TG, cholesterol ester and 1 molecule of apoB-100. They also have a small 
amount of apoE and apoC. Chylomicrons and VLDL particles are relatively rich in 
TG and are often referred to as TG-rich lipoproteins (TRL), they are mainly 
concerned with the delivery of TG to tissues. In contrast, the smaller LDL and HDL
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particles are involved with the tr ansport of cholesterol to and from cells respectively 
(Frayn 2003).
In summary, the main physiological functions of endogenous lipoproteins include 
the following; The transport of triglyceride fatty acids derived from the liver via 
VLDL to peripheral tissues for energy storage (the hydrophobic character of TG 
makes it an efficient and dense fonn to store energy and it is the main fonn of fat 
stored in the body). The transport of cholesterol from the liver to peripheral tissues 
for synthesis of steroid honnones and cellular membranes mediated through LDL 
and finally the transfer of cholesterol from peripheral tissues to the liver for 
elimination from the body mediated by HDL.
1,2 HDL structure, function, metabolism and importance of 
therapeutic targeting
1.2.1 The structure, composition and metabolism of HDL
1.2.1.1 Heterogeneity o f  human HDL
HDL are the smallest and densest of the plasma lipoproteins (Table 1, page 16). As 
with other plasma lipoproteins, the mature form of HDL particles is spherical when 
viewed by electron microscopy with a highly hydrophobic core consisting of 
cholesterol ester and a small amount o f triglyceride. The outer surface is a molecular 
monolayer comprising unesterified cholesterol, phospholipids and bound 
apolipoproteins. Figure 5 shows the structure of a mature HDL particle. However, a 
minor population of HDL exists as discoidal particles and consists only of surface 
constituents which fonn a molecular bi-layer of unesterified cholesterol and
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phospholipids surrounded by apolipoproteins (Barter & Rye 2005). Discoidal HDL 
particles are nascent forms of HDL and their concentration is generally low in 
plasma. They exist transiently in this form and are rapidly converted into the 
spherical form by LCAT. The main apolipoproteins of human HDL are apoA-I and 
apoA-II, which comprise 70% and 20% of total HDL proteins respectively. There 
are also several minor apolipoproteins associated with HDL, including apoA-IV, 
apoCs, apoD, apoE, apoJ and apoM (Barter 2002; Rye et al. 2006; Xu & Dahlback 
1999).
HIGH-DENSITY LIPOPROTEIN
-Choiesterol EsterPhoepho&wd
Tt^yceride
M o A .I
DIAMETDt: 78-lOOA
Figure 5 HDL structure
A mature HDL is a spherical particle consisting o f a hydrophobic core with cholesterol ester and 
triglyceride and a monolayer outer surface with unesterified cholesterol and phospholipid. 
Apolipoproteins such as apo A-1, apo A-I I and other minor apolipoproteins dip into the hydrophobic 
core with their hydrophobic domains (Grundy 1990).
HDL are heterogeneous and vary in shape, size, density, composition and surface 
charge (Barter 2002). Figure 6  shows the heterogeneity of human HDL. HDL in 
human plasma have been classified into two major chemically and functionally 
distinct subpopulations of particles on the basis of their two main characteristic 
apolipoproteins composition: apoA-1 and apoA-II (Figure 6 ). One subpopulation 
comprises HDL that consists of only apoA-I without apoA-II (A-I HDL), while 
another comprises particles that contain both apoA-I and apoA-II (A-I/A-II HDL)
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(Cheung & Albers 1984). ApoA-I is divided approximately equally between A-I 
HDL and A-I/A-II HDL in most human subjects, while most of the apoA-Il is in A- 
I/A-II HDL (Cheung & Albers 1984; Bekaert et al. 1992). Bekaert et al (1992) 
isolated a third minor HDL subpopulation (A-II HDL) from human plasma, with the 
use of sequential immunoaffmity chromatography. The subpopulation lacks apo A-I 
but contains apoA-II as its main or sole apolipoprotein. In addition, in human 
plasma, up to 10% of the HDL contain neither apo A-I nor apo A-II but have apoE as 
their main apolipoprotein constituent (Krimbou et al. 2003).
Particles sh a p e
Discoidal 
(prep-mig rating)
Apolipoprotein com position
Spherical
(a-migrating A-I HDL A-I/A-II HDL A-II HDL
Particle size a n d  density
HDL2b HDL2a HDL 3a HDL
10.6nm 9.2nm
1 .0 6 3 < d < 1 .1 2 5 g /m i
Lipid-poor 
3b HDL^c prep-HDL
8.4nm 8.0nm 7.6nm 5 . 6 / 3 . 5nm
1 . 1 2 5 < d < 1 .2 1 g /m i  d > 1 .2 1  g/mi
Figure 6 Heterogeneity o f human HDL
Based on the particle shape and migrating profile, HDL can be divided into spherical «-migrating 
HDL and discoidal preP-migrating HDL. Based on the apolipoprotein compositions, HDL can be 
divided into apoA-I containing HDL, apoA-I/A-II containing HDL and apoA-II containing HDL. 
Based on the density and particle size, HDL can be divided into HDLz (HDL 2 b and HDL 2 ,), HDL 3 
(HDL],, HDL]b and HDL^c) and lipid-poor prePHDL. Light blue ellipsoids in A-I HDL and A-I/A-II 
HDL indicate apoA-I, pink ellipsoids in A-I/A-II HDL and A-II HDL indicate apoA-II (modified 
from Barter 2002).
Human HDL can also be separated into two major subfractions (HDL] and HDL3) 
and a minor subfraction HDLi on the basis of sequential density ultracentrifugation. 
The major subfractions are referred to as HDL2 (1.063<d<1.125 g/ml) and HDLs
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(1.125<d<1.21 g/ml) respectively. These two stibffactions can be further divided into 
five distinct subpopulations on the basis of particle size by non-denaturing gradient 
polyacrylamide gel electrophoresis (PAGE) (Blanche et a l  1981), Two distinct 
subffactions HDL2b(mean diameter 10.6 nm) and HDL2 a (9.2 nm) are in the density 
range of HDL2. In addition, HDL3 includes three subfractions termed HDLsa (8.4 
nm), HDL]b (8.0 nm) and HDL]c (7.6 nm) respectively (Figure 6). Most of the A- 
I/A-II HDL is found in the HDL3 density range, while A-I HDL is the prominent 
component of both HDL2 and HDL3 (Cheung & Albers 1982).
The heterogeneity of HDL extends to variations in surface charge resulting in 
different electrophoretic mobility. When separated by agarose gel electrophoresis, 
HDL has either prealpha (prea), alpha (a), prebeta (preP) or gamma (y) migration 
(Kunitake et a l 1985; Huang et a l 1994; Asztalos et a l 1993). The a-migrating 
HDL particles comprise the major proportion of HDL in plasma and exist as mature, 
spherical fonns like the other lipoproteins. They include the HDL2 and HDL3 
subfractions as well as A-I HDL and A-I/A-II subpopulations (Barter 2002). Most 
apoA-I circulates as aH DL (Rye & Barter 2004). PrePHDL is a discoidal particle 
consisting of one or two molecules of apoA-I combined with phospholipids and 
possibly a small amount of unesterified cholesterol (Barter 2002). GammaHDL are 
discoidal particles that contain apoB but no apoA-I (Huang et a l  1994). Prea, a  and 
preP-migrating HDL particles can be further divided into 11 distinct apoA-I 
containing HDL subclasses by two dimensional electrophoresis (Asztalos et a l 
2004; Asztalos et a l  1993) (Figure 7). There are three a  apoA-I containing HDL 
subclasses, three prea apo A-I containing HDL subclasses, two prePi apo A-I 
containing HDL subclasses (around 70 kDa) and three prep2 apoA-I containing HDL
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subclasses (around 325 kDa-440 kDa) (Castro & Fielding 1988).
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Figure 7 HDL subclasses separated by 2-dimensional electrophoresis
A shows the apolipoprotein A-I (apoA-I)-containing HDL subpopulations separated by two- 
dimensional non-denaturing agarose PAGE o f a normolipidemic, healthy male subject. The 
rectangular inset represents the first dimensional separation on an agarose gel (separation based on 
charge). A duplicate o f that agarose strip was applied to the top o f a concave gradient polyacrylamide 
gel (3 35%) and electrophoresed in the second dimension (separation based on size). Molecular mass 
standards are shown on the left. B panel shows a scheme o f the apoA-I containing HDL 
subpopulations in human plasma. The lighter shading indicates apoA-I containing subpopulations; the 
darker shading represents apoA-I and apoA-II containing subpopulations (Asztalos et al. 2005).
1.2.1.2 Main apolipoproteins o f  HDL— apoA-I
The concentration of apoA-I in normal healthy subjects ranges from 1.1 mg/ml to 2.1 
mg/ml. Apo A-I, the major protein component of HDL (70%), was one of the first 
apolipoproteins to be identified and characterised. In plasma, the majority o f apoA-I 
exists in the HDL fraction (80 90%), however, there are small levels of apoA-I 
present in the density fraction of d>1.21 g/ml and in the TRL fraction (Eisenberg 
1984). ApoA-I was observed in the TRL fraction containing apoB-48, indicating the 
intestine but not only the liver produces TRL particles with apo A-I (Velez-Carrasco 
et al. 1999). Vélez-Carrasco et al (1999) proposed that apoA-I in the TRL fraction 
was synthesized from the intestine only and that apoA-I found in the HDL fraction 
was synthesized by the liver.
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Both human subjects and mice with apoA-I deficiency fail to forni normal HDL 
particles (Fielding & Fielding 1995; Meagher 2004). ApoA-I deficiency increases 
the sensitivity to atherosclerosis in LDL receptor deficient mice. As the major 
protein component of high-density lipoproteins, apoA-I plays a key role in the 
biogenesis and atheroprotective functions of HDL (Meagher 2004).
The amino acid sequence and length of apoA-I from different species is variable, 
however, its N-teiininal domain is highly conserved (Frank & Marcel 2000). Human 
mature apo A-I is a 243 amino acid polypeptide with a molecular weight of 28.1 kDa. 
It is synthesized as a 267 amino acid pre-proprotein mainly in hepatic and intestinal 
cells (Chau et al. 2006). This pre^protein contains an 18 amino acid leader sequence, 
which is cleaved during transit through the Golgi secretion pathway, resulting in the 
secretion o f a 249 amino acid proprotein (Chau et a l  2006), An extra cleavage of the 
N-tenninal hexapeptide by an extracellular metalloproteinase results in the formation 
of mature apoA-I(Ajees et a l 2006) . Mature apo A-I contains a series of 22- and 11 
amino acid repeat sequences in the primary structure (Frank & Marcel 2000; Ajees et 
a l 2006). X-ray crystallography and computer modelling, suggests they are 
organized into amphipathic a-helices with hydrophobic and hydrophilic faces in the 
secondary structure (Figure 8 ) (Ajees et a l 2006). The amphipathic character of a  
helices allows apoA-I to bind str*ongly with various lipid classes such as 
phospholipids and cholesterol through its hydrophobic face and interact with the 
aqueous phase through the hydrophilic face. Thus, a  helices offer a conformational 
m otif for HDL formation, increase the stability of the particles and enable apoA-I to 
interact with the cell membrane and collect cholesterol (Frank & Marcel 2000). The 
apoA-I self-associates easily in aqueous media without the existence of lipid and this 
may stabilise the lipid-free form of apoA-I (Vitello & Scanu 1976). When its
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concentration is lower than 0 . 1  mg/ml or guanidine hydrochloride is present in the 
solution, apoA-I is detected in the monomeric form (Frank & Marcel 2000).
C-tcr C-tcr
N-lcr N-lcr
Figure 8 Overall stereoview of the structure o f the lipid-free form of apoA-I
The six helices in the structure are rendered as C“ worms, coloured blue (A), pink (B), yellow (C), 
lavender (D), cyan (E) and red (F) and labelled. Loops are coloured gold. Hydrophobic residues are 
shown as green sticks (Ajees et al. 2006).
The structure of apoA-I in aH DL particles has not yet been established but is 
proposed to have a belt-like conformation (Zannis et al. 2006). In discoidal HDL the 
structure of apoA-I has been described using different models (Segrest 1977; Segrest 
et al. 2000; Segrest et al. 1999; Panagotopulos et al. 2001; Koppaka 2001). In the 
belt model, two apoA-1 molecules are wrapped in an antiparallel orientation around 
the edge of a discoidal lipid bilayer containing 160 lipid molecules (Figure 9).
Figure 9 Belt model o f discoidal HDL
‘The blue helical belt represents the 22- and 11- residue repeating amphipathic a-helical units o f 
apoA-I oriented parallel to the phospholipids bilayer surface’ (Zannis et al. 2006).
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ApoA-I cycles between lipid-poor and lipid-rich fonns in a series o f reactions. In 
vitro, the cycling of apoA-I involves several identifiable steps: 1) Monomolecular, 
pre(3-migrating, lipid-poor apoA-I is generated when it is lost from a-migrating, 
spherical HDL during their remodelling to smaller particles. 2) This lipid-poor 
apoA-I acquires phospholipids and cholesterol from the cell membrane to form prep- 
migrating, discoidal HDL particles. 3) Discoidal A-I HDL converts into small a  
migrating, spherical HDL3 via the action of LCAT. 4) Small a-migrating, spherical 
HDL] particles continue to increase size to form large a-migrating, spherical HDL2 
particles and 5) The large a-migrating, spherical HDL2 particles are remodelled by 
plasma factors and preP-migrating, lipid-poor apoA-I is disassociated from the 
particles (Rye et al. 2006; Barter 2002).
1,2,1,3 Main apolipoproteins o f  HDL— apoA-II
In humans, apoA-II is the second major apolipoprotein of HDL, accounting for about 
20% of HDL protein. In normolipidemic humans, the average apoA-II plasma 
concentration is about 3.0-3.5 mg/ml (Bu et ah 1994), although more than 20% of 
patients with coronary artery disease (CAD) seem to have concentrations between 
4.0 and 6.0 mg/ml (Blanco-Vaca et a l  2001). ApoA-II is mainly associated with 
HDL, however there is still a small fraction associated with chylomicrons and VLDL 
(Blanco-Vaca et a l 2001). ApoA-II is mainly synthesized as a 100 amino acid 
precursor pre-protein by hepatic cells with a co-translational cleavage of an 18- 
residue-long signal peptide resulting in the foimation of proapoA-II (Tailleux et a l  
2002). Matuie apoA-II is generated after a post-translational proteolytic cleavage of 
a 5-residue-long prosegment (Ala-Leu-Val-Arg-Arg) attached to the NH 2 teiminus 
(Tailleux et a l  2002; Blanco-Vaca et a l  2001). In plasma, the majority of human
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apoA-II is present as the homodimer formed by two polypeptide chains of 77 amino 
acids linked by a disulphide bridge at residue 6  (Brewer, Jr. et al. 1972; Bolanos- 
Garcia & Miguel 2003). Figure 10 shows the apoA-II homodimer and its complex 
with p-octyl glucoside (a widely used lipid surrogate).
10OA 100A
A B
Figure 10 ApoA-II crystal structure
‘A: The lipid-free apoA-Il crystal structure shows that it consists o f disulphide-bonded homodimers 
with a  hierarchical organization. A stereopair o f the 12 independent chains is shown as wavelet 
approximations to chain paths with helical residues shown as thick tubes. The four chains o f the first 
tetramer (A-D) are given different colours and the other two tetramers are coloured shades o f blue. 
Yellow bonds designate the disulphide linkages. B: (3-octyl glucoside-bound apoA-Il stereopair o f the 
eight independent dimmers, one o f the two arrays in the asymmetric unit, is shown as wavelet 
approximations to chains. The four chains o f the first tetramer (A, B, I and J) are given different 
colours and the other three tetramers are coloured shades o f blue’ (Bolanos-Garcia & Miguel 2003).
There are other forms of apoA-II existing in plasma, including the apoA-II/apoE,
apoA-II/apoH and apoA-II/apoD heterodimers and an apoA-II monomer (Tailleux et
al. 2002). Each apoA-II protomer exhibits three a-helices with a specific amino acid
distribution (helices 7 30, 39 50 and 51 70), which are punctuated by proline
residues in a similar manner to that observed in apoA-I (44 243) (although less
uniformly) (Bolanos-Garcia & Miguel 2003; Kumar et al. 2002).
1.2.1.4 Minor apolipoproteins o f  HDL complex
Apolipoprotein M: A relatively newly identified apolipoprotein M (apoM) is a 
plasma apolipoprotein predominately present in HDL, with a small amount also
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found in TRL and LDL (Xu & Dahlback 1999). The apoM concentration in plasma 
is much lower compared to other apolipoproteins in HDL. It is from 10 to 19 pg/ml 
(Skupien et al. 2007). ApoM belongs to the lipocalin family with an 8 -stranded anti­
parallel p-barrel structure (Figure 11) (Duan et al. 2001).
H4.3
Figure 11 Ribbon drawing o f apoM 3D structure
Predicted secondary structure elements and loops are labelled as L1-L8. Loops L I, L3, L5 and L7 are 
located near the opening o f the binding pocket. The other loops (L2, L4, L6  and L 8 ) are on the 
opposite end. The glycosylated A snl35 residue is shown. The predicted S-S bonds are displayed in 
yellow. A conserved contact in the lipocalin family that corresponds to apoM residues Arg 149, Trp47, 
His43 and Leu44 is illustrated. A sphere highlights the lipocalin binding cavity (Duan et al. 2001).
ApoM is a 188 amino acid protein with a molecular weight of 26 kDa (Xu & 
Dahlback 1999). It is mainly synthesized by the liver and kidney (Xu & Dahlback 
1999). The results from a study using apoM deficient mice suggest that it plays an 
important role in the formation of pre^HDL (Wolfrum et al. 2005). ApoM is 
associated with HDL anti-atherogenesis by its effect of increasing efflux of 
cholesterol to HDL from foam cells, protection of LDL from oxidization and anti- 
inflammation (Christoffersen et al. 2006; Feingold et al. 2008; Christoffersen et al.
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2008; Duan et a l  2001; Huang et a l  2007).
Apolipoprotein E: In 1973, apolipoprotein E (apoE) was first reported in noimal 
human VLDL by Shore et al (1973). ApoE is an arginine rich glycoprotein with a 
molecular weight of 34.2 IcDa synthesized mainly by the liver, kidney and adrenal 
gland (Blue et a l  1983), In healthy people, more than 60% apoE is present in HDL 
(Cohn et a l  1996). ApoE was shown to be present in different subclasses of HDL 
including aHDL and prepHDL and yHDL (which contains apoE only) in human 
plasma (Ki'imbou et a l  1997; Huang et a l 1994). It was also found to be present in 
HDLi in rat plasma (Lusk et a l  1979). ApoE flmctioiis have been extensively 
studied over a period o f four-decade. It is well documented that apoE is anti- 
atherosclerotic by its involvement in HDL metabolism and inhibition of platelet 
aggregation (Riddell et a l  1997). ApoE is also associated with the pathophysiology 
of Alzheimer’s disease by inhibiting neuron cell growth (Nathan et a l  1994).
1,2.1.5 HDL metabolic pathway
The metabolism of HDL is inversely related to risk of atherosclerotic cardiovascular 
disease and involves complex dynamics in its pathway and its inteiTelationship with 
other lipoproteins. The formation, conversion, transformation and degradation of 
HDL are regulated by the reverse cholesterol transport (RCT) pathway, which 
promotes the efflux of excess cholesterol from peripheral tissues and returns it to the 
liver for biliary excretion. Cholesterol is an essential constituent of the cell 
membrane and acts as a precursor of steroid hormones and bile acids. The 
cholesterol in plasma either originates from dietary cholesterol that enters the body 
as a part of chylomicrons or is synthesized by various tissues (Figure 12). Although
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cholesterol is synthesized by all somatic cells, the liver is its main producer in 
vertebrates.
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Figure 12 Major cholesterol transport pathways between liver and peripheral tissues.
FC, free cholesterol; CE, cholesteryl ester; VLDL, very low density lipoprotein; LDL, low density 
lipoprotein; HDL, high density lipoprotein; CMs, chylomicrons; CETP, cholesteryl ester transfer 
protein; A BC A l, ATP-binding cassette transporter A l; SR-BI, Scavenger Receptor Class B Type I. 
Arrows indicate the direction o f net transport; red arrows indicate reverse cholesterol transport and 
blue arrows indicate forward cholesterol transport, while the green arrows indicate uptake o f dietary 
cholesterol and excretion o f cholesterol (modified from (Frayn 2003)).
The catabolism of cholesterol is mainly carried out in the liver and is very limited in 
most extrahepatic tissues. In the liver, cholesterol is converted to bile acids that are 
heavily reused in an enterohepatic circulation. Cholesterol is secreted as a 
component of VLDL particles by the liver, which become LDL particles after 
hydrolysis of their TG by lipoprotein lipase and hepatic lipase. LDL particles are 
then taken up by peripheral tissue cells and hepatic cells via the LDL receptor. This 
transport pathway is named forward cholesterol transport and it is shown as a blue 
line in Figure 12. In contrast, RCT has three important steps. First, cholesterol is
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removed from peripheral tissues by HDL particles via interaction with the receptor 
ATP-binding cassette transporter A l (ABCAl). Second, free cholesterol (FC) is 
converted into cholesterol ester (CE) by LCAT and third CE’s selective uptake by 
the liver is promoted by scavenger receptor class B type I (SR-BI). An alternative 
fate for the cholesterol in HDL particles is transfer to VLDL/LDL via the action of 
CETP and uptake by the liver through interaction with the LDLA^LDL receptor. 
This is referred as indirect reverse cholesterol ti*ansport.
1.2,1.6 The main components involved in the HDL metabolic pathway: 
A TP-binding cassette tran sp o rte r A l (ABCAl) ABCAl is a cell membrane 
transporter from the A-subclass o f tlie ABC family of transporters, which uses ATP 
as an energy source and transports a wide variety of molecules across the plasma 
membrane. It is a 2261 amino acid, 240 IcDa protein and is mainly expressed in the 
placenta, liver, macrophages, lung, adrenal glands, brain, fetal tissues and various 
other tissues (Zannis et a l  2006). ABCAl promotes the efflux of cellular 
phospholipids and cholesterol from cell membranes to lipid-poor apoA-I resulting in 
the formation of discoidal apoA-I containing HDL (Barter 2002). The mechanism of 
ABCAl and apoA-I interaction in promoting the efflux of cholesterol is still unclear 
and several proposed models have been described (Zannis et a l  2006; Wang & Tall
2003).
In humans, mutations in ABCAl (Tangier disease) block the formation of discoidal 
and spherical HDL leading to extremely low HDL concentrations. Deficiency of 
ABCAl in experimental mice generated by homologous recombination results in 
little or no plasma HDL (Aiello et a l 2003). The ABCAl transporter plays a key 
role in apoA-I lipidation and HDL formation in the entire RCT process.
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Lecithin:Cholesterol A cyltransferase (LCAT) LCAT is a 416 amino acid soluble 
esterase synthesized in the liver and located on the surface of HDL particles or found 
in lipid-free fonn in human plasma (McLean et a l 1986). LCAT has two different 
activities including a-activity and ^-activity for which the substrates are HDL and 
LDL respectively (McIntyre 1988). ApoA-I on HDL is the prefeiTed activator of a - 
LCAT, with discoidal apoA-I HDL particles being superior to spherical apoA-I HDL 
particles as substrates (Barter 2002). LCAT converts cholesterol and lecithin 
(phosphatidylcholine) to cholesterol esters on the surface of HDL particles and also 
triggers the estérification of LDL cholesterol (Wang & Briggs 2004). LCAT plays an 
important role in promoting cholesterol efflux from peripheral cells to HDL particles 
after the initial cholesterol efflux mediated by ABCAl to apoA-I, through which the 
cholesterol molecules enter the RCT pathway (Figure 12, page 29) (Wang & Tall 
2003; Rye et a l 1999). Mutations in LCAT are related to classical LCAT deficiency 
and low HDL levels. Classical LCAT deficiency prevents the estérification of 
cholesterol in HDL and results in the accumulation of dense free cholesterol rich 
HDL particles in plasma (McIntyre 1988). Fish eye disease (FED) is associated with 
LCAT a-activity deficiency characterized with impaired cholesterol estérification in 
HDL but not in LDL resulting in a low total plasma HDL-C (McIntyre 1988).
Scavenger Receptor Class B Type I (SR-BI) SR-BI was originally identified as a 
scavenger receptor closely related to CD36, a member of the scavenger proteins 
(Acton et a l  1994). It is a 509 amino acid, 82 IcDa membrane glycoprotein and 
expressed mainly in the adrenal gland and liver. SR-BI is also found in other tissues 
and cells including the testis, the brain, the intestine, endothelial cells, macrophages, 
astrocytes and monocytes (Barter 2002; Zannis et a l 2006). SR-BI is a 
ti’ansmembrane protein and contains two transmembrane domains (Zannis et al.
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2006). The ligands of SR-BI include HDL, LDL and VLDL. As the first identified 
HDL receptor, SR-BI mediates the selective uptake of HDL cholesterol. Increased 
SR-BI expression may also result in the increased fractional clearance rate of apoA-I 
(Webb et al. 2002). SR-BI was found to be involved in the process of delipidating 
HDL2 and generation of smaller HDL remnants, but not the formation of pre(3HDL 
(Webb et al. 2004). Over expression of SR-BI in cultured cells has been shown to 
result in an increase in HDL-dependent cholesterol efflux rate, suggesting that HDL 
dependent cholesterol efflux rate is related to SR-BI expression (Ji et al. 1997). SR- 
BI has been identified in the macrophages o f human atherosclerotic lesions (Wang & 
Briggs 2004). This is consistent with a proposed role of SR-BI in mediating HDL 
dependent cholesterol efflux in the arterial wall (Wang & Briggs 2004).
Cholesteryl ester transfer protein (CETP) CETP is a 476 amino acid hydrophobic 
glycoprotein with a molecular weight of 76 kDa. It is mainly expressed in the liver, 
spleen and adipose tissue and is also expressed at lower levels in small intestine, 
adrenal gland, skeletal muscle, kidney and heart (Kleiicx et al. 2006). CETP 
promotes the exchange of cholesterol ester, tiiglyceride and (to a lesser extent) 
phospholipids between plasma lipoproteins. Its substrate specificity is regulated by a 
lipid transfer inhibitor protein (Wang & Briggs 2004). Specifically, CETP mediates 
the net transfer of tiiglyceride from VLDL to LDL and HDL as well as the transfer 
of cholesterol esters from LDL and HDL to VLDL (Figure 13). CETP thus plays an 
important role in the remodelling of HDL particles resulting in the formation of TG- 
rich HDL particles. These particles are further hydrolysed by hepatic lipase and 
endothelial lipase leading to the formation of smaller, denser HDL particles (Barter 
& Rye 2007), CETP deficiency is associated with higher HDL level (rich in CE) and 
larger LDL particles (rich in TG) (Brown et al. 1989; Sakai et al. 1995).
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Figure 13 Role of CETP in reducing HDL size
TG: Triglyceride. CE: cholesterol ester; TRL: triglyceride rich lipoprotein; EL: endothelial lipase;
HE: hepatic lipase; FFA: free fatty acid (Barter & Rye 2007)
Hepatic Lipase (HL) HL is an endothelial enzyme and a member of the TG lipase 
family that is involved in HDL metabolism. Hepatic lipase is a 476 amino acid 
protein produced in the liver (Wang & Briggs 2004). In vitro experiments have 
shown that HL is capable of hydrolyzing various lipids including monoacylglycerol, 
diacylglycerol, TGs, phospholipids and CEs (Wang & Briggs 2004). HL hydrolyses 
the TGs and phospholipids of all lipoprotein fractions and its preferred substrates are 
the lipids in large HDL partieles (Barter 2002). HL also enhanees the uptake of HDL 
cholesterol esters mediated by SR-BI. Over expression of HL in mice resulted in the 
significant reduction of total cholesterol (34%), HDL-C and a reduced HDL particle 
size, while HL deficiency in humans is associated with increased larger HDLi and 
hypertriglyceridemia (Demant et al. 1988; Busch et al. 1994).
Endothelial Lipase (EL) EL is a 482 amino acid plasma glycoproprotein with a 
molecular weight o f 6 8  kDa (Hirata et al. 1999; Jaye et al. 1999). EL is a member of
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TG lipase gene family which also includes lipoprotein lipase, hepatic lipase and 
pancreatic lipase. EL has a significantly higher phospholipase activity and a 
relatively lower TG activity than other lipases (Jaye et a l  1999; McCoy et a l 2002). 
Ulike other members of the lipase family, EL is expressed by endothelial cells and is 
also synthesized by other cells such as hepatocytes and macrophages (Jaye et a l 
1999). It has been shown that HDL is the prefened substiate of EL as it hydrolyses 
HDL more effectively than other lipoproteins (McCoy et a l  2002). It plays an 
important role in HDL metabolism. Over expression of EL in mice was associated 
with a dramatically reduced level of HDL-C and apoA-I, increased catabolic 
clearance rate of apoA-I and also increased uptake of apoA-I by kidney and liver 
(McCoy et a l  2002; Maugeais et a l  2003; Jaye et a l 1999). In apoA-I ti*ansgenic 
mice with hepatic lipase loiockout the inhibition of EL activity resulted in the
formation of larger HDL particles and increased HDL-C level (Jin et a l  2003).
Phospholipid T ransfer P rotein (PLTP) PLTP is an 81 IcDa plasma glycoprotein 
that is partially associated with HDL and mediates the transfer o f phospholipids 
between HDL and other plasma lipoproteins. It especially promotes the transfer of 
phospholipids from chylomicrons and VLDL to HDL (Barter 2002; Wang & Briggs
2004). Wlien incubated with HDL], PLTP triggered the generation of both larger and 
smaller particles than HDL] (Jauhiainen et a l  1993). It may also be involved in the 
transfer o f phospholipids from aH D L to prefJHDL (Rao et a l  1997). Increased 
PLTP activity is associated with a higher HDL cholesterol level and larger particle 
size (Huuskonen et a l  2001). PLTP deficiency in animals is associated with lower 
HDL levels (Huuskonen et a l 2001).
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1.2.1.7 Summary o f HDL metabolic pathway
The described plasma factors LCAT, CETP, EL, HL and PLTP play crucial roles in 
the processes of assembly and remodelling o f HDL. Figure 14 shows a summary of 
the HDL metabolic pathway with intracellular modelling by different lipases and 
transporters.
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Figure 14 HDL secretion, mature pathway and modelling mechanism.
Lipid-poor apoA-I is secreted by liver and intestine, follow ed by acquisition o f  cholesterol and 
phospholipids from liver via A B C A l and chylom icrons and V LDL/LD L via LPL to form 
nascent pre-P HDL particles. The enzym e LCA T esterifies the free cholesterol m olecules to form 
cholesteryl ester, which m igrate to the core o f  the HDL particle to form m ature a-m igra ting  
HDL] particles. H D L] particles can acquire additional phospholipids from TRL via efflux 
m ediated by PLTP to form  a-m igra ting  HDL]. CETP-m ediated heteroexchange o f  HDL CE with 
chylom icron and VLDL TGs results in CE depletion and TG enrichm ent o f  HDL. HL and EL 
m odification o f  TG -rich HDL releases lipid-poor apoA-I and HDL rem nant particles. L ipid-poor 
apoA-I is excreted through the kidney and lost irreversibly. A B C A l: A TP-binding cassette 
transporter A 1; PL: phospholipid; FC: free cholesterol; HL: hepatic lipase; EL: endothelial 
lipase; LCAT: lecithin:cholesterol acyltranferase; SR-BI: scavenger receptor class B type I; LPL: 
lipoprotein lipase; PLTP: phospholipid transfer protein; CETP: cholesteryl ester transfer protein; 
CE: cholesteryl ester and TG: triglyceride. Blue arrows indicate protein transfer and red arrows 
indicates lipid transfer.
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ApoA-I secreted by liver and intestine will gain cholesterol and phospholipids from 
the cell membrane via ABCAl-mediated efflux and collect cholesterol and 
phospholipids from VLDL and chylomicrons after their hydrolysis by LPL. This 
process results in the fomiation of the nascent discoidal pre)3HDL in plasma. In 
addition, discoidal HDL particles are also assembled in the plasma from the 
individual components, or are generated as products of the catabolism of triglyceride 
rich HDL (Wang & Tall 2003; Rye et a l  1999).
After fonnation, nascent prepHDL particles acquire additional cholesterol and 
phospholipids from peripheral tissues mediated by ABCAl and fomi the FC rich 
prePHDL. FC molecules on the surface of the particles are esterified by LCAT and 
converted into cholesterol ester. Cholesterol ester is highly hydrophobic and 
migrates into the core of HDL particles. This process results in the conversion of 
discoidal prepHDL to small spherical a-m igrating HDLs. HDLs expands to become 
larger HDLz as it accepts more FC from cells either mediated by SR-BI or passive 
diffusion. FC is subsequently converted into CE by the action of LCAT. This leads 
to a further change in HDL particle composition and size. PLTP is also involved in 
the increase of a-migrating HDL size by transferring phospholipids from VLDL and 
LDL to HDL. CETP promotes exchange of CE in HDL for TG in chylomicrons and 
VLDL resulting in CE depletion and TG enrichment o f HDL (Lewis & Rader 2005). 
FIL and EL are also involved in the hydrolysis of large TG-rich HDL particles 
resulting in the fonnation of smaller HDL particles. The combined activities of 
CETP, EL and HL also result in a net reduction of mature HDL particle size and the 
generation of smaller a-migrating HDL] and lipid-poor apoA-I. Cholesterol esters 
from HDL] transfened to VLDL and LDL mediated by CETP are removed from
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plasma as a component o f these lipoproteins, when VLDL and LDL are taken up by 
the liver through interaction with the LDL receptor. The relationship between HDL 
and LDL/VLDL is thus characterized by the exchange of cholesterol ester, 
phospholipids and TG mediated by CETP and PLTP (Figure 14). The lipid exchange 
between these lipoproteins is important as it removes excess cholesterol from the 
periphery for metabolic disposal or recycling processes and has a major impact on 
the composition, size and level of HDL and thus regenerates functional HDL for 
additional rounds of RCT (Wang & Briggs 2004). Removal of the larger HDL] is 
mediated by CE-selective uptake by SR-BI in the liver or steroidogenic tissues. 
Hepatic SR-BI may also contribute to the modification of circulating HDL particles, 
promoting their uptake and degradation. Particles and lipid-poor apoA-I generated 
by the catabolism of mature HDL may recycle, acquiring free cholesterol from cell 
surface membranes and once again become mature HDL.
Lipid-poor apoA-I is independently metabolized after its dissociation from the 
remodelling of a-migiating, spherical A-I HDL. It has several potential fates (Figure
15). It may be relipidated and retained in the plasma. The relipidation of lipid-poor 
apoA-I can be achieved by direct combination with small a-migrating HDL particles 
to form large spherical HDL particles. Lipid-poor apoA-I also gains phospholipids 
and free cholesterol via the action of ABCAl to form pre(3-migrating HDL which 
may again recycle in the plasma (Rye & Barter 2004). ApoA-I may also be filtered 
by the renal glomerulus and then degraded by the proximal tubular cell receptors 
cubulin/megalin. Cubulin is a 460 IcDa endocytic receptor and plays an important 
role in the catabolism of HDL and clearance of apoA-I. Megalin is a multi-ligand 
receptor o f the LDL gene family and is co-expressed with cubulin. They are highly 
expressed in the renal proximal convoluted tubule, visceral yolk sac, ileum and
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placenta (Lewis & Rader 2005; Wang & Briggs 2004).
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Figure 15 Metabolic fate o f lipid-poor apoA-I in plasma
The monomolecular form o f pre(3-migrating, lipid-poor apoA-I in plasma may either be excreted 
through the kidney and be irreversibly lost or it may be relipidated and retained in the plasma. 
Lipidation may be achieved by direct incorporation into pre-existing, small a-m igrating, spherical 
HDL particles in a process linked to LCAT-mediated particle expansion. Lipid-poor apoA-I may also 
accept phospholipids and unesterified cholesterol either by transfer from plasma lipoproteins or from 
cells in the process mediated by A B C A l, to form pre(3-migrating discoidal HDL. The preP-migrating 
discoidal HDL is subsequently converted into a-m igrating spherical HDL by the action o f LCAT. 
HDL: high density lipoprotein; ABCAl : ATP-binding cassette transporter A l ; LCAT:
lecithin:cholesterol acyltransferase; PL: phospholipids; UC: unesterified cholesterol; CE: cholesterol 
ester (Rye & Barter 2004).
1.2.2 HDL functions
Atherothrombotic cardiovascular disease remains an important cause of mortality 
and morbidity throughout most o f the world. This is thought to be triggered by the 
accumulation of cholesterol enriched apoB-containing lipoproteins (such as LDL) in 
arteries and their subsequent uptake by arterial wall macrophages promoting the 
formation of macrophage foam cells (Wang & Tall 2003). It has been shown that 
HDL are atheroprotective and that plasma HDL cholesterol and apoA-I 
concentrations are inversely related to the risk of atherosclerotic cardiovascular 
disease (Figure 16) (Kontush & Chapman 2006). Key population studies, including
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the Framingham Heart Study, the Prospective Cardiovascular Münster (PROCAM) 
Study, the Helsinki Heart Study (HHS) and the Multiple Risk Factor Intervention 
Trial (MRFIT), have suggested an inverse relationship between the level of HDL-C 
and coronary heart disease (CHD). Several epidemiological studies indicate that low 
HDL cholesterol concentration is an independent predictive risk factor for CHD and 
that a 0.0259 mM decrease in HDL-C is associated with an increased CHD risk of 
approximately 3% in women and 2% in men (Kontush & Chapman 2006). A 0.0259 
mM increase in HDL-C is associated with 2 to 5% reduced risk of CHD (Barter & 
Rye 1996).
FC^PL Peripheral cell
ABCAl Cholesterol efflux capacity 
AnticKidative activity 
Anti-inflammatory activity
Cholesterol efflux capacity 
Antkxxidative activity 
Anti-inflammatory activity
O  O  I
Lipid-free Al
CE |HDL3
FC.CE Hepatocyte
Cholesterol efflux capacity 
Cholesterol influx capacity 
Andoxidative activity 
Anti-inflammatory activity 
Antiapoptotic activity 
Antithrombotic activity 
Anti-infectious activity 
Vaaodilatory activity
Figure 16 Biological activities of normal functional HDL.
Interconversion between lipid-free apolipoprotein A-I, discoid lipid-poor prePHDL, spherical small, 
dense HDL 3 and large, light HDL] mediated by lecithinxholesterol acyltransferase (LCAT), 
cholesteryl ester transfer protein (CETP), phospholipid transfer protein (PLTP), hepatic lipase (HL), 
endothelial lipase (EL), ATP-binding cassette A l (A B CA l) and scavenger receptor type B1 (SR-BI) is 
schematically shown in solid lines. Biological activities o f HDL particles are indicated in the light 
purple boxes. FC: free cholesterol; PL: phospholipids, PO N l: paraoxonase 1 (Kontush & Chapman 
2006).
HDL's protective effect against cardiovascular disease is complex and is not fully 
understood. Although RCT from macrophages to liver and biliary excretion is
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believed to be the most probable mechanism of HDL’s cardiovascular protective 
effect, many other HDL properties have been shown to be involved in the anti­
atherogenic activities such as inhibition of foam cell formation, inhibition of 
oxidation of LDL, anti-inflammation, inhibition of endothelial cell dysfunction, 
antiapoptosis, antithrombotic effects, anti-infectious and vasodilatory actions (Figure
16) (Kontush & Chapman 2006; Lewis & Rader 2005). HDL can also stimulate the 
movement of endothelial cells and the production of endothelial nitric oxide 
production (Schaefer et a l  1992).
M acrophages R C T and Foam  Cell Form ation In 1973, Ross and Glomset first 
proposed the relationship between RCT and atherosclerosis fonnation. After decades 
o f work, the relationship between RCT and atherosclerosis is still a hypothesis more 
than an established fact (Cuchel & Rader 2006). It has been clearly proved that the 
physiological process of RCT occurs in all peripheral tissues, however, in 
atherosclerotic lesions, the macrophage is the primaiy cell overloaded with 
cholesterol. Not all cholesterol efflux from tissues (such as the liver or intestine) is 
directly relevant to atherosclerosis. Macrophages play an important role in the 
immune system and are involved in the immune response in vertebrates (Figure 17). 
The interaction between macrophages and T cells in the inflammatory response may 
also contiibute to the development of atherosclerosis (Wang & Tall 2003). As a 
chronic inflammatoiy disorder, the typical characteristics of atherosclerosis include 
the accumulation of macrophages and T lymphocytes in the arterial intima and the 
increase of several inflammatoiy markers in plasma (Barter et a l  2004). Oxidized 
LDL is delivered to lysosomes after it is taken up by macrophages via scavenger 
receptors and its cholesterol ester is hydrolyzed to free cholesterol and fatty acids. 
The fi.*ee cholesterol is subject to re-esterification and is stored intracellularly. The
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accumulation of cholesterol esters in macrophages results in the formation of foam 
cells, which are characterized by the accumulation of lipid droplets (mainly oxidized 
LDL and modified LDL) (Hurt et al. 1990). The formation of foam cells affects the 
development of atherosclerosis and is one of the early events o f atherogenesis (Hurt- 
Camejo et al. 1992). This atherogenesis process is associated with inflammation and 
damage of endothelial cells. Although there is no direct evidence that the foam cell 
alone is responsible for lesion formation, it is generally believed that delaying or 
preventing foam cell formation can help prevent atherogenesis.
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Figure 17 Antioxidant and anti-inflammatory properties o f HDL
Atherosclerosis is an inflammatory disorder initiated by an accumulation and subsequent oxidation o f 
LDL in the arterial intima. The oxidized LDLs stimulate endothelial cells to express monocyte 
chemotactic protein-1 (MCP-1) that, in turn, attracts monocytes into the subendothelial space. 
Oxidized LDLs also promote the differentiation o f monocytes into macrophages that take-up the 
oxidized LDL in a process converting them into foam cells. HDL promotes cholesterol efflux from 
foam cells. Macrophages secrete cytokines, some o f  which will stimulate the endothelium to produce 
adhesion molecules. These adhesion molecules can trap the monocytes and start the cycle to form 
foam cells. The properties o f HDL inhibiting the express o f adhesion molecules, will reduce 
monocyte infiltration into the artery wall (Barter et al. 2004).
HDL particles (HDL: and HDLs) promote the cellular cholesterol efflux that remove 
free cholesterol molecules from macrophages mediated by SR-BI and prevent the
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fonnation of foam cells (Ji et a l  1997). The inhibitory effects of HDL on the 
formation of atherosclerotic lesions are associated with their ability to prevent 
cholesterol ester accumulation by stimulating cholesterol efflux from macrophage 
cells in the vessel wall (Figure 17) (Barter et a l  2004).
A ntioxidation HDL antioxidative activity typically inhibits LDL oxidation (Figure
17). The central role of LDL in atherogenesis is due to LDLs binding to the complex 
mati'ix beneath the endothelium, which causes an accumulation of apoB in the artery 
wall (Nievelstein et a l  1991). The antioxidative action of HDL is functionally 
dependent on the presence of lipoproteins and enzymes processing antioxidative 
properties (Kontush et a l  2003). One of the mechanisms of antioxidant activity of 
HDL may be mediated by removing the oxidative molecules. ApoA-I, the major 
apolipoprotein component o f HDL, plays a key role in inhibiting LDL oxidation 
and/or delaying it by the removal o f LDL lipid hydroperoxides and oxidized 
phospholipids from LDL and/or artery wall cells (Navab et a l 2004). HDL are the 
major caiTiers of plasma lipid hydroperoxides in animal models of atherosclerosis 
and in humans (Marathe et a l  2001; Nanjee et a l 1999). The enzymes involved in 
the HDL antioxidative activities include paraoxonase 1 and platelet-activating factor 
acetylhydrolase, which hydrolyzes oxidized phospholipid from LDL (Navab et a l 
2004; Nievelstein et a l  1991). The heterogeneity of HDL leads to a different 
contribution of different HDL subclasses to antiatherosclerosis. Research indicates 
that the smaller HDL] particles are more efficient than larger HDL] particles in 
acquiring oxidized lipids, which is consistent with their distinct cholesterol efflux 
capacity (IContush et a l  2003). As a consequence, small, dense HDL] potently 
protects LDL against oxidation.
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Anti-inflammation Research indicates that HDL are involved in first line protection 
from vims infection in the human and mice innate immune system (Kontush et al. 
2003; Navab et al. 2001). Data obtained from a rabbit model demonstrates that the 
anti-inflammatory activity of HDL is associated with inhibition o f the expression of 
adliesion molecules, reduction of neutrophil infiltration within the arterial wall and 
diminution of reactive oxygen species generation (Kontush et al. 2003). Adhesion 
molecule expression inhibition by HDL may be mediated by both apolipoproteins 
and phospholipids (Van Lenten et al. 2001). In comparison with the larger HDL2 
particles, smaller HDLa particles are more efficient in inhibiting adhesion molecule 
expression in endothelial cells and this is consistent with the potent antioxidative 
activity of small HDLs particles (Kontush et al. 2003). HDL also hydrolyses 
proinflamrnatory oxidized lipids via the action of HDL-associated enzyme and 
inhibits the synthesis of platelet-activating factor and attenuates monocyte MCP-1 
expression (Kontush et al. 2003).
Endothelial Dysfunction and antithrombotic actions HDL may also afford 
cardiovascular protection. In endothelial cells HDL promote the synthesis and the 
release of atheroprotective signalling molecules such as nitric oxide (NO) by 
upregulating the expression of endothelial NO synthase (eNOS) (Schaefer et al. 
1992). Furthermore, HDL can maintain the lipid environment in caveolae for eNOS 
and allow it to colocalize with its partner signalling molecules. HDL can also 
stimulate eNOS through the SR-BI activated signalling pathway. Moreover, this 
pathway allows HDL to protect endothelial cells fiom apoptosis and promotes their 
growth and migration (Schaefer et al. 1992). Evidence also indicates that HDL are 
antithrombotic and protective against arterial and venous thrombosis.
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1.2.3 HDL as a therapeutic target
Type 2 diabetes is associated with a two to four times higher risk of cardiovascular 
disease (CVD) than in non-diabetic people and is the major contributor to the 
morbidity and moriality of type 2 diabetes. Diabetes is an independent risk factor for 
the development of clinical atherosclerotic cardiovascular disease with 50% of 
deaths caused by coronary heart disease (CHD) (Marso & Stern 2003). 
Cardiovascular disease is a multifactorial disease and the cause o f the relationship 
between CVD and type 2 diabetes is not yet clear (Turner et a l  1998). The 
Framingham Study showed that the relative risk of cardiovascular death in patients 
with diabetes was 2.1 for men and 4.9 for women respectively compared to healthy 
subjects. The increased CHD risk was associated with a low level of HDL-C, which 
is apparent at all concentr ations of LDL cholesterol (Frenais et a l 1997). In addition, 
the concentration of apoA-I in plasma has also been shown to be inversely correlated 
with atherosclerosis risk. Thus, targeting HDL as a therapeutic strategy is important. 
It is also important to understand the regulation, function and metabolism of HDL 
and in particular how HDL can reduce atherosclerosis.
Evidence has shown that raising HDL-C has substantial potential as an anti­
atherogenic strategy (Shah & Chyu 2005). Table 2 shows the main reasons that HDL 
is selected as a therapy target. Potential strategies include increasing apoA-I 
production, promoting RCT and delaying catabolism of HDL cholesterol or apoA-I. 
Deficient antiatherogenic activities of HDL in metabolic disease can be corrected by 
therapeutic approaches targeted to increase HDL-cholesterol levels and to nonnalize 
the intravascular metabolism and physicochemical properlies of HDL (Kontush et a l  
2003). Research progress in understanding the mechanism of HDL metabolism, RCT 
and other HDL functions will enable development of new therapies. Therefore, HDL
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metabolism and macrophage RCT have become major targets for the development of 
new therapeutic drugs for atherosclerotic cardiovascular disease (Lewis & Rader
2005).
Epidemiologic evidence o f  an inverse relationship between HDL cholesterol and coronaiy hear t
disease_______________________________________________________________________________________
Preclinical studies showing atheroprotective effects 
Infusion o f  homologous crude HDL in Rabbits
Intravenous injection o f  wild-type reconstituted HDL and HDL made from recombinant apoA-I 
Milano
Transgenic models over expressing HDL-related proteins 
Gene tr ansfer o f  HDL-related proteins 
Biologic plausibility
Vascular protective biologic effects o f  HDL and HDL-related proteins demonstrated in vitro and 
in vivo clinical trials suggesting clinical efficacy 
Phase II study o f  intravenous injection o f recombinant apoA-I Milano
Trials o f  HDL-raising drugs: frbrates and niacin___________  __________________________________
Table 2 HDL as a therapeutic strategy for prevention o f cardiovascniar disease
(Shah & Chyu 2005)
Data from animal experiments indicates that atherosclerosis can be regressed by 
apoA-I over expression, which promotes macrophage RCT (Zhang et a l 2003; 
Tangirala et a l 1999). Various lai'ge scale clinical trials also suggest that therapeutic 
enhancement o f the HDL level will slow the progression o f atherosclerosis and 
reduce cardiovascular risk (Chapman et a l  2004).
Therapeutic approaches have been developed which increase HDL cholesterol levels 
either by activating LCAT, ABCAl and upregulating SR-BI or down-regulating 
CETP or by applying reconstituted or recombinant HDL or HDL mutants (Cuchel & 
Rader 2006; Chapman et al. 2004). Intravenous inftision of wild type apoA-I, milano 
or apoA-I synthetic mimetic peptides also promote macrophage RCT in human 
(Cuchel & Rader 2006). HDL related gene therapies have also stimulated a great 
deal of interest. Many drugs designed using these strategies aie either in the 
preclinical testing stage or being used in various phases of clinical development 
(Figure 18).
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HDL-Based Therapeutics
R ec o m b i n a n t  HDL 
, rApo  A- Imilnno)
A po  A-I niirnetic 
P ep t i de s  (D4F)
CETP inhibit ion 
diugs, vaccine
V a s c u la r  P ro tective  Effects  o f  H DL  
Smal l  and its A po lipopro te ins :
moiec i i ip s  A n  Idea W h o s e  T im e for Testing  is Here  
I p Shah PK . e t  al ■ Circulat ion 2001
SR-BI  
upi  epufat ion
H  D l  . r.s .s o  f; ia  I anl.'^ndnnt-i 
P a r . t o x n n a ^ i p  P A T - A H
RXR  , PPAR.  
LXR 
A yo n i s l s
HDL-related  
Gene  Therapy
r rll/ciirP’Ct'plrit.mtancmsts
Figure 18 HDL based therapeutics
Schematic shows the various potential methods or interventions for exploiting the vascular protective 
effects o f HDL and its associated molecules. CETP indicates CE transfer protein; LUV, large 
unilamellar vesicles made from phospholipid; PL, phospholipid; RXR, retinoid X receptor; PPAR, 
peroxisomal proliferator activator receptor; LXR, liver X receptor; SR-BI, scavenger receptor B type I 
(Shah & Chyu 2005).
1 .3  A p p l i c a t i o n  o f  i s o t o p e  t e c h n i q u e s  t o  s t u d y  l i p o p r o t e i n  m e t a b o l i s m
The transport of lipoproteins in humans is in a constant dynamic state. The 
concentrations of lipoproteins vary not only between different individuals but also 
between different times in the same subject. Stable isotope methodology is an 
established technique that enables determination of the kinetics o f lipoproteins in 
vivo. Thus, an in vivo kinetic study using isotopes to label either the protein 
component or lipid component o f lipoproteins can provide an insight into the 
metabolism of lipoproteins. Kinetic studies can be undertaken using stable isotopes 
due to the high sensitivity of gas chromatography mass spectrometry (GC-MS) 
instrument, which allows a low isotopic enrichment to be measured.
Atoms of the same atomic number but different atomic weights are called isotopes. 
Elements can exist in both stable and unstable (radioactive) forms (Mellon & 
Sandstrom 1996). Most elements of biological, ecological and environmental
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research interest (including Carbon, Hydrogen, Oxygen, Nitrogen and Sulphur) have 
two or more stable isotopes existing in the natural environment, with the lightest of 
these present in much greater abundance than the others. The isotopes most often 
used as biological tiacers are (carbon) and *^ N (nitrogen), which have a natural 
abundance of 1.11% and 0.37% respectively (Mellon & Sandstrom 1996).
To gain insights into the factors regulating the plasma level of some proteins (such 
as apoA-I), in vivo kinetics of these proteins in humans have been studied using both 
exogenous and endogenous labelling methods (Ooi et a l  2006). Exogenous labelling 
has commonly been performed with a radioisotope, while endogenous labelling has 
been perfomied with either radioisotopes or stable isotopes. Each methodology has 
its own advantages and limitations. The exogenous labelling technique includes 
several key steps including isolating a target protein from subjects, iodinating it with 
l ‘^^  and re-injecting the labelled target back into the subjects. The endogenous 
labelling technique enables the synthetic pathway to be labelled by intioducing a 
labelled precursor o f the protein of interest. Compared to exogenous labelling with 
radioactive isotopes, endogenous labelling with stable isotopes has several 
advantages. 1] It is safer for the subjects. 2] Production rates (PR) of different 
proteins can be studied directly because the proteins are labelled simultaneously 
when synthesized. 3] It avoids any lipoprotein modification produced during the 
procedure of isolation or labelling for reinjection (Dwyer et a l  2002).
The principle of the endogenous stable isotope labelling technique is to introduce a 
stable isotopic tracer with a different molecular mass from the major compound 
(tracee) into the dynamic system (the body). Their different masses enable their 
precise detection. The term tracee refers to the substance of interest, which is traced
47
kinetically (Cobelli et a l 1992). The term tracer is defined as a labelled substance, 
which is used to trace the kinetics of the tiacee (Cobelli et a l  1992). The tracer can 
be introduced into the plasma by injection, intravenous infusion, or oral ingestion. 
Metabolic samples can be collected and tracer to tiacee levels detennined from 
blood, urine or breath samples at timed intervals (Umpleby & Sonksen 1987). The 
important characteristics of an ideal isotope are that it is identical to the tiacee in 
tenns of physical and chemical properties, that it does not disturb the system under 
study when introduced and that it has a detectable difference from the tracee (Rashid 
et a l 2006). Because this stable isotope technique relies on adding trace amounts of 
compounds, which are artificially enriched with the rare isotope of the element of 
interest, it is referred to as an isotope tracer technique (Mellon & Sandstiom 1996).
L-[5,5,5-^H]] leucine, L-[1-^^C] leucine and [^^Ce] phenylalanine are often used to 
determine protein kinetics. Endogenous 1-*^C labelled leucine has been used to study 
the in vivo kinetics of apoA-1 by various groups (Ooi et a l  2006) and L-[1-’^C] 
leucine was used in the present study. The use of the endogenous labelling stable 
isotope technique to determine HDL apoA-1 kinetics has a high correlation with 
exogenous radioactive tiacer methods, with a coiTclation coefficient as high as 0.98 
(Rashid et a l  2006).The difference in mass of stable isotope tracers and tiacee is 
detected by mass spectrometer (MS).
1.3.1 Principles of GC-MS
A GC-MS instrument is made up of two components: the gas chromatography (GC) 
and MS. Amino acid mixtures are separated by GC into individual pure amino acids; 
which are then identified and quantified by the MS.
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Different ionisation methods are used to identify and quantify the target of interest. 
They are electron impact ionisation (El) and chemical ionisation (Cl). El is the most 
appropriate technique for relatively small neutral organic molecules which can easily 
be vaporized without decomposition. During the process of El, energetic electrons 
(70 eV) interact with a gas phase analyte to produce radical ions. El frequently 
causes a high level of fragmentation by numerous cleavage reactions.
Compared to El, Cl is a lower energy process. In Cl mode, the analytes are exposed 
to a large excess of a reagent gas (eg methane, ammonia and isobutane) in the ion 
chamber and ions are produced through proton tr ansfer induced by an electron beam. 
The proton transfer between reagent gas molecules will result in the formation of an 
ionization plasma. Positive and negative ions of the analyte are formed by reactions 
with this plasma. There are two different types of Cl, negative chemical ionization 
(NCI) and positive chemical ionization (PCI).
To use NCI, an analyte must be able to generate a negative ion and stabilize a 
negative charge. NCI is often used for the analysis of compounds containing acidic 
groups or electronegative elements such as halogens. PCI produces less 
fr agmentation and usually yields a higher abundance of the molecular ion than EL 
Almost all neutral analytes can form positive ions through Cl and be analyzed by 
PCI.
1.3.2 Detection of isotopic enrichment by GC-MS
To detect isotopic enrichment by GC-MS, amino acid samples needs to be 
derivatised to render highly polar molecules sufficiently volatile so that they can be 
eluted at reasonable temperatures without thermal decomposition or molecular re­
arrangement.
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After derivatisation, amino acid derivatives are firstly injected into the GC column 
where they are separated on the basis of their volatility. Helium, as the earner gas, 
canies the volatile derivatives as they move through the column. The column is 
located inside a specialised oven which controls the temperature of the column when 
the samples move through. Samples are ionized in the ion source. After ionization, 
the ions then travel through an electro-magnetic field that filters ions according to 
their mass. The abundance o f an ion with a specific mass is detected and sent to the 
computer where a mass spectrum is generated.
The enrichment of an isotopically labelled tracer above normal background is often 
expressed as units of atom percent excess (APE). A labelled amino acid is 
administered to measure the synthesis rate of plasma proteins. This is incorporated 
into the plasma proteins and by measuring the enrichment of the protein over time, 
the synthesis rate and clearance rate of the protein can be calculated.
1.4 Hypothesis and aims;
1.4.1 Hypothesis:
There is evidence that HDL metabolism changes in pathological conditions such as 
type 2 diabetes and metabolic syndrome (Xu et a l  2001a). Results indicate that 
smaller and denser HDL accumulate in the plasma of patients with type 2 diabetes 
and hyperlipidaemia (Yang et a l  2005). This may be due to an increased fr actional 
clearance rate of large HDL particles, however, it also may be the result of an 
impairment in the maturation of pre(3HDL, or conversion of small HDL] to larger 
HDL2 particles. PrepHDL plays a central role in cholesterol efflux in RCT and HDL 
metabolism pathway, thus it is important to be able to measure the kinetics of 
prepHDL and aHDL in both normal physiology and pathophysiology. A study of
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prep]HDL kinetics study has been reported by a French group who used gel filtration 
fast protein liquid chromatography system (FPLC) to separate a prePiHDL fraction 
from plasma (Chetiveaux et a l 2006). The plasma had to be diluted to separate 
prePiHDL using this methodology. ApoA-I may dissociate from aH D L in such a 
diluted environment and lead to an overestimation of prep iHDL concentiation and 
production rate. To avoid any possible disassociation caused by dilution, in this 
project, a methodology was investigated to separate prepHDL and aHDL with 
traditional agarose electrophoresis. aH DL contains both HDL2  and HDL3 subclasses 
and to further investigate aHD L kinetics, HDL2 and HDL3 kinetics were additionally 
detennined after their separation with sequential ultracentrifugation.
1.4.2 Aims
The primaiy aim of this project was to develop a method to measure prepHDL 
apoA-I and aHD L apoA-I synthesis and clearance rates in vivo in healthy subjects 
using stable isotope techniques. A secondary aim was to measure HDL2 and HDL3 
synthesis and clearance rates. ApoA-I emichment will be measured by GC-MS in 
different subclasses after infusion of the stable isotope tracer L-[1-'^C] leucine. The 
kinetics of apoA-I in different subclasses will be studied in healthy subjects to 
investigate the synthetic pathway of HDL subclasses in normal physiological 
conditions.
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Chapter 2 General Methodology
2.1 Clinical protocol
Following an overnight fast, a bolus of L-[1-'^C] leucine (Cambridge Isotopes, 15 
mg/ml, '^C enrichment 99%) was injected intravenously as a priming dose (1 mg/kg), 
followed by a constant infusion (1 mg/kg/h) of the labelled leucine for 9 hours by 
using an IVAC 560 pump (IVAC, Hampshire, UK). Blood samples were taken at 
baseline and every hour for 9 hours. Three time points (0 hour, 6  and 9 hours) were 
used for the measurement o f the apoA-I and plasma lipid concentration. Blood 
samples for a-ketoisocaproic acid (a-KIC), the deamination product of leucine, 
which provides a measure of intracellular leucine enrichment, were taken at regular 
intervals throughout the study (0, 1, 4, 6 , 7, 8  and 9 hours) (Figure 19). The study 
protocol was approved by Local Research Ethics Committee and a written consent 
was given by all subjects.
Intravenous bolus 
o f  ^^ C Leucine 
(Img/kg)
■12 fasting
Constant infusion of ^^C-Leucine (1 mg/kg/h) for 9hours
Sample for a-KIC
1 I 1 1 1
I I I t  ■ I I I I I L - i  I I I I i I I
1 9 hour
Baseline
t ! t t t t t t t t
Blood sampling time points for leucine 
enrichment
Figure 19 Clinical study protocol and sampling time points
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2.2 Analytical methodology
2.2.1 Materials
Unless otheiwise stated the chemical reagents used in this project were obtained
from Sigma-Aldrich Ltd (Gillingham, Dorset, UK), Fisher Scientific UK Ltd
(Loughborough, Leicestershire, UK) and Bio-Rad Laboratories (Richmond, CA,
USA). All the sterile vacutainers containing different anticoagulants for blood
sampling were obtained from Becton Dickinson UK Limited (Oxford, UK). The
protocols for the preparation of buffers and solutions are included in the appendix I.
The majority of SDS-polyacrylamide gels (SDS-PAGs) prepared and used in this
project were 1 mm in thiclcness and all other gels with thickness greater than 1 mm
*
are declared in the text.
2.2.2 Plasma and lipoprotein separation
Blood samples were taken with sterile syringes and collected in chilled sterile 
vacutainers containing different anticoagulants. Samples were mixed immediately by 
inverting the tube 8-10 times and were then placed on ice. Blood for HDL separation 
by ultiacentrifugation ( 8  ml), pre(3HDL and aH D L separation (3 ml) and apoA-I 
concenhation ( 1  ml) was collected in tubes containing EDTA at a final concentration 
of 0.1%. Blood samples for plasma lipid (TG and cholesterol) concentration 
deteiinination (1 ml) and a-KIC enrichment (1 ml) were collected in lithium heparin 
containing tubes. Samples for measurement of insulin (1 ml) were collected in tubes 
containing clot activator and gel. Insulin samples were left for at least 30 minutes to 
allow the fonnation of clots before centiifugation, while other samples were 
centrifuged immediately after blood sampling. Plasma was separated from red blood 
cells at 2500 rpm (1439 x g) for 10 minutes at 4°C by centrifugation (Sorvall legend 
RT centi'ifiige. Thermo Fisher Scientific Inc, Waltham, MA, USA). Total HDL
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(1.063<d<1.21 g/ml) was isolated from 3 ml fresh plasma by sequential 
ulti'acentrifugation using an optima LE-80K ultracentiifuge (Type 50.4 Ti rotor, 
Beckman Instalments, Palo Alto, CA, USA) at 40000 rpm (relative centi'ifugal force: 
172301 X g) for 24 hours at 4°C after separation of VLDL, IDE and LDL. Plasma 
samples for aHDL and prepHDL separation, lipid and apoA-I concentiation and a -  
KIC enrichment were stored at -80°C.
2.2.3 HDL2 and HDL3 separation by ultracentrifugation
HDL2 (1.063<d<1.125 g/ml) and HDL3 (1.125<d<1.21 g/ml) factions were isolated 
from 3 ml fresh plasma by ultracentrifugation using an optima LE-8 OK 
ultracentrifuge. In brief, three ml fresh plasma was transferred into ultraclear tubes 
(Beckman Instruments, Palo Alto, CA, USA) coated with 2% polyvinyl alcohol and 
the density was adjusted to 1.063 g/ml with sodium bromide (NaBr) density solution. 
The mixture was centrifuged at 37000 rpm (147425 x g) for at least 20 hours at 4°C 
and VLDL, IDL and LDL were removed together. The remaining solution was 
transfeiTed to a 4 ml volumetric flask and the total volume adjusted to 4 ml with 
density solution (d= 1.063 g/ml). The solution was mixed well and 3 ml transferred to 
a new ultraclear vial. The density was adjusted to 1.125 g/ml with NaBr density 
solution. The mixture was centrifuged at 40000 rpm (172301 x g) for 48 hours at 4°C 
to separate HDL2 fractions. After collection of HDL2 , the remaining solution was 
transfeiTed to a 4 ml volumetric flask and the total volume adjusted to 4 ml with 
density solution (d=1.125 g/ml). The solution was mixed well and 3 ml was 
transferred to a new ultraclear vial and the density was adjusted to 1 . 2 1  g/ml with 
NaBr density solution and the mixture was again centrifuged at 40000 ipm (172301 
X g) for 48 hours at 4°C to separate HDL3 . After collection, the final volume of 
HDL2 and HDL3 fi'actions was adjusted to 2 ml using 0.9% saline. HDL2 and HDL3
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fractions were stored at -20°C until further analysis.
2.2.4 Delipidation of HDL fraction separated by ultracentrifugation
Lipid in HDL particles was removed from proteins by delipidation using a methanol- 
diethyl ether solvent system (Kaipe & Hamsten 1994). In brief, 400 pi HDL fraction 
was added to 4 ml ice cold methanol in a 10 ml round bottom glass tube. Ice cold 
diethyl ether (4 ml) was then added to the delipidation mixture and vortexed to 
ensure efficient delipidation. The samples were centrifuged at 4000 ipm (3684 x g) 
for 30 minutes at 1°C and then the solvent was gently poured off. Another 4 ml ice 
cold diethyl ether was immediately added to the samples. The samples were vortexed 
and centrifuged for another 2 0  minutes under the same conditions as described 
above. After centiifugation, the diethyl ether was poured off. Samples were dried at 
room temperature by placing the tubes upside down on a rack for 2 0  minutes. 
Seventy pi sample buffer (pH 6 .8 ) for sodium dodecyl sulphate polyaciylamide gel 
electi’ophoresis (SDS-PAGE) was added to each sample to dissolve the proteins. 
Samples were then frozen at -20°C until SDS-PAGE was perfonned.
2.2.5 Measurement of apoA-I concentration
HDLz, HDL] and plasma apoA-I concentiation were measured by an 
immunoturbidimetiic method using an ABX Mira Plus (Horiba ABX, Montpellier 
Cedex, France), which is based on an immunochemical reaction. Reagents included 
ABX Penti a Apo AI (a fraction of purified immunoglobulins from rabbit antiserum) 
and immunogen (apoA-I from human HDL). In the assay, apoA-I interacts with its 
specific antibody and forms immune complexes, which scatter a beam of light 
passing through the sample. The intensity of the scattered light is in direct proportion 
to the concentration of apoA-I in the sample. ApoA-I concentration was calculated
55
using a standard curve. Internal quality controls (QCs) were prepared with low and 
high concentration apoA-I (0.88 and 2.58 mg/ml) respectively and inter-assay 
coefficient of variations (CV) were 3.5% and 0.38% respectively (n=3).
2.2.6 Measurement of plasma TG and HDL TG
Plasma TG and HDL TG was measured using an ABX Mira Plus analyser using TG 
assay kits (Horiba, ABX, Noithampton, UK). The colorimetric indicator 
quinoneimine was detected by colorimetry. Reagent ABX Pentra Triglycerides CP 
included ATP, lipoprotein lipase, glycerokinase, glycerol-3-phosphate oxidase and 
peroxidase. The enzymatic determination of triglycerides was according to the 
following reactions (Figure 20).
Lipoprotein lipase 
Triglycerides + H2O ---------------------------- >  Glycerol + fatty acids
Glycerokinase
Glycerol + ATP ----------------------- >  Glycerol-3-phosphate + ADR
Glycerol-3-Phosphate + 02 GlyceroW-phosphate Oxidase ^  h^Q  ^+ DHAP
Peroxidase
2H2O2 + 4-AAP + p-Chlorophenol ------------------->  Quinoneimine + 4H2O
Figure 20 Enzymatic reactions to determine triglycerides with ABX Mira Plus
DHAP = Dihydi'oxyacetone phosphate, 4-AAP = 4-aminoantipyrine (Test insti'uctions for Mira 
inshuments).
The assay QC included a low QC (mean concentration 1.22 mmol/1, range from 1.03 
to 1.41 mmol/1) and a high QC (mean concentration 2.07 mmol/1, range from 1.76 to 
2.38 mmol/1). These were assayed after each calibration. Low QC and high QC CVs 
were 3.3% (n=10) and 4.97% respectively (n=10).
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2.2.7 Measurement of plasma and HDL fraction cholesterol
Plasma cholesterol and cholesterol in HDL fractions were determined by ABX Mira 
Plus colorimetry using a total cholesterol assay kit (Horiba, ABX, Northampton, 
UK). The colorimetric indicator was quinoneimine produced from the enzymatic 
reaction shown in Figure 21. Reagent ABX Pentia Cholesterol CP included 
cholesterol esterase, cholesterol oxidase, peroxidase, 4-aminoantipyrine and phenol. 
The QCs included a low QC (mean concentration 2.6 mmol/1, range 2.08-3.12 
mmol/1) mg and a high QC (mean concentration 4.99 mmol/1, range 4.33-5.65 
mmol/1). There were assayed after each calibration. For plasma cholesterol 
concentration determination, low QC and high QC CVs were 2.7% (n=10) and 1.6% 
respectively (n=10). For HDL ftactional cholesterol concentration low QC CV was
4.4 % (n=6 ). The High QC was not measured.
CHECholesterol ester + H2O — '— ^  Cholesterol + Fatty acid
CHOCholesterol + O2 ---------- >  Cholesterol-3-one + H2O2
2 H2O2 + 4-Amlnoantlpyrine + Phenol ^  Quinoneim ine + 4 H2O
Figure 21 Enzymatic reactions to determine cholesterol with ABX Mira Plus
CHE = Cholesterol Esterase, CHO = Cholesterol oxidase, POD = Peroxidase (Test instnictions for 
Mira instniments).
2.2.8 ApoA-I separation with SDS-PAGE
ApoA-I was isolated fi'om other apolipoproteins in HDL by 4-10 % discontinuous 
SDS-PAGE using a Tris-glycine buffer system containing 0.1% SDS (pH 8.5). Two 
layers of SDS-PAG were cast into a PROTEAN II gel cast (Bio-Rad Laboratories, 
Richmond, CA, USA). A low pH tris base-SDS buffer system (Tris base 0.25M, 
SDS: 0.2%, w/v, pH 6 .8 ) was used for the 4% stacking gel and a high pH tris base-
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SDS buffer system (Tris base 0.75M, SDS: 0.2%, w/v, pH 8 .8 ) for the 10% resolving 
gel. The top stacking gel can increase the resolution of protein separation and 
sharpen the sample bands on the lower resolving gel (Sambrook et a l  1989). In brief, 
delipidated samples (Chapter 2, section 2.2.4, page 55) were heated at 110°C for 5 
minutes and then immediately transferred to an ice box. SDS in a hot buffer 
linearises proteins and gives them a net negative charge. Then samples were 
separated on SDS-PAGE maintained at 10°C with a recirculating water cooling 
system at a constant voltage (80 V) for 16 hours. The gel was stained using a silver 
stain kit. The silver staining system included three steps. First the gel was fixed with 
methanol and acetic acid for 20 minutes. This was followed by twice washing for 20 
minutes with nanopure H2O (Bamstead Nanopure Diamond, Triple Red, 
Buckinghamshire, UK). Then the gel was stained with silver staining solution for 10 
to 20 minutes. The staining reaction was stopped with 5% acetic acid for 15 minutes 
when an ideal stain effect had been achieved. ApoA-I was identified by comparing 
its migrating distance with known molecular weight standards and pure apoA-I.
2.2.9 Immuno-detectioii of apolipoprotein A-I; Western Blotting
After HDL fractions were separated on SDS-PAGE, apolipoproteins were 
transfened to a 0.2 p,m nitiocellulose membrane (Amersham Pharmacia Biotech, 
Inc. Bucks, UK) by electiophoretic transfer or pressure distribution transfer (Kurien 
& Scofield 2006). Electiophoretic transfer was carried out in transfer cassettes with a 
glycine transfer buffer containing 20% methanol (pH 8.3) and run at a constant 
voltage (30 V) for 24 hours. Apo A-I protein was detected by immuno-detection. In 
brief, free protein binding capacity of the membrane was blocked by incubation with 
a blocking buffer (pH 7.5) containing 5% (w/v) non-fat dry milk for 1 hour on a 
shaking table (Orbital mixer, Celltech, RS, USA) at room temperature. After three
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times washing with 100 ml Phosphate Buffered Saline (PBS, pH 7.4) containing 
0.05% Tween 20 (PBST) for 10 minutes, the membrane was incubated with a 
specific primaiy antibody (Goat polyclonal to human apoA-I, Autogen Bioclear, 
Wiltshire, UK) at room temperature. The excess primaiy antibody was washed off 
the membrane with 100 ml PB ST for 10 minutes three times and then the membrane 
incubated with secondaiy antibody (Donkey polyclonal to goat IgG H&L, Autogen 
Bioclear, Caine, Wiltshire, UK) linked with the enzyme alkaline phosphatase (AP) in 
blocking buffer for 1 hour at room temperature. This can activate an alkaline 
phosphatase-substrate reaction. Excess secondaiy antibody was washed off by 
incubating the membrane with 100 ml PBST for 10 minutes three times. ApoA-I was 
immuno-localised by staining the membrane with AP Conjugate Substrate Kit for 1 
minute. The staining reaction was tenninated by adding nanopure H2 O.
2.2.10 Apo A-I hydrolysis
After SDS-PAGE separation, the apoA-I band was excised ftom the gel and placed 
into an oven proof glass tube. The tubes were filled with 1 ml 6  M hydrochloric acid 
(HCl) to hydrolyse apoA-I into amino acids and heated at 120°C for 24 hours with a 
standard heating block (VWR international, West Sussex, UK) (Schaefer et a l 
1992). After hydrolysis, 5 ml nanopure H 2O was added to the hydiolysate and 
vortexed with a Vortex-genie 2 (Scientific Industries, Inc. Bohemia, New York, 
USA). This diluted hydrolysate was transferred to a pre-washed cation exchange 
chromatography column for purification of amino acids.
2.2.11 Ion exchange chromatography
Ion Exchange Chromatography (lEC) relies on ionic interactions between the 
charged molecules (such as amino acids and proteins) in the sample with the charges
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immobilized on the solid support. In cation exchange chromatography, positively 
charged ions in the mobile phase bind to a negatively charged solid support resin. 
Amino acids in the hydrolysate solution (at low pH) are positively charged and bind 
to the resins (Figure 22). To elute the amino acids, ammonium hydroxide (NH4 OH) 
was added to raise the pH of the mobile phase buffer, so that the amino acids became 
less protonated and their ionic interaction with the resin were weakened. This 
procedure purified amino acids and removed impurities.
S a tT iy l e
a p p l 'C .T l lo n Ion E x ch an g e  
C h rom a tog raphy  (lEC i
Figure 22 The principle o f cation ion exchange chromatography
A: Sample application; B: Elution. (Tosoh Bioscience LLC 2009)
Polypropylene columns (Evergreen Scientific, CA, USA) for lEC were filled with 1 
gram of AG50W-X8 cation exchange resin 100-200 mesh per column. In brief, resin 
was weighed and washed with five times nanopure H2 O in a beaker. A 1 g aliquot of 
resin was added to columns which were first wet with 1 ml nanopure H2 O. The 
columns were then pre-washed with 5 ml 4 M NH4OH three times to elute any 
possible contamination. Nanopure H2 O (5 ml) was added to rinse the columns four 
times. The columns were then washed with 5 ml 4 M HCl three times followed by 5 
ml nanopure H2 O rinsing four times. The columns were then ready for the 
purification of hydrolyzed samples. ApoA-I hydrosylate solution was added to the 
columns. The columns were rinsed with nanopure H2 O until the pH value of the
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eluted water from the column was nearly 7. NH4OH (3 ml, 4 M) was added to the 
column to elute amino acids from the column and the sample was collected. Samples 
were h'ozen overnight at -20°C and then freeze-dried using a freeze diyer 
(ModulyoD Freeze Dryer, Thermo Fisher Scientific Inc, Waltham, MA, USA).
2.2.12 Derivatisation of leucine to determine isotopic enrichment by GC-MS
Freeze-dried samples need to be derivatised to determine leucine emichment 
(Dwyer et a l 2002). In the derivatisation reaction, leucine is converted into an 
oxazolinone derivative, which is volatile and thermally stable (Figure 23) (Dwyer et 
a l 2 0 0 2 ).
N H 2
C H 3 CH  C H 2  C  -*COOH
d : H 3  H
TFA/TFAA 
i  110°C, 5 min
O
CH 3 CH
CH3
Figure 23 Chemical structure o f  leucine and the oxazolinone derivative.
The stai* (*) labelling indicates '^C position (Dwyer et a l  2002).
Emichment was measured by GC-MS using negative ion chemical ionization. In 
brief, 100 pi trifluoroacetic anhydride (TFAA, Fluka, Buchs, Switzerland) and
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trifluoroacetic acid (TFA, Fluka, Buchs, Switzerland) (1:1, v:v) were added to the 
fieeze-dl'ied samples. Samples were capped tightly and heated at 110 °C in a heating 
block for 5 minutes. Five himdred pi toluene and 1 ml nanopure H2 O were added to 
the samples which were then vortexed. After brief centrifugation, the toluene layer 
was ti'ansfeiTed to a GC vial with a glass pipette for GC-MS analysis.
2.2.13 Determination of leucine isotopic enrichment by GC-MS
2.2.13.1 GC-MS parameters fo r  the determination of^^Cleucine isotopic 
enrichment
^^C-leucine was used to measure the kinetics of apo A-I in this project. Thus the 
isolation and measinement o f emichment of leucine from apoA-I is of primaiy 
interest for this project. The oxazolinone derivatives of naturally abundant leucine 
isotopes ^^C and ^^C have a molecular mass of 209 and 210, respectively. The 
analysis of oxazolinone derivatives of ^^C and ^^ C leucine would enable the 
measurement of apo A-I leucine emichment. Table 3 smnmaiises the GC-MS 
protocol for the determination o f leucine emichment.
GC oven 
Conditions
Initial Temperature: 50°C for 1 minute
Ramp: 1 l°C/minute to 110°C, 30°C/minute to 280°C
Run Time: 12.12 minutes
Inlet 1:5 Split Injection 
Initial Temperatme: 250°C. 
Pressure: 4.06psi.
Split Flow: 3.4 ml/minute. 
Gas Flow: 40
MS conditions MS in the negative chemical ionization (NCI) mode 
Selected Ion Mode (SIM)
Ions: 209.0 (m) and 210 (m+1)
Solvent Delay: 5.0 minutes 
MS Quad: 150°C.
MS Som'ce: 200°C
Table 3 GC-MS protocol for determination o f leucine enrichment
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2.2.13.2 Enriched leucine standard curve
To determine the sensitivity and linearity of GC-MS, a range of standards were 
prepared as a standard curve with L-^^C-leucine and L-[1-^^C]-leucine (Table 4). 
Because o f the low turnover rate of apoA-I, a relatively small emichment range 
(from 0 to 1.96 APE) was prepared. Norleucine was added as an independent control 
to monitor the performance of the GC-MS. In each individual standard sample, the 
concentration ratio of ^^C-leucine and norleucine was 1:1.
Samples
(n= 1 2 )
^^C-leucine
(pg/pl)
Norleucine
(fig/W)
'^C-leucine
(pg/pl)
theoretical
APE
Theoretical 
^^C/^^C ratio
1 0.005 0.005 0 0 0
2 0.00498 0.00498 0 . 0 0 1 0 0.0999 0 . 0 0 1
3 0.00495 0.00495 0 . 0 0 2 0 0.1996 0 . 0 0 2
4 0.00493 0.00493 0.0030 0.2991 0.003
5 0.0049 0.0049 0.0040 0.3984 0.004
6 0.00488 0.00488 0.0050 0.4975 0.005
7 0.00485 0.00485 0.0060 0.5964 0.006
8 0.00482 0.00482 0.0075 0.7444 0.0075
9 0.00476 0.00476 0 . 0 1 0 0 0.9901 0 . 0 1 0
1 0 0.00471 0.00471 0.0125 1.2346 0.0125
1 1 0.00465 0.00465 0.0150 1.4778 0.015
1 2 0.00455 0.00455 0 . 0 2 0 0 1.9608 0 . 0 2 0
Table 4 Preparation o f new enriched leucine standard curve with low enrichment range
ratio: the concentration ratio o f L-[l-*^C]-leucine to L-^^C leucine. APE: atom percent excess
Samples were analyzed with a GC-MS system (7890A GC system, Agilent 5975C 
inert XL EI/CI MSD, Agilent Technologies, woldngham, Berkshire, UK). Samples 
were injected with an Agilent 7683 autosampler. The GC was equipped with a BP5 
30 metre 0.25 mm irmer diameter (ID), 0.25 pm film capillary column (J&W 
Scientific, Inc. CA, USA) using helium as the carrier gas (1 ml/minute). The GC-MS 
was operated in a Cl mode using methane as the reagent gas.
The measured APE was plotted against theoretical enrichment (APE) to obtain the 
standard curve (Figme 24). A linear” relationship (r^=0.9986) was observed with a
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slope almost equal to unity (0.962).
2.4
y = 0. 9624x + 0. 0318
LU
CL< r  = 0. 9986■D
I  1.2
(/}mI  0.8
0.4
0 0.4 0.8 1.2 1.6 2 2.4
Theoretical APE
Figure 24 Leucine standard curve
Results are presented as mean ± SEM (n=5). APE: Atom percent excess. 
2.2.14 Determination of plasma a-KIC isotopic enrichment
Isotopic enrichment of a-KIC (Figure 25) was determined by a modified method of 
Ford et al (1985). Plasma samples were stored at -80°C prior to extraction. On 
thawing, proteins were precipitated from 0 . 1  ml plasma with 1 ml ethyl alcohol. 
After centrifugation at 2500 rpm (1439 x g) for 10 minutes at 4°C, the supernatant 
was evaporated under oxygen free nitrogen (generated by Nitroflow, Parker 
Filtration and separation, Parker Hannifin Ltd, Maidston, UK) using a sample 
concentrator (TECHNE, Bibby-Scientific Ltd, Staffordshire, UK) at 50°C using a 
heating block (TECHNE, Bibby-Scientific Ltd, Staffordshire, UK). The residue was 
dissolved in 0.2 ml water and reacted with 0.1 ml 1,2-phenylenediamine (2% in 4 M 
HCl) at 90°C using a heating block for 1 hour. After cooling the samples to room 
temperature, ethyl acetate (1 ml) was added to extract the keto-acids. The keto-acids
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present in the top layer were transferred to a clean vial. This extraction step was 
repeated and the combined extracts were dried over anhydrous sodium sulphate. The 
solvent was evaporated under oxygen free nitrogen at room temperature. The dried 
residues were derivatised with 100 pi acetonitrile and 100 pi N-Methy 1-N-(tert- 
butyldimethylsilyl) trifluoroacetamide with 1% trimethylcholorsilane (MTBSTFA, 
Fluka, Buchs, Switzerland) and heated at 120 °C using a heating block for 45 
minutes to form the quinoxalinol-tert butyl dimethylsilyl (TBDMS)-quinoxalinol- 
TBDMS derivative. This derivative was kept in the final reaction mixture until 
analysis when the excess reagent was removed under oxygen free nitrogen at room 
temperature. The sample was then prepared for GC-MS by adding 100 pi decane.
LUQ_<■o
3(/>rod>
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= 0.99916
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Theoretical APE
Figure 25 a-K IC  standard enrichment curve
Results are presented as mean ±SEM (n=4). APE: Atom percent excess.
Isotopic enrichment was determined by selected ion monitoring of fragments at m/z 
259 (m) and 260 (m+1) by El on a GC-MS using a BP 5 capillary column (30 m x 
0.25 mm ID x 0.25 pm film). Chromatographic peaks were integrated and the 
*^C/*^C-area ratio of a-KIC calculated. The isotopic enrichment was calculated as
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APE. Figure 25 shows a-KIC standard enrichment curve (n=4).
2.2.15 Investigation of contamination from glassware
During measurement of the isotopic enrichment of leucine, contamination may come 
from glassware used for hydrolysis. This will contaminate samples during 
hydrolysis. The extent of contamination coming from glassware was investigated by 
washing glassware with HNO3 and comparing this with the glassware not washed 
with HNO3. The HNO3 washing procedure included three steps. In brief, the glass 
tubes were filled fully with concentrated HNO3 and left to stand at room temperature 
for 5 minutes. The HNO3 was removed and a further 1 ml HNO3 was added. The 
tubes were vortexed. This remaining HNO3 was removed and the glass tubes were 
washed with nanopure H2O. Then the glass tubes were filled fully with 4 M NH4OH 
and left to stand at room temperature for 5 minutes. After the NH4OH was removed, 
another 1 ml 4 M NH4OH was added to the tubes followed by vortexing. After the 
remaining NH4OH was removed, the glass tubes were washed with H2O until the pH 
was nearly 6 . The glass tubes were heated at 120°C using a heating block until they 
were completely dried.
2,3 Development of Methodology: 2-Dimensional Electrophoresis
2.3.1 First dimension: Agarose electrophoresis
aHD L and prepHDL were separated by agarose gel electrophoresis. Briefly, 0.6% 
low electi'oendosmosities agarose (Fluka, Buchs, Switzerland) with a high gelling 
temperature was cast into a flat-bed gel cassette (CHU20 maxi-cooled horizontal gel 
unit, Sie-plas, Southam, Warwickshire, UK) and mn with 25mM, pH 8 . 6  Tris-tricine 
(Tricine from Acros Organics, Geel, Belgium) buffer (Asztalos et al. 1993). Ten pi 
plasma diluted with 20 pi Tris-tricine buffer containing 10% glyceride and 0.01 %
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bromophenol blue was loaded on agarose gel. The gel was mn at 170 V for 3 hours. 
Pure human apoA-I and human albumin were used to identify the position of 
prepHDL and aH D L respectively. The agarose gel was stained with 0.05% 
coomassie blue R250 (BDH Ltd. Corston, Bath, UK) prepaied with methanol/ acetic 
acid solution (methanol: H2 O: acetic acid = 9:9:1, v:v:v). Excess dye was removed 
by a prolonged period of destaining with the same methanol/acetic acid solution.
2.3.2 PrepHDL and aHDL extraction procedure
After staining, prepHDL and aH DL bands were excised, cut into small pieces and 
freeze-di'ied overnight. Three ml of 1% SDS (BDH Ltd. Corston, Bath, UK) solution 
was added to the fi*eeze-dried gel which was left for 2  hours at room temperature to 
exti'act proteins (Mukai et ah 2003). The supernatant was removed and extraction 
was repeated by washing the gel with 3 ml 0.2% SDS twice for prepHDL and three 
times for aHDL. All the solutions were collected in 10 ml vials and frozen at -20°C 
overnight. Samples were concentrated in a freeze diyer and stored at -20°C in the 
freezer.
2.3.3 Sudan Black B prestained plasma
Sudan Black B (0.2 mg) was prepared in 20 ml ethanol and glycerol (4:1, v:v) or 20 
ml ethylene glycol, to give a final concentiation of 1%. After Sudan Black B was 
dissolved, the staining solution was filtered through whatman No.5 filter paper to 
remove the undissolved sediment. Plasma (1 ml) was diluted with Sudan Black B 
staining solution by 5:1 (v:v) in a 1.5 ml plastic vial and incubated at 37°C for 2 
hours in an oven (Binder Gmb, Tuttlingen, Gennany). Prestained plasma was 
centi'ifuged at 4000 ipm (2700 x g) for 5 minutes with a bench top centi'ifiige (Bri 
Multifunction Jouan Centi'ifiige, Thenno Fisher Scientific Inc, Waltham, MA, USA)
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and the supernatant was tiansfened to a new 1.5 ml plastic vial and a 50 pi sample 
was loaded onto an agarose gel.
2.3.4 Ethanol precipitation and diethyl ether delipidation
Four ml ice cold ethanol was added to the tubes containing the HDL proteins 
extracted from agarose gel and mixed well. The tubes were kept on ice for 1 hour. 
After the proteins were precipitated, the tubes were centrifuged at 1°C, 4500 rpm 
(4662 X g) for 1 hour. The blue supernatant, which contained almost all the 
coomassie blue R250, was gently decanted. Four ml ice cold diethyl ether was added 
to each tube which were then centrifuged under the same conditions as described 
above. The clear supernatant was decanted gently without disturbing the precipitates. 
The tubes were left to diy in the air at room temperature for 20 minutes and 70 pi 
sample buffer (pH 6 .8 ) for SDS-PAGE was added to dissolve the proteins.
2.3.5 Second dimension SDS-PAGE
SDS-PAGE (4-10% discontinuous gel) was prepared to separate apolipoproteins 
from aH DL and prepHDL and iim as described in Chapter 2 section 2.2.8 (page 57). 
The gels were stained with coomassie blue R250 or silver stain. ApoA-I was 
identified by comparing migrating distances with Icnown molecular weight Precision 
Plus Protein Standards. The identification was also confirmed with western blotting 
described in section 2.2.9 (page 58).
2.4 Data analysis and calculations
The isotopic enrichment of leucine was calculated from the isotope ratio and then 
converted to APE, calculated as:
APE (%)= [(Rt-Ro)/(Rt-Ro+l)l x 1 0 0  Equation 1
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where Rt and Ro are the isotopic area ratios of m +l/m  (210/209) for the sample at 
time t and baseline sample at time zero, respectively (Batista et a l 2004). The 
fractional secretion rate (FSR) of HDL apoA-I was calculated using a regression 
model.
FSR (pools/day)
= (Slope of the apoA-I enrichment time curve/ K IC a p e) x  2 4 , Equation 2
where plasma a-ketoisocaproate ( K I C a p e )  is the precui'sor pool enrichment of 
hepatic intracellular leucine used for estimating protein synthesis (Ford et a l 1985). 
In a steady state, the FSR is equal to fractional catabolic rate (FCR). The production 
rate (PR) was calculated from the product of the FSR and the pool size. The pool 
size was calculated fi'om the product of mean apoA-I concentration (mean 
concentration of apoA-I in four pooled HDL samples) and the plasma volume (PV) 
divided by body weight. PV was calculated using Equation 5 and 6  (Pearson et a l  
1995). In brief:
PR (mg/kg/day) = FSR x HDL apoA-I pool size Equation 3
Apo A-I pool size (mg/kg) = HDL apo A-I concentration x PV / BW Equation 4
For males,
PV (ml) = 1578 X  S Equation 5
For females
PV (ml) = 1395 X  S Equation 6
where S: surface area (m^)
S (m^)=BW X  Height®^^  ^x 0.007184 Equation 7
where BW: body weight (kg), Height (m)
The body mass index (BMI) is a statistical measurement of body fat based 
comparison of a person's weight and height. BMI does not measure the percentage of
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body fat but reflects a person’s “fatness” or “thinness” against their height.
BMI(kg/m^)=Weight(kg)/height^(ni^) Equation 8
The formula to calculate recovery rate of each extraction is shown in Figure 26. 
Total recovery rate is:
R=R1+R2+R3h i-Rn. Equation 9
where Rn is the recovery rate of the nth extraction. Since 3 ml SDS solution was 
added to the ffeeze-dried agarose gel, Va in the formula was 3 (Figure 26). Vtn was 
the volume taken out from the samples at the nth SDS extraction.
VtiR 1  = — ^ x 1 0 0 %Va
’’ “ • w . - V n X - V t .  ( 1 - R 1 - R 2 - R 3 ) > 1 0 0 %
VtnRn=-----------------  (1- l R i ) x 1 0 0 %
nVa- I v ihi
Figure 26 Formula to calculate the recovery rate o f each extraction from agarose gel
Va=Volume added to freeze-dried agarose gel samples (same volume for each extraction), 
Vt=VoIume taken out from agarose gel samples: Rn= recovery rate at nth extraction: Vtn: the Volume 
taken out from agarose gel at nth extraction.
After the proteins were extracted from agarose gel and freeze-dried, the samples 
were dissolved in a volume of sample buffer (Vy). The concentration of apoA-I 
(CapoA-i) in sample buffer can be quantified by different methods such as density 
scanning. Afterwards, apoA-I concentration of prepHDL and aHDL ( C h d l )  in 
plasma (Vp) can be further calculated after determination of the amount of extracted 
proteins. The apoA-I concentration in prepHDL and aHDL can be calculated as:
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C h d l=  CapoA-i X Vb X R /V p  Equation 10
Mangeais et al (2001) used norleucine as an internal standard to estimate the 
concentiation of apoA-I according to the norleucine to leucine ratio. The human 
apo A-I molecule contains 243 amino acids including 37 leucine molecules, which 
contributes to 14.96% by weight. The amount o f leucine was calculated based on the 
leucine to norleucine ratio and the quantity of apoA-I could be calculated 
accordingly.
Hieu/inor Pieu/I*nor Equation 11
where R is ratio and P is peak area.
L eu (m g )= R n o r/ieu  *Nor(mg)= Pieu/Pnor *Nor(mg) Equation 12
ApoA-I(pg)=leu(pg)/14.96%==6.685 Pieu/Pnor *Nor(mg) Equation 13
CapoA-i (pg/pl)= ApoA-I(pg)/VbL Equation 14
where CapoA-f concentiation of apoA-I, VbL: Volume of extracted protein samples 
loaded on gel. aHDL and prepHDL apoA-I concentration can be calculated with 
Equation 14.
Results are presented as mean ± SEM. Microsoft Excel 2003 was used to analyze 
data and generate graphs and cuiwes. Significant differences were analyzed with 
paired two-tailed t test by the software SPSS 15. In all the comparisons, a P<0.05 
was considered statistically significant.
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Chapter 3 Development of SDS-PAGE and GC-MS to 
determine the Idnetics of HDL separated by 
ultracentrifugation
3.1 Introduction:
The main objective for this part of the project was to set up and improve a previously 
established method to determine the kinetics of total apo A-I in total HDL 
(1.063<d<1.21 g/ml) separated by ulti'acentrifugation with endogenous stable 
isotopes (^^C-leucine). This process required developing SDS-PAGE and GC-MS. 
This was put into practice by analysing enriched apoA-I in samples fi'om 4 diabetic 
patients taken from a previous study where patients were studied before ( 0  month) 
and after ( 6  months) exercise intei-vention (Alam et a l 2004). Any contamination 
from chemical reagents and glassware used in the experiments was investigated to 
determine their effects on apo A-I enrichment levels. In addition, HDL] and HDL] 
fractions from healthy subjects were isolated by sequential ultracenti'ifugation as 
described Chapter 2 (section 2.2.3, page 54). Their migrating profiles on SDS-PAGE 
were investigated.
3.2 Method development
3.2.1 Separation of apo A-I with SDS-PAGE
Following ulti'acenti'ifugation, HDL apolipoproteins were separated by SDS-PAGE 
after delipidation o f a '^C-leucine enriched sample taken at 8  hours during a *^C- 
leucine infusion. In brief, 400 |li1 HDL fi'action was delipidated with methanol and 
diethyl ether as described in Chapter 2, section 2.2.4 (page 55). The sample was then 
diluted with 200 pi sample buffer (pH 6 .8 ) and heated at 110 °C with a heating block 
for 5 minutes, cooled on ice immediately after removal fi'om the heating block. To
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determine the optimal amount of sample to load onto the gels to obtain a good 
separation, 5 pi, 10 pi, 25 pi, 50 pi and 60 pi samples were loaded on a 4-10% 
discontinuous SDS-PAG (Chapter 2, section 2.2.8, page 57). Electrophoresis was run 
at 80 V for 16 hours. The silver stained gel is shown in Figure 27A. The biggest 
band (red arrow) was identified to be apo A-1 according to the migration distance of a 
pure apoA-1 standard and confirmation of results by western blotting (Figure 27B). 
Also as, apoA-I comprises 70% of the total HDL proteins, it will be the largest band 
on the gel. The maximum volume that can be loaded on to a 1 mm SDS-PAG is 60 
pi.
Std A1 5)i1 10(11 23(11 30(il OOjil Sid
-  S  »IÔ O K D  ^  g e  M  * * 4
IS K D ^ I  -V 10 T5KD
50K U #
ApoA-I
HDL M o le c u le&t
360 300 420 460
S3 i I- i
m m «Sm
Figure 27 Total HDL migration on SDS-PAGE and western blot o f apoA-I
A: One HDL fraction sample (400 pi) was delipidated and diluted with 200 pi sample buffer after 
delipidation. Different volumes (from 5pl-2.5%  to 60pl-30%) o f sample were loaded on 4-10% 
discontinuous SDS-PAGE to compare the separation profile. B: Western blotting o f apoA-I from total 
HDL fraction (from Anita Lo)'. C: Different time point samples were separated on SDS-PAGE. 
ApoA-I bands o f identical size were cut from the gel for hydrolysis. The orange arrows indicate the 
migrating position o f apoA-I. AI: pure apo A-I. Std: Protein standard.
After identification of apoA-I, different time point samples were delipidated and 
dissolved in 70 pi sample buffer (pH 6 .8 ). ApoA-I was separated on SDS-PAGE by 
loading 50 pi of the samples. Since some studies suggest that SDS-PAGE gels may
’ Figure 278: The western blotting o f HDL apoA-I was carried out by Anito Lo who did her MSc 
project in this lab.
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contain a contaminant that may eiToneously increase the background enrichment of 
apoA-I (Dwyer et al. 2002), only bands of identical size were cut from the gel for 
investigation in a subsequent experiment (Figure 27C).
Following separation on SDS-PAGE, the apoA-I from different volumes of HDL 
sample was excised for emichment analysis by GC-MS. The GC-MS results are 
showed in Table 5.
209 (m) 2 1 0  (m+1 ) 210/209(m+l/m)
5 pi HDL (apoA-I) 46226763 4530372 0.098
10 pi HDL(apoA-I) 72867238 7217458 0.099
25 pi HDL(apoA-I) 121115551 12207166 0 . 1 0 1
50 pi HDL(apoA-I) 122626883 12323673 0 . 1 0 0
60 pi HDL(apoA-I)
.  i_ . _____ .L f  13.r^
132803563 13388030 0 . 1 0 1
One HDL fi action sample (400 pi) was from a study in vivo labelled w ith leucine, which collected 
at 480 minutes dm'ing a *^C-leucine infusion. A fter delipidation, it was diluted with 200 pi sample 
buffer. Different volumes (from 5 pi to 60 pi) o f sample were separated on a SDS-PAGE and then 
hydrolyzed with 1 ml 6  M  HCl. The isotopic enrichment was measured by GC-MS. Tracer/tracee 
ratio: 210/209.
There was no significant difference in the tracer/tracee ratio (m+l/m ) of apoA-I 
among all of the HDL samples (Table 5). This suggests that apoA-I emichment can 
be measured in as little as 10 pi HDL fr action (equal to 5 pi HDL sample /200 pi 
sample buffer*400 pi HDL fraction = 10 pi HDL fraction), which is equal to apoA-I 
fr'om 15 pi plasma.
3.2.2 Identification of contamination during determination of enrichment
The target apolipoprotein pre|3HDL apoA-I has a low concentration in plasma with a 
relatively low turnover rate. This makes background noise significant when isotopic 
enrichment is determined by a sensitive GC-MS method. A previous study has 
indicated that contamination can originate fr om reagents, gels and glassware (Dwyer 
et al. 2002). Following prepHDL and aHDL apoA-I isolation by SDS-PAGE the
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apoA-I band was excised and hydrolyzed in 6  M HCl. After hydrolysis, amino acids 
were pmified with ion exchange chromatography and then derivatised for GC-MS. 
All these steps have the potential to introduce contamination. To minimize possible 
contamination, the source had to be first identified. To determine possible 
contam ination sources, tubes and chemicals used during the hydrolysis and ion 
exchange chromatography were investigated.
3.2.2.1 Measurements o f  contamination from  glass tubes and H Cl used fo r  
hydrolysis
Figure 28 shows the contam ination analysis procedure used to investigate 
contam ination from HCl and glassware. Glass tubes were divided into 3 groups and 
each group included 4 identical tubes. Vials in group 1 were washed with 
concentrated HNO3 (a powerful oxidizing agent) and 4 M NH 4 OH (Chapter 2, 
section 2.2.15, page 6 6 ). After the wash step, tubes were filled with 1 ml 6  M HCl 
(hydrolysis reagent) then heated at 120°C for 24 hours (referred as to step 1 
hydrolysis). HCl fiorn the tubes was then transferred to prewashed lEC columns 
(cation) to pmify the hydrolysates (Chapter 2, section 2.2.11, page 59). The samples 
eluted fi'om lEC column were fi’eeze-dried and then derivatised (Chapter 2, section 
2.2.12, page 61) followed by GC-MS analysis (Chapter 2, section 2.2.13, page 62). 
The emptied tubes in group 1 were again filled with 1 ml 6  M HCl and reheated for 
another 24 hours at 120°C (referred as to step 2 hydrolysis). Hydrolysates fi'om step 
2  hydrolysis were treated in the same way as described above for step 1 hydrolysis 
for GC-MS analysis.
To identify the effect o f washing with HNO 3 , tubes in group 2 were filled with 1 ml 
6  M HCl heated at 120°C for 24 hours (step 1 hydrolysis) without HNO 3 treatment
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and then followed by step 2 hydrolysis as described above for group 1. To further 
measure contamination from HCl, tubes in group 3 were filled with a large volume 
of 6  M HCl (5 ml ) and incubated at 120°C for 24 hours (step 1 hydrolysis). This 
was followed by step 2 hydrolysis as described above for group 1. All HCl 
hydrolysates from step 1 hydrolysis and step 2 hydrolysis were eluted through lEC 
columns followed by freeze drying and derivatisation. The enrichment of the 
chemicals was analyzed by GC-MS.
Group 1 
(n=4)
Group 2 
(n=4)
Group 3 
(n=4)
HNO3 & N H,OH No pre treatment No pre treatment
prewash procedure
HCl
1 ml 6M HCl 
prehydrolysis 
24h 120 “C
HCl
\
\
Step 1 
GC-MS
\
1 ml 6M HCl 
hydrolysis 
2 4 h 120 "C
HCl \
1 ml 6M HCl 
prehydrolysis 
24h 120 “C
\
Step 1 
GC-MS
HCl \
\
Step 2 
GC-MS
1 ml 6M HCl 
hydrolysis 
24h 120 “C
HCl \
5 ml 6M  HCl 
prehydrolysis 
24h 120 *C
\
Step 1 
GC-MS
HCl \
\
Step 2 
GC-MS
1 ml 6M HCl 
hydrolysis 
24h 120 *C
V\ Step 2 
GC-MS
Resin columnsResin colum ns Resin colunms
Figure 28 Investigation o f contamination in glass tubes and HCl
Group! tubes were washed with HNO 3 and NH 4 OH, while group 2 and 3 tubes were not washed. All 
the tubes were incubated with 6  M HCl twice. After incubation for 24 hours, HCl was transferred to 
lEC column and the enrichment o f the acid was analyzed by GC-MS.
3.2.2,2 Determination o f  the contamination from  polyacrylamide gel
Contamination may also originate from the SDS-PAG itself. To determine the 
contamination associated with the SDS-PAGs and the silver staining technique, three
HDL samples (400 pi) labelled with '^C-leucine obtained from a leucine infusion
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clinical study at different time points (300, 390 and 420 minutes) were delipidated 
and dissolved in 200 pi sample buffer (pH 6 .8 ). Fifty pi samples were loaded into 
every other well of a SDS-PAG and each sample was loaded twice symmetrically 
(Figure 29). After electrophoresis at 80 V for 16 hours, the gel was divided into two 
halves. One half was washed with 200 ml H2O and the other half was silver stained. 
After silver staining, the stained gel was used as a reference to localize the position 
o f the apoA-I band on the other half gel without staining. ApoA-I bands were 
excised from both stained and non stained gels and hydrolyzed with 1 ml 6  M HCl at 
120°C for 24 hours. The amino acids were purified with lEC and the isotopic 
enrichment was analysed by GC-MS.
Figure 29 Schematic diagram of samples loaded on SDS-PAGE to compare staining and non­
staining the gel with silver
Three HDL fraction samples (400 pi each) named 1, 2 and 3 were delipidated and dissolved with 200 
pi sample buffer (pH 6.8). Samples (50 pi) were symmetrically loaded on a SDS-PAGE. After the 
electrophoresis, the gel was divided into two halves. The green line indicates the position where gel 
was cut. One half o f the gel was stained with silver and the other half was not stained.
Another SDS-PAG was prepared without loading any samples. The gel was divided
into two halves as the described above. One half was washed with 200 ml nanopure
H2O after electrophoresis and the other half was silver stained. Different sizes o f gel
(1 cm^, equal to the size o f apoA-I band and 3 cm^) from both halves were excised
and hydrolyzed with 1 ml 6  M HCl at 120°C for 24 hours. The hydrolysates were
washed through lEC columns. The isotopic enrichment of the gels was analyzed by
GC-MS.
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3.2.3 Measurement of apoA-I fractional catabolic rate in HDL isolated by 
sequential ultracentrifugation
After HDL apoA-I was isolated with 4-10% discontinuous SDS-PAGE (section 
2.2.8, page 57). ApoA-I bands was hydrolyzed with 1 ml 6  M HCl as described in 
Chapter 2, section 2.2.10 (page 59) and amino acids were pui'ified by ion exchange 
chromatography (section 2.2.11, page 59). After derivatization (section 2.2.12, page 
61) emichment was measured by GC-MS (section 2.2.13, page 62). A standard 
calibration curve was prepared as described in Chapter 2, section 2.2.13.2 (page 63) 
and was run before and after each batch of samples on GC-MS. Samples were 
applied to GC-MS only if  the standar ds achieved a slope of between 0.95-1.05.
3.3 Results
3.3.1 Separation of apoA-I from HDL] and HDL3 fraction by SDS-PAGE
After the SDS-PAGE was set up and used to separate apoA-I from total HDL 
fraction, the migrating profiles of HDL] and HDL3 fractions isolated by sequential 
ultracentrifugation (refer to Chapter 2, section 2.2.3, page 54) were studied. In brief, 
400 pi HDL] and HDL3 fractions were delipidated with methanol and diethyl ether 
as described in Chapter 2, section 2.2.4 (page 55). The samples were then diluted 
with 70 pi sample buffer (pH 6 .8 ) and 50 pi sample was then loaded on 4-10% 
discontinuous SDS-PAGE (equal to 50/70*400=285 pi). Figm*e 30 shows HDL] and 
HDL3 migrating profiles on SDS-PAGE. Pure apoA-I was used as a standard to 
identify the migration position o f HDL] and HDL3 apoA-I. Blue arrows indicate the 
position of apoA-I. The results indicated that apoA-I from 285 pi HDL] and HDL3 
firactions can be well separated by SDS-PAGE and the isotopic enrichment of 
leucine from apoA-I can be measmed by GC-MS.
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H D L 2 H D L 3 AI
  _______________________  ApoA-IApoA-I
Figure 30 Comparison o f HDL: and HDL, migrating profiles
HDL: (L063<d<1.125 g/ml) and HDL3 (1.125<d<1.21 g/ml) were isolated by sequential 
ultracentrifugation and separated on a 4-10% discontinuous SDS-PAGE at 80 V for 16 hours. Blue 
arrows indicate the position o f ApoA-1. Al: pure apoA-1.
3.3.2 Measurement of the contamination from glass tubes and HCl
The possible contamination from tubes and HCl was analyzed and the results are 
shown in Table 6 . Any contamination o f step 1 hydrolysis in group 1 tubes came 
from HCl, since the tubes were prewashed with HNO3 . Comparing step 1 hydrolysis 
results between group 1 and group 2 (no prewash), the peak area (209) was reduced 
by 108% in group 1 (n=4). The result indicates that prewashing tubes with HNO3 can 
effectively reduce the contamination from glassware. There was no difference in 
peak area and ratios in step 2  hydrolysis between group 1 and 2  tubes which were 
similar to the area and ratios found after prewashing with HNO3 . This suggests that 
there is also contamination from HCl in step 2 of group 1 and group 2 tubes. The 
contamination associated with step 1 hydrolysis in group 2  tubes was from both 
glassware and 1 ml 6  M HCl. After increasing 6  M HCl volume to 5 ml in group 3 
step 1 hydrolysis, the peak area o f leucine was dramatically increased compared to 
group 2 step 1 hydrolysis (386%) and group 1 step 1 hydrolysis (707%). This also
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confirmed that HCl itself can be source o f  contamination.
Samples Step 1 hydrolysis Step2 hydrolysis209 (m) 210(m +l) (m +l)/m 209 (m) 2 1 0  (m+ 1 ) (m+ 1 )/m
1-HN03 1191 35 0.029 784 73 0.093
2-HN03 540 49 0.091 919 2 0 0 . 0 2 2Group 1 3-HN03 959 85 0.089 730 69 0.095(n=4) 4-HN03 103 0 0 . 0 0 0 1048 93 0.089
Mean 698 42 0.052 870 64 0.075
l-H CL(lm l) 345 29 0.084 1061 99 0.093
2-HCL(lml) 1746 157 0.090 708 62 0.088Group 2 
(n=4) 3-HCL(lml) 2186 2 0 2 0.092 865 77 0.089\ i i  -rj 4-HCL(lml) 1558 142 0.091 901 8 6 0.095
Mean 1459 133 0.089 884 81 0.091
l-HCL(5ml) 1718 25 0.015 1274 119 0.093
2-HCL(5ml) 7850 749 0.095 1269 1 2 2 0.096Group 3 
(n=4) 3-HCL(5ml) 1245 117 0.094 977 92 0.0944-HCL(5ml) 11735 1082 0.092 2474 231 0.093
Mean 5637 493 0.074 1499 141 0.094
Table 6  Comparison o f step 1 and step 2 hydrolysis from glass tubes with or without washing 
with HQVO3
Data from GC-MS detennination, the peak area o f  ^^C-leucine derivative (M olecular weight is 209) 
and ^^C-leucine derivative (Moleculai-weight is 210). 209 (m): 210(m): m +l/m .
The contamination fiom HCl and other chemical reagents was unavoidable, thus the
amount of HDL samples used for emichment analysis were increased when loaded
on SDS-PAGE, ie after delipidation of 400 fil HDL fiaction, samples were dissolved
in 70 pi sample buffer and 50 pi sample (71.4%) was loaded onto SDS-PAGE. The
mean leucine peak area of 285 pi HDL fraction apoA-I (71.4% of 400 pi HDL
fraction used for delipidation, n=10) was 4.37 x 10*^  determined by GC-MS. The
contamination pealc area from 1 ml 6  M HCl was 0.016% of apoA-I peak area from
285 pi HDL fraction and the contamination from both glassware and 1 ml 6  M HCl
was 0.033% of pealc area from 285 pi HDL fiaction. Wlien the sample size was large,
the contamination from 1 ml 6  M HCl and glassware would have a relatively small
effect on the determination o f apoA-I enricliment in total HDL.
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3.3.3 Measurement of the contamination from polyacrylamide gel
Table 7 shows data from 1 cm^ of gel samples, which were the same size as the 
apoA-I bands excised from the gel for the kinetic study. Comparison of gel samples 
which were either non-stained or stained with silver showed no significant difference 
between peak area and tracer/tr-acee ratio (210/209). This indicates silver staining 
may not introduce contamination to enrichment measurement.
Gel samples Nonstained gel Stained gel
(n=3) 209 2 1 0 (m +l)/m 209 2 1 0 (m+l)/m
S g -l( l cm^) 4540 429 0.094 4412 425 0.096
Sg-2(1 cm^) 2496 246 0.099 2429 236 0.097
Sg-3(1 cm^) 2873 271 0.094 2488 228 0.092
Mean 3303 315 0.096 3110 296 0.095
p* 0.84
HDL (300) 544732 52782 0.097 473025 45575 0.096
HDL (390) 592760 57780 0.097 596720 58542 0.098
HDL (420) 459367 44877 0.098 579388 56954 0.098
Mean 532286 51813 0.097 549711 53690 0.098
Gel/HDL (from 100 pi) 0.62% 0.57%
Gel/HDL (from 285 pi) 0.08% 0.07%
p* 0.77
Table 7 Comparison o f contamination from SDS-PAGE with or without staining
Data from GC-MS determination, tlie peak area o f *^C-leucine derivative (M olecular weight is 209) 
and ‘^ C-leucine derivative (M olecular weight is 210). 209 (m): 210(m): m + l/m ; 300, 390 and 420 are 
sampling times in minutes. Fom* hundred pi HDL fr-action at 300, 390 and 420 minutes were 
delipidated and dissolved in 200 pi sample buffer for SDS-PAGE. Each sample was loaded on SDS- 
PAG with 50 pi, which equated to 100 pi HDL fraction. In apoA-I kinetics study, 400 pi HDL 
fr action were delipidated and dissolved in 70 pi sample buffer for SDS-PAGE. Each sample was 
loaded on SDS-PAG with 50 pi, which equated to 285 pi HDL fraction. Sg-1, 2 and 3; small size o f 
gel 1, 2 and 3. P*: impaired two tailed t-test between ion 209 peak area from nonstained gel and 
stained gel.
Table 7 also indicates tliat 1 cm^ non-stained bianic gel contributed to 0.62% of the 
peak area reading of non-stained apoA-1 originating from 100 pi HDL fraction, 
while 1 cm^ stained blanlc gel contributed to 0.57% peak area of stained apoA-1 fr om 
a 100 pi HDL fraction.
Table 8  shows the data from 3 cm^ gel samples which were three times the size of 
apoA-1 bands excised from gels for the kinetic study. There was no significant
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difference in peak area and tracer/tracee ratio between stained and non-stained gels. 
This again confirmed that silver staining may not introduce contamination. 
Contamination from 3 cm^ gel was higher than in 1 cm^ gel samples (Table 7 and 
Table 8 ). Therefore, by reducing the amount o f gel excised to 1 cm^, contamination 
from this source was minimised. The contamination from 3 cm^ gel samples 
contributed to as much as 1.1% of apoA-I peak area from 100 pi HDL fractions, but 
it only contributed to 0.13% of apoA-I pealc area from 285 pi HDL fractions (71.4% 
of 400 pi HDL fraction used for delipidation). The results also suggest that the use of 
a relatively lai'ger amount of sample can significantly reduce contamination and 
minimise its significance. Thus increasing sample size is a practical way to reduce 
the significance of contamination in this study.
Gel samples (n=3) Nonstained gel209(m) 210(m +l) (m +l)/m
Stained gel
209(m)210(m+l) (m +l)/m
Lg-1 (3 cm^) 7178 681 0.095 5720 542 0.095
Lg-2(3 cm^) 5640 532 0.094 5659 532 0.094
Lg-3(3 cm^) 4581 444 0.097 6593 613 0.093
Mean 5800 552 0.095 5991 562 0.094
Gel /  HDL (from lOOpI) 1.09% 1.08%
Gel/HDL (from 285 pi) 0.13% 0.14%
P* 0.83
Table 8  Contamination from polyacrylamide gel
Data from GC-MS determination, the peak aiea o f ^^C-Ieucine derivative (M olecular weight is 209) 
and ‘^ C-leucine derivative (M olecular weight is 210). 209 (m): 210(m): m +l/m ; Lg-1, 2 and 3: lai'ge 
size o f  gel 1 ,2  and 3. P*; unpafred two tailed t-test between ion 209 peak aiea from nonstained gel 
and stained bel.
The contamination from 4 M NH 4 OH solution and nanopure H 2 O (both used in the 
lEC) was also analyzed (data not shown) and results indicate these solutions also 
increased the contamination background during ion exchange chromatography when 
compared to a blank. However, tire levels were much smaller than that associated 
with polyacrylamide gels and contributed to a contamination o f less than 0 .0 1 % 
compared to a 285pl HDL fraction.
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3.3.4 Other possible means to minimise contamination
It was also possible to reduce contam ination during the consecutive injection of 
samples into the GC/MS by frequently changing (every 30 samples) the wash 
solvent (toluene) and removing the waste on the GC autosampler tray. Results 
suggest that this can reduce by up to 60% contamination in the blank control solvent 
sample. Blank samples (toluene only) were also included between each group of 
samples. The samples in an individual group were sequenced from low to high 
enrichment when loaded on GC-MS. I f  the last samples had a large concentration 
and high emichment, 3 blanlc solvent samples were run before the next group to 
reduce any contamination.
3.3.5 Isotopic enrichment, PR and FCR of apoA-I for the test study samples
Table 9 shows the lipid profile o f 4 diabetic subjects before and after the exercise 
intervention study ( 0  month and 6  months).
81 82 83 84 Mean
0 m 6 m 0 111 6 m 0 m 6 m 0 m 6 m 0 m 6 m
ApoA-I (tng/ml) 1.2 1.4 0.9 1.1 1.23 1.5 0.6 0.8 1.03=0.3 1.19+0.2
HDL-C (mM) 0.90 1.0 0.4 0.7 1.21 1.57 0,5 0.5 0.83=0.2 0.9+0.2
ApoA-I pool size 
(mg/kg) 37.4 45.9 34.0 40.1 47.3 56.6 21.1 26.4 353:5 422+6
BW (kg) 83.5 81.6 96.2 91.6 102.5 102.5 104 102.5 91.4 =t4.8 89.8+5.3
Table 9 Lipid profile o f 4 type 2 diabetic subjects before and after the exercise study
0  in indicates 0  month; 6  m indicates 6  months.
HDL apoA-I enrichment (APE) was determined at baseline and at timed intervals for 
9 hours as shown in Figure 31. Samples were analyzed from 2 hours, since 
enrichment was very low before this time due to the relatively low turnover rate o f 
apoA-I. The FSR o f HDL apoA-I was estimated using a regression model and 
kinetic analysis of tracer-to-tracee ratios achieved by fitting a regression line to the 
APE of apoA-I vs time data (Chapter 2, section 2.4, Equation 2, page 69). In this
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case (fasting study), the FSR is equal to FCR. The apoA-I PR was then calculated 
(Equation 3, page 69).
1.4
0.8LUCL< 0.6
0.4
0.2
0 2 31 4 5 6 7 8 9
Time (hour)
Figure 31 Comparison o f leucine enrichment o f apoA-I in 4 diabetic patients before and after a 
6 month exercise study
Results are presented as mean ± SEM (n=4). Blue diamond (♦) indicates the study at 0 month. Pink 
square (■) indicates the study at 6  months. APE: Atom percent excess.
The HDL apoA-I kinetic parameters are described in Table 10. Compared to the data 
at 0 month, HDL apoA-I PR and FCR at 6  months were not significantly different 
(n=4). All the data were in expected range.
Subjects ApoA-I FCR(pools/day) ApoA-I PR mg/kg/day
(n=4) 0  month 6  months 0  month 6  months
1 0.27 0.30 9.95 13.76
2 0.44 0.30 15.05 1 2 . 0 0
3 0.37 0.44 17.69 25.11
4 0.32 0.42 6.71 1 1 . 0 2
M eaniSEM 0.354=0.04 0.374=0.04 12.354=2.47 15.474=3.26
P ( 0  vs 6  month) 0.80 0.25
Table 10 HDL apoA-1 kinetic parameters
FCR: fractional clearance rate. PR: production rate.
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3,4 Discussion:
The enrichment cui*ve (Figure 31, page 84) from which apoA-I kinetic data were 
calculated showed that the isotopic enrichment o f leucine increased with time. The 
FCR and PR of HDL apoA-I in diabetic patients was similar to the apoA-I kinetics 
data from the patients with type 2 diabetes studied by Prenais et al (1997).
3.4.1 Separation of apoA-I from HDL fractions by SDS-PAGE
SDS-PAGE is a technique routinely used to separate proteins. In the cuiTent project, 
it was set up to isolate apoA-I fi'om HDL fractions separated by sequential 
ulti'acenti'ifugation. It was found that a 1 mm thick SDS-PAGE, could achieve a 
good separation of apoA-I and produce large non-overlaping protein bands for up to 
285 |Lil of the HDL fractions including total HDL, HDL2 and HDL3 after 
delipidation. Since apoA-I has a low turnover rate in plasma the leucine isotopic 
enrichment is low. However, applying a larger sample size onto SDS-PAGE allowed 
an accurate measurement of the isotopic enrichment of leucine by GC-MS.
3.4.2 Minimisation of contamination
During the determination o f isotopic enrichment of leucine by GC-MS, 
contamination cannot be completely removed because it not only comes from 
glassware but is also detected in the chemicals themselves used in the experiments 
(Dwyer et a l 2002). It was considered that if the contamination from background 
contributed to less than 5% of the leucine peak area, the results would not be 
significantly affected. The results confinned that contamination originated fi’om 
chemical reagents and glassware used in the experiment, however, by increasing 
sample size the contamination from the background became less significant and 
should not affect the kinetic data.
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3.4.3 The Idnetics of HDL fraction apoA-I from patients with type 2 diabetes
Compared to apoA-I PR in normal lean subjects from previously published studies 
(Ooi et a l 2006), the study showed that HDL apoA-I PR (12.354=2.47 mg/lcg/day, at 
baseline) was normal in the patients with type 2 diabetes. The 95% confidence 
interval of PR was 10.7 13.4 mg/kg/day in studies using stable isotopes (Table 11) 
(Ooi et a l 2006). However the HDL apoA-I FCR (0.354=0.04 pools/day) in the 
current study was much higher than that in these normal subjects (0.18 0 . 2 2  
pools/day, Table 11). This result is identical to the work of Frenais et al (1997) using 
stable isotopically labelled L-[5,5,5-^H] leucine, who studied HDL apoA-I kinetics 
in patients with type 2  diabetes not treated with exogenous insulin.
Variables Radioisotope
95%
confidence
interval Stable isotope
95%
confidence
interval P-valiie
Cholesterol (mmol L"’) 5 -1 0 i0 '1 3 (4-83-5-34) 4-15+0-15 (3-27-4-44) <0-001
Triglycerides (ramolL"’) b 0 9 i0 '0 7 (0-96-1-22) 0-74+0-07 (0-60-0-89) 0-002
Higli-densitjdipoproteiii (HDL)-cliolesterol (mniolL"’) 1-48+0-05 (1-38-1-58) 1-45 + 0-06 (1-33-1-56) 0-615
Low-deiisitj'lipoprotein (LDL)'Cholesterol (m inolL^) 3-15+0-11 (2-93-3-39) 2-42 + 0-14 (2-15-2-70) 0-001
Apolipoprotein A-I (apoA-I) (g L"‘) 1-26 + 0-04 (1-18-1-34) 1-40+0-05 (1-31-1-49) 0-052
H D L apoA-1 fractional catabolic rate (FCR) (pools day"') 0-24 + 0-01 (0-22-0-26) 0-20 + 0-01 (0-18-0-22) 0-02S
HD L apoA-I production rate (PR) (mg"' kg” ' day”') 12-4 + 0-55 (11-3-13-5) 12-1 + 0-67 (10-7-13-4) 0-767
Table 11 Clinical and biochemical characteristics o f lean subjects from radioisotope and stable 
isotope studies
Comparison between radioisotope and stable isotope study was performed using One-way ANOVA. 
P<0.05 was statistically significant (Ooi et a l 2006).
Their studies have shown that in comparison with normal subjects, HDL apoA-I 
FCR was significantly increased (0.394=0.016 vs 0.214=0.06 pools/day, f<0.05), 
whereas HDL apoA-I PR was not different from that of controls (Frenais et a l 
1997). The results thus suggest that in this group o f type 2 diabetic patients, the 
lower concentrations o f apoA-I and HDL-C were die result of increased FCR of 
HDL apoA-I.
86
ApoA-I concentration in plasma is determined by both its secretion rate and 
fractional clearance rate, however, the relative contributions of the PR and FCR to 
apoA-I concentration are still unclear. The isotopic method used to measure apoA-I 
kinetics has been shown to affect the conclusion. The data from 16 published 
radioisotope and 13 stable isotope studies were pooled together and the kinetic data 
were compared (Ooi et ah 2006). Table 11 shows the clinical and biochemical 
characteristics of the lean subjects from radioisotope and stable isotope studies (Ooi 
et a l  2006). Through a Pearson correlation analysis, the results from the 16 
radioisotope tracer studies suggested that in healthy subjects HDL apoA-I FCR was 
significantly correlated with HDL-C and apoA-I concentrations (r = -0.651, P < 
0.001 and r -  -0.542, P<0.001, respectively), whereas HDL apoA-I PR was not 
significantly correlated with HDL-C and apoA-I concentrations (r = -0.228, P — 
0.147 and r = 0.171, P = 0.279) (Ooi et a l  2006). In the case of stable isotope 
studies in healthy subjects, the results indicated that HDL apoA-I PR was the main 
determinant of apoA-I concentration (r = 0.414, P — 0.015) but not that of HDL-C 
concentration {r = -0.103, P  = 0.561) and no significant difference was found 
between the HDL apoA-I FCR and the concentrations of HDL-C and apoA-I (Ooi et 
a l 2006). The difference in methodologies and the subject characteristics may be the 
main reasons that led to these discrepancies. With exogenous labelling possible 
conformational changes o f lipoproteins/apolipoproteins during isolation and radio- 
iodination may change their physical and chemical properties and alter metabolic 
properties (Rashid et a l  2006). After the re-injection of exogenous labelled 
lipoproteins (tracer) into a subject, the particles are not recycled but result in the 
decay curwes (Ooi et a l  2006). With stable isotope labelling methodology, the 
compartmental model used may impact on the estimation of kinetic parameters by
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accounting for the return o f tracer from slow turn-over pools (Ooi et a l 2006). 
Finally, the subjects in the radioactive kinetic studies were relatively more 
dyslipidaemic (with high total cholesterol, TG and LDL-C) with lower apoA-I 
concentrations than the subjects in the stable isotope studies. This may also result in 
a difference between stable and radioactive studies (Ooi et a l 2006).
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Chapter 4 Development of 2-dimensional electrophoresis
4.1 Introduction:
Ultracentrifugation is a robust and effective method for the separation o f lipoproteins 
and has been used to determine the kinetics of apoB and apoA (Ikewaki et a l 1993). 
Traditionally, plasma lipoproteins and HDL (1.063<d<1.21 g/ml) are separated by 
sequential ultracentrifugation based on differential flotation. However, reports 
suggest that a combination of high salt concentrations (NaBr is used in 
ultracentrifugation) and high centrifugal forces may damage the integrity of certain 
HDL subpopulations and lead to the dissociation of apoA-I from HDL (Kunitake & 
Kane 1982; Cheung & W olf 1988). Furthermore lipid-poor or lipid free apoA-I 
cannot be completely recovered in the density range of 1.063<d<1.21 g/ml, but is 
also present in the density range of d>1.21 g/ml (Cheung & Albers 1979). 
Approximately 5% apoA-I and 9% apoA-I were observed in the density range of 
1.21<d<1.25 g/ml and d>1.25 g/ml respectively (Cheung & Albers 1979). In the 
study by Cheung & W olf (1988), 4-14% apoA-I was measured in the density range 
greater than 1 . 2 1  g/ml fr action.
A previous study compared HDL fractions isolated by FPLC and sequential density 
ultracentrifugation (1.063<d<1.25 g/ml) using 2-dimensional electrophoresis (Figure 
32) (Chetiveaux et a l  2002). This study suggested that during the ultracentrifugation 
procedure, not only was pre(3HDL lost, but that some of the aH DL subclass particles 
were also affected. Larger a-migrating particles have also been reported to be found 
in the density range greater than 1.21 g/ml (Asztalos et a l 1993). Thus in the density 
range larger than 1.21 g/ml, the apoA-I may not only originate from pre(3HDL but 
may also have been dissociated from mature aHDL and also contain a small amount
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of aHDL. If dissociated apoA-I from aHDL joined the prepHDL pool, the 
interpretation of kinetic data from pre^HDL and aHDL subclasses would be 
inaccurate. Taking this into consideration, ultracentrifugation cannot be used to 
determine the kinetics of prepHDL. Thus it is necessary to find a new method that 
avoids both disturbing HDL subpopulation integrity and losing the prepHDL class. 
The primary aim of this project was to set up a method that enables the measurement 
of both aHDL and prepHDL kinetics.
aHDL prap.-HDL
aHDL
m
\
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HDL Isolated by FPLC Standard
Figure 32 Western blotting with anti-apoA-1 o f a two-dimensional electrophoresis o f total HDL 
isolated by ultracentrifugation and FPLC followed by apoA-I immunoblotting
(Chetiveaux et al. 2002).
To measure HDL subclass kinetics, it is very important to separate the particles 
intact first and then apoA-I in these particles can be further separated and analysed. 
To avoid the possible structural and compositional changes of HDL particles caused 
by sequential ultracentrifugation, a modified 2-dimensional electrophoresis (2-DE) 
was set up to separate apoA-I directly from plasma based on both charge and 
molecular weight.
Traditional 2-DE is a method that separates proteins based on their isoelectric point 
in the first dimension by isoelectric focusing and molecular weight in second
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dimensional SDS-PAGE, To enhance the resolution of 2-DE, protein samples have 
to be fully denatured, disaggregated, reduced and solubilised to achieve complete 
dismption of molecular interactions. This ensures that each spot represents an 
individual polypeptide (Gorg et a l 2004).
Unfortunately, the tiaditional 2-DE technique is not suitable for the separation of 
HDL particles. However, a modified 2-DE method has been reported which allows 
the isolation of HDL subclass particles (Asztalos et a l 1993). In this modified 2-DE 
protocol, HDL fiom plasma was divided into 11 distinct subclasses on non­
denatured PAGE after the separation of pre(3HDL, aHD L and preaHDL on an 
agarose gel (refer to Figure 7, page 22). In combination with immunodetection, the 
technique proved to be a robust method which facilitated the comparison of HDL 
subclass profiles between normal physiological and pathological conditions 
(Asztalos et a l 2004). However, this method is not suitable for the quantification of 
leucine enrichment of apoA-I because of the existence o f other proteins in HDL 
subclasses. ApoA-I containing HDL subclasses may overlay with other proteins (of 
similar molecular weight) during the 2-DE separation process. Without western 
blotting, it is difficult to detennine the position of apo A-I containing HDL on a gel. 
Even if  the apoA-I containing particles were excised from the polyaciylamide gel, 
fiirther extraction of apoA-I from the gel followed by a delipidation procedure and 
isolation from other HDL proteins would make this methodology more complex.
In order to detennine apoA-I isotopic enrichment in each apoA-I containing subclass, 
a different modified 2-DE was investigated. This method combines a non-denatured 
first dimensional agarose gel and a denatured second dimensional SDS-PAGE 
separation. With this method, a relatively large plasma sample was loaded onto an
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agarose gel. After separation of prepHDL and aHDL by agarose electrophoresis, 
individual bands of prepHDL and aH D L were excised. Proteins were extracted from 
the agarose gel bands with SDS solution. This allowed the isolation o f apoA-I from 
both aHDL and prepHDL by SDS-PAGE. This novel application of the 2-DE 
technique enables the analysis of the kinetics of prepHDL and aHDL kinetics 
simultaneously. Western blotting was earned out to confimi the apoA-I position on 
SDS-PAGE.
4.2 Development of a two dimensional electrophoresis separation
4.2.1 Agarose gel electrophoresis (dimension 1)
A flat-bed agarose electrophoresis system was used to separate HDL subclasses from 
plasma. General use agarose (gelling temperature: 36°C) with low electro- 
endosmosities (LE) was used. After lunning the gel at 250 V for 1 hour, the running 
buffer temperature was found to increase up to 70°C. The gel was dried with layers 
o f filter paper and stained using a silver stain kit, but no proteins were observed, 
possibly due to an overheating effect. To solve this temperature problem, pre-cooled 
running buffer and an electrophoretic cassette were used in combination with placing 
the cassette on ice in a large glass tiay while lunning the gel. A lower voltage (170 
V) was also applied. These measures decreased the buffer temperature to 40“C. 
However, there were still no clear protein bands obseived as the gel was completely 
dark after silver staining. Several possible causes were investigated. These included 
the staining method, contamination from the filter paper and an investigation of the 
type of agarose used for electiophoresis. Coomassie blue R250 staining system was 
used instead of the silver stain. Western blotting was also used to detennine apoA-I 
directly through transferring protein particles to nitrocellulose membrane to avoid
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any possible contamination from filter paper used to dry the gel. However, all these 
efforts did not yield good results until LE agarose with a high gelling temperature 
(42°C) was tested. To maintain the running buffer at low temperature, a flat-bed 
electrophoresis cassette with a water cooling system was used. In addition, the 
running buffer inside the cassette had to be replaced with pre-cooled running buffer 
half way through the electrophoretic separation.
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Figure 33 Comparison o f staining agarose gel with coomassie blue R250 and silver stain
A: the first half o f the gel was stained with 0.125% coomassie blue R250, B: the other half o f the gel 
was stained with silver. C: HDL was isolated with gradient density ultracentrifugation and stained 
with amido black (from (Biere et al. 1996), shown for comparison). Green arrow indicates the 
position o f prePHDL; red arrows indicate the position o f aH D L; blue arrow indicates the position o f 
albumin; Al: pure human apoA-I, AL: human albumin. Std: standard human plasma protein. Alb: 
albumin, a l  : a l  globulin, a 2 : a 2  globulin, p: P globulin, y: y globulin.
To determine how much sample could be detected on the gel, different amounts of 
plasma 5, 10 and 15 pi were loaded onto the gel. After electrophoresis, the gel was 
cut into two halves and stained with a silver stain and coomassie blue R250 to 
demonstrate which was the most suitable staining method for the agarose gel. Good 
separation of aHD L and prepHDL was observed (Figure 33). Compared to the gel 
stained with silver (Figure 33B), the gel stained coomassie blue R250 (Figure 33A) 
had a better separation profile and was identical to that previously reported (Figure 
33C) (Biere et al. 1996). The silver stained gel showed that there was a long staining
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tail observed after the a-m igrating HDL band (Figure 33B). Being a more sensitive 
method, silver staining generally showed high background staining. These results 
suggest that a high gelling temperature agarose is important for flat-bed based 
agarose electrophoresis and that coomassie blue R250 stain is more suitable for this 
agarose gel application.
4.2.2 HDL separation on agarose gel
Lipoprotein particles are separated on the basis of surface charge on an agarose gel. 
Purified apoA-I has prep-migrating mobility and was used to identify the position of 
prepHDL (Asztalos et al. 1993). PrepHDL was shown to be located in the position 
of the yellow arrow in Figure 34. Albumin has a-migrating mobility and was used to 
identify the position of a-migrating HDL. aHDL was shown to be located in the 
position of the red arrow in Figure 34.
Al PL PL AL
Albumin
Figure 34 Plasma separation on LE agarose gel stained with 0.125% coomassie blue R250.
The red arrow indicates a-m igrating HDL; the yellow arrow indicates the preP-migrating HDL; the 
blue arrow indicates albumin. Al: pure apo A-I; PL: plasma; AL: albumin.
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To get an improved separation, different concentrations of agarose gel (0.5%, 0.6%, 
0.65% and 0.7%) were prepared to determine which percentage gave the best 
separation (Figure 35). Because of temperature problem, 0.5% agarose was not easy 
to handle and was removed from the comparison group. Results indicate that the 
0.6% gel achieved the best separation for a-migrating HDL and prep-migrating 
HDL (Figure 35).
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Figure 35 Comparison o f plasma separation profile on agarose gels with different 
concentration: 0.7%, 0.65% and 0.6% respectively
The gels were stained with 0.125% coomassie blue R250. A: 0.7% agarose gel. B: 0.65% agarose gel. 
C: 0.6% agarose gel. The red arrows indicate a-m igrating HDL. The purple arrows indicate 
prePHDL. AL: albumin; PL: plasma; HDL: HDL fraction from ultracentrifugation (1.063<d<1.21 
g/ml).
4.2.3 Effect of sequential ultracentrifugation on HDL particles and apoA-I
To detect how ultracentrifugation o f plasma samples affected the migrating profile 
on agarose, an HDL fraction isolated by sequential ultracentrifugation 
(1.063<d<1.21 g/ml) was analyzed on an agarose gel. Only aHD L was observed 
(Figure 36). This result indicates that as expected prepHDL was lost during the 
isolation of HDL particles using sequential ultracentrifugation within the density 
range between 1.063 g/ml and 1.21 g/ml.
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Figure 36 Comparison o f the separation profile o f an HDL fraction (1.063<d<1.21 g/ml) from  
sequential ultracentrifugation with that o f plasma on an agarose gel.
The HDL fraction has only one band in the a-m igrating position. PL: plasma; HDL: HDL fraction 
isolated by sequential ultracentrifugation. The red arrows indicate a-m igrating HDL; The purple 
arrow indicates prepHDL.
4.2.4 SDS-PAGE electrophoresis (dimension 2)
After setting up the first dimensional agarose electrophoresis, the second 
dimensional electrophoresis was tested using a denatured SDS-PAGE. After agarose 
electrophoresis, the agarose gel was stained with coomassie blue R250 overnight and 
treated with 300 ml destain solution for 2 hours three times. The lane containing the 
sample was excised from the agarose gel. The proteins in preaHDL, aHDL and 
preP-migrating HDL were separated on SDS-PAGE by placing the lane of agarose 
on the top of a polyacrylamide gel (Figure 37A). The apoA-I migrating position was 
identified using a prestained standard protein with known molecular weight (Figure
37). Although in the agarose gel, a prea HDL was not always clearly observed, an 
apoA-I band was very clear in the second dimension. This may be due to the agarose 
gel not being destained for long enough, so that the preaHDL band could not be 
distinguished from the blue background. The gel (Figure 37A) did not show a clear 
separation of the apoA-1 from different isolated HDL subclasses. This would make it 
difficult to determine the enrichment of apoA-I from specific HDL particles.
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Figure 37 Second dimensional SDS-PAGE
A: After plasma separation on agarose gel and the gel was stained with coomassie blue R250, each 
lane was excised and placed on the top o f the 4-10% discontinuous SDS-PAGE, B: Individual bands 
rather than the whole lane were excised from the agarose gel after staining with coomassie blue R250 
and put into the individual wells. The green arrows indicate the possible postion o f apo A-I.
In order to isolate apoA-I from individual HDL subclasses, the comb used to set up
the second dimensional SDS-PAGE was modified. Several small wells were
prepared instead of the one long well. After the first dimensional agarose gel was
stained with coomassie blue R250, the different bands were cut from the gel and put
into the individual wells (Figure 37B). Using this technique, the proteins from the
different particles were clearly separated making it possible to measure apoA-I
enrichment from different HDL particles.
4.2.5 Identification of apoA-I on the second dimensional SDS-PAGE
Because the agarose gel strips from the first dimensional electrophoresis were put on 
the top of the SDS-PAGE without any previous treatment, there was the possibility 
that the proteins in these bands could migrate on SDS-PAGE either as a single
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protein, intact particles or as particle remnants. SDS in the sample buffer and 
running buffer is a detergent, which gives proteins a negative charge thus migration 
in gels is dependent on molecular size. Therefore, to confirm that the band below the 
31 kDa standard protein band was apoA-I, western blotting was carried out (Figure
38).
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Figure 38 Comparison o f second dimensional SDS-PAGE stained with coomassie blue R250 and 
western blotting.
After the first dimensional agarose gel stained with coomassie blue R250, two whole lanes o f 
separated plasma were excised and placed on the top o f the SDS-PAGE, A: H alf o f the SDS-PAGE 
stained with coomassie blue R250. B: Transfer o f the protein from the second half o f the SDS-PAGE 
to a nitrocellulose membrane. ApoA-I was detected by immunoblotting. PL: plasma; Std: prestained 
standard proteins; a : aH D L; pre(3: preaHDL; p: P migrating band and Ori: origin o f the plasma 
sample on first dimensional agarose gel. The red ellipse indicates a long tail observed in aH D L lane. 
The red arrow in Figure A indicates possible apoA-II migrating postion and that in Figure B indicates 
apo A-1 migrating postion.
SDS-PAGE was prepared and two agarose gel strips were put on top of the SDS- 
PAGE. After electrophoresis, the gel was cut into two halves. One half was stained 
with coomassie blue R250 and the other half was used for western blotting by
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transfeiTing the proteins to a nitrocellulose membrane by electrophoretic ti'ansfer 
(Figure 38). Western blotting with an apoA-I antibody indicated that apoA-I was 
present in preaHDL, aHD L and prepHDL. ApoA-I was also observed in the p- 
migrating particle and in the origin of the agarose gel. In the p rea particle, another 
band was observed at 16 IcDa, which possibly was apoA-II, however, this needed to 
be confinned by further experiments such as western blotting with an apoA-II 
antibody or comparison with a pui'e apoA-II standard. A long tiail above apoA-I was 
obseiwed along the aH D L lane (Figure 38, red ellipse). This may be either a non­
specific reaction, or apoA-I protein bound to the HDL subclass particle remnants.
Therefore, an important question to consider is how apolipoproteins in HDL subclass 
particles migrate in the second dimensional SDS-PAGE immediately after HDL 
subclasses are separated by an agarose gel. It is unclear how SDS in the buffer and 
gel affects particle structure and the association between lipid and apolipoproteins, 
as proteins may combine with lipids and migrate in the form of particles or particle 
remnants.
4.2.6 Effect of SDS (in gel and buffers) on protein migration
Two dimensional electrophoresis and western blotting were can ied out to detennine 
how SDS affects the association between proteins and lipid (Figure 39). After aHDL 
and prepHDL were isolated from 20 pi plasma, the whole agarose gel lane was 
excised and put on the top of SDS-PAGE (labelled as a-ori. Figure 39). The lane PL 
shows proteins separated from 20 pi plasma which were directly loaded on the SDS- 
PAG without delipidation. Western blotting with an apoA-I antibody showed that 
plasma proteins separated in one dimension by SDS-PAGE had a large amount of 
apoA-I in the position of the 190 kDa standard, which fell into the molecular weight
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range of a  HDL particles (Figure 39B yellow arrow). A considerable amount of 
apoA-I was found in the position of 31 kDa and this should be pure apoA-I (Figure 
39B, red arrow). A similar result was also observed in the migration of aHDL 
particles (Figure 39B, pink arrow). However, two other bands were also observed 
(Figure 39B, green and blue arrows).
a  prep p Ori PL Std a  preP p Ori PL Std
S  Æ  190kd ^
i 2 5 k d  , #
■ 4 ^82kd
lOkd 
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#
Figure 39 Two dimensional electrophoresis and western blotting
After 2-DE, the proteins were transferred to the nitrocellulose membrane by pressure distribution for 
3 hours at room temperature. The membrane was incubated with antibodies and apoA-I detected by 
immunodetection. A: SDS-PAG stained with coomassie blue R250 after pressure transfer. B: ApoA-1 
was immunolocalised on the nitrocellulose membrane stained with an AP stain system, a : aH D L, 
preP: prePHDL, P: P migrating band and Ori: origin o f the plasma samples from first dimensional 
agarose gel. Different colour arrows indicate the apoA-I spot detected by western blotting.
Western blotting indicates that the SDS in the running buffer (0.5% SDS) and gel
(0.1% SDS) itself may not be able to dissociate apoA-I completely from HDL
particles. Thus a further step is needed to treat the agarose gel band containing HDL
subclasses before carrying out the second dimensional electrophoresis. Several
different methods were investigated as described below.
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4.2.7 Investigation of methods to extract proteins from agarose gel
4.2.7.1 Heating method
Fifty pi plasma was separated on an agarose gel and stained with coomassie blue 
R250. Individual aHDL and prepHDL agarose bands were excised from the gel. The 
gel bands were freeze-dried to remove all the destaining solution. Then 200 pi 
sample buffer (pH 6 . 8  with 0.5% SDS) was added and the samples which were 
heated at 110°C in a heating block for 5 minutes. This allowed SDS to fully react 
with proteins and separate them from lipid in the agarose bands. The melted agarose 
was then loaded onto a SDS-PAG (Figure 40A). The SDS-PAG was silver stained as 
described in Chapter 2, section 2.2.8 (page 57) instead of coomassie blue R250, 
because silver staining is a more sensitive protein staining method.
a  prep AI/AII a Std
ApoA-I
ApoA-II
A Bl
Figure 40 Separation by SDS-PAGE of proteins extracted from aH D L and prePHDL using 
heating and isopropanol
A: aH D L and prePHDL bands were heated in sample buffer and proteins were isolated by SDS- 
PAGE. B: Agarose and proteins with large molecular weight in aH D L and prepHDL bands were 
precipitated with isopropanol and the small proteins were retained. Pure apoA-I and apoA-lI were 
used as standards, a : aH D L, preP: prePHDL, AI/AII: apoA-I and apoA-II. Std: standard proteins with 
known molecular weight Red arrow indicates apoA-1 and Blue arrow indicates apoA-Il.
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This method had two problems. The first one was a large sample volume (>250 pi) 
after melting the agarose gel due to the large size of agarose bands. This exceeded 
the maximum voliune o f the sample well for loading samples, which is 60 pi on a 1 
mm SDS-PAG. This required a large loading sample well on SDS-PAGE. A 3 mm 
thickness SDS-PAG was prepared, but this required a longer staining time. The 
second problem was that it was difficult to apply the melted gel to the SDS-PAG 
because o f its high temperature. The plastic pipette tips used for loading samples 
were twisted by the high temperature, however when the temperature decreased, 
samples (with the melted agarose gel) would stick in the tips. As soon as the tip was 
put into the gel cassette, the mnning buffer cooled samples down immediately. This 
method resulted in a large loss of sample material. Figure 40A shows that the bands 
are faint and that the main cause of loss included the low amount of samples loaded 
and a thicker SDS-PAG (3 mm). Thus this method is not practical or effective and 
was not used for the kinetic study samples.
4.2.7.2 Isopropanol precipitation
The aim of this method was to use isopropanol to precipitate proteins with large 
molecular weight and agarose and retain the proteins with small molecular weight 
including apoA-I in the solvent. This method has been previously used to precipitate 
apoB in plasma and has proved to be veiy effective (Beghin et a l  2000). Fifty pi 
plasma was separated on agarose gel and stained with coomassie blue R250. 
Individual aHDL and prepHDL agarose bands were excised from the gel. 
These aHD L and prepHDL agarose bands were collected in 10 ml heat resistant 
round bottom glass tubes and the volume of each band was estimated by weight. 
Three times this volume o f sample buffer was added to the bands which were then 
heated at 110°C in a heating block for 5 minutes. The tubes were cooled to 50°C and
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an equal volume of ice cold isopropanol added to the melted agarose gel. The 
samples were vortexed and a white floccule formed. The samples were then 
centrifuged at 4000 rpm (3684 x g) for 30 minutes at 1°C. The supernatant was 
transfeiTed to a new 10 ml vial by decanting and the precipitated agarose and large 
proteins were discarded. The solvent was removed by a speedvac system (Savant 
SC210A, Theiino Fisher Scientific Inc, Waltham, MA, USA). Seventy pi sample 
buffer (pH 6 .8 ) was then added to dissolve the proteins. Samples were then applied 
to SDS-PAGE. As shown in Figure 40B a large amount of protein was also lost with 
this method.
4.2.7.3 Precipitation with methanol/diethyl ether
Precipitation with methanol/diethyl ether (1:1, v:v) was also investigated as a 
metliod to remove the gel and precipitate proteins. The experimental design was to 
first precipitate agarose and proteins at the same time and remove all the solvent, 
acetic acid, water and coomassie blue R250. The second step separated the agarose 
gel and proteins. At room temperature proteins but not agarose dissolve in sample 
buffer. The proteins and agarose can be easily separated by cenh'ifugation after 
adding sample buffer. Proteins can then be concentrated by fi'eeze diying. In detail, 
the method was as follows. Fifty pi plasma was separated on agarose gel and stained 
with coomassie blue R250 and individual aHDL and prepHDL agarose bands were 
excised from the gel. These aH D L and prepHDL agarose bands were collected in 
1 0  ml heat resistant round bottom glass tubes and the volume of each band was 
estimated by weight. Three times this volume in sample buffer was added and then 
the bands were heated at 110°C in a heating block for 5 minutes. The melted gel was 
cooled to approximately 50°C before it reformed a gel and then 8  ml ice cold
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methanol/diethyl ether (1:1, v:v) was added to the tubes. The samples were vortexed 
and then centiifuged at 4000 rpm (3684 x g) for 30 minutes at 1°C. Agarose and 
proteins were precipitated together after centiifugation. However, the precipitate was 
veiy solid and difficult to dissolve and mix well in sample buffer. Thus, it was 
difficult to tell if proteins were completely dissolved in the buffer and this method 
was not investigated fuither.
4.2.7.4 SDS extraction procedure
Mukai et al (2003) have shown that 1% SDS solution can be used to extiact the 
proteins from an agarose gel. Wlien an excised agarose gel band which had been 
thinly sliced was immersed in 1% SDS solution, an equilibrium in protein between 
the gel and 1% SDS solution was achieved in 10 minutes (Mukai et a l  2003). To 
investigate this method, aH DL and prepHDL bands were cut into small pieces. SDS 
solution (1%) was added to each vial. However, the extraction procedure required a 
large volume of SDS solution to extract proteins because there was a large volume of 
gel. Therefore a large amount of SDS would be introduced into samples and lead to a 
large volume of sample buffer (200 pi) required to dissolve them. This will then 
cause a problem with SDS-PAGE as the sample volume is limited by the size of 
wells on the gel. To overcome this problem, the agarose bands were cut into flat 
slices (thickness of approximately 1 mm) and freeze-dried (Figure 41). Three ml 1% 
SDS solution was added to the vial and 2 ml solution was taken out after 2 hours 
when equilibrium had been achieved. It was shown to be achieved in 10 minutes by 
Mukai et al (2003). Thus 2/3 (66.7%) proteins were extracted in this method. This 
also allowed the calculation of the proportion of proteins extracted each time when 
an equilibrium was reached between the gel and solution (Figure 41, page 105). The
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effectiveness of the SDS extraction procedure with and without a pre-treatment 
freeze-drying step was compared.
3ml SDS  
added
3 hours
room temperature
2 ml SDS was 
transferred out 
after equilibrium
Figure 41 Schematic diagram of SDS extraction
A: After plasma aH D L and prepHDL were separated on agarose gel and stained with coomassie blue 
R250, individual aH D L and prepHDL bands were excised. The agarose bands were then cut into 
small pieces and fi-eeze-dried, which then had a very small volume. B; After adding 3 ml 1% SDS 
solution, the gel was hydrated and proteins were dissolved in SDS solution. Equilibrium was reached 
after 2 hours at room temperature. C: After equilibrium 2 ml solution was transferred to a new dram 
vial. It contains the same concentrations as the vial B, thus the percentage o f proteins transferred is 
66.7%.
Experiment A: One hundred and fifty (150) pi plasma was separated on an agarose 
gel. Individual prepHDL and aHDL bands were washed three times with 3 ml 1% 
SDS solution after staining the gel with coomassie blue R250. The extracted proteins 
were concentrated by freeze drying to remove water and then 1 0 0  pi sample buffer 
was added to the sample. Fifty pi (50% of the sample) of sample was applied onto an 
SDS-PAGE (Figure 42A). Experiment B: Seventy five pi plasma was separated on 
agarose gel. In this experiment, individual aHDL and prepHDL bands were sliced 
and tfeeze-dried before they were washed three times with 3 ml 1% SDS. The 
extracted proteins were concentrated by freeze drying to remove any water and then 
100 pi sample buffer was added to the sample. Fifty pi sample was applied onto an 
SDS-PAGE. Although the amount of plasma loaded onto agarose in experiment B 
was half that of experiment A, the apoA-1 band (Figure 42B) was stronger. This
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result indicates that freeze-drying the agarose bands improves the SDS extraction 
procedure.
std origin aH D L preP H D L  apoA-Iex H D l
150kd —
150kd
OOkd
250 kd
150kd
lOOkd
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B
Figure 42 Separation by SDS-PAGE of proteins extracted from aH D L and prepHDL using SDS
A : proteins from 150 |il plasma (without freeze-drying agarose bands), B proteins from 75 pi plasma 
(with freeze-drying agarose bands). Origin: the origin o f samples on agarose gel; apoA-I: pure apoA- 
I; apoA-I from agarose: pure apoA-I was loaded on the agarose gel and then extracted from the gel 
with 1% SDS solution.
Western blotting was carried out to identify apoA-I after proteins were extracted 
with SDS. Fifty pi plasma was separated on the U  dimensional agarose gel and 
individual aHDL and prepHDL bands were excised, thinly sliced and freeze-dried 
overnight. After washing three times with 1% SDS, the extracted proteins were 
concentrated by a freeze dryer to remove any water and then 1 0 0  pi sample buffer 
was added. Fifty pi sample was then applied onto an SDS-PAG (Figure 43A). Figure 
43B shows the western blot o f this gel. Proteins were transferred from the SDS-PAG 
to a cellulose membrane by pressure distribution. After 4 hours transfer, the SDS- 
PAG was stained with silver stain and apoA-I was detected on the cellulose 
membrane by immunodetection (Chapter 2, section 2.2.9, page 58). The results 
indicated that a substantial amount of apoA-I from aHDL and prepHDL was 
isolated from the agarose gel after the SDS extraction procedure.
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Figure 43 SDS-PAGE migrating profile o f proteins extracted from agarose gel with 1% SDS 
and its duplicate western blot.
A: SDS-PAG was stained with silver stain kit. B: western blot. Proteins were transferred to the 
nitrocellulose membrane by pressure distribution, which generated a duplication o f the protein 
migrating pattern on the membrane. The red arrows indicate the apoA-I from aH D L and prefîHDL 
respectively.
4.3 Preliminary study to determine prePHDL and aHDL kinetics 
with 2-dimensional electrophoresis
4.3.1 Subjects
To explore the possibility of using agarose electrophoresis combining with SDS 
extraction method to separate and measure the kinetics of apoA-I in aHDL and 
prepHDL, a healthy female volunteer was recruited. Table 12 shows the physical 
characteristics of this subject.
A ge (year) 35 H D L -T G  (mmol/1) 0.06
B W  (kg) 65 L D L -C  (mmol/1) 1.52
H eigh t (cm ) 172 L D L -T G  (mmol/1) 0.16
BM I (kg/m ^) 21.97 PL-C  (mmol/1) 3.04
H D L -C  (mmol/1) 1.02 P L-T G  (mmol/1) 0.52
Table 12 Characteristics o f subject
PL: plasma; C: cholesterol; TO: triglyceride; BW: body weight; BMI: body mass index.
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4.3.2 Methodology
This preliminary study used the same clinical protocol described in Chapter 2
(section 2.1, page 52), except that there was an additional blood sample at 3 hours.
Two dimensional electrophoresis was applied to analyze these samples. To minimize
contamination effects, a large sample size was applied. In brief, 160 pi plasma
samples were loaded onto agarose gel to separate aHDL and pre(3HDL at 170 V for
3 hours. After staining with coomassie blue R250, individual aH D L and prepHDL
bands were excised and proteins were extracted with 1% SDS solution 4 and three
times respectively. The extracted proteins were concentrated by freeze-diying and
then 150 pi sample buffer was added (pH 6.8). ApoA-I was isolated by SDS-PAGE
as described in Chapter 2 section 2.2.8 (page 57). The apoA-I bands were excised
from the gel, hydrolyzed by 1 ml 6 M HCl, purified by ion exchange
chromatography, then derivatised and analysed by GC-MS (Chapter 2 from section
2.2.10 to 2.2.13, page 59 to 63). Thus the analytical procedure was the flowing:
Agarose electrophoresis—>Freeze dry prep and aHDL bands SDS extraction 
^SD S-PA G E —^ Hydrolysis —> lE C —>Derivatization—>GC-MS
4.3.3 Results
GC-MS results indicated that the average peak area of leucine from aH D L was 1.8x 
10  ^ and that of prepHDL was 6.5x10"^. The relatively smaller peak area of prepHDL 
made it difficult for GC-MS to determine the '^C enrichment. To overcome these 
problems, prepHDL derivatised samples were concentiated by evaporation using 
oxygen fi-ee nitrogen. In brief, prepHDL derivatives in toluene were exposed to 
oxygen free nitrogen to reduce the volume from 300 pi to 30 pi. After concentrating 
approximately 10 times, the leucine peak area from prepHDL was 0.3x10^ (more 
similar to aHDL) allowing enrichment to be measured. Figure 44A shows the GC-
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MS peak of leucine from aHDL and Figure 44B shows the GC-MS peak of leucine 
from pre(3HDL after being concentrated 10 times. Figure 44C shows the GC-MS 
peak of leucine from prepHDL before being concentrated.
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Figure 44 The abundance o f aH D L and pre|3HDL (concentrated 10 fold)
A: GC-MS result shows that the abundance o f  aH D L is very large, while the abundance o f prepHDL 
is smaller. To make the abundance o f prePHDL bigger, the prePHDL samples were concentrated 10 
fold. B: The abundance o f prePHDL after concentrating 10 fold. C: The abundance o f prePHDL 
before concentrating. The red arrows indicate the same range o f abundance (y axis) in figure B and C.
Figure 45 shows the enrichment o f a-KIC which was used as a measure of 
intracellular leucine enrichment. The plateau of a-KIC APE was 6.42%.
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Figure 45 a-ketoisocaproate (a-K IC) enrichment
APE; Atom percent excess.
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The enrichment o f apoA-I from aHDL and pre(3HDL is shown in Figui'e 46. The
FCR was calculated as described in Chapter 2 using Equation 2 (page 69). The FOR 
of prepHDL was 0.247 pools/day and aHD L was 0.19 pools/day respectively.
0.6
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0
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Figure 46 The isotopic enrichment o f leucine in apoA-I from prePHDL and aH D L
APE: Atom percent excess; Blue diamond ($): prepHDL; Pink square (□): aH D L
The GC-MS result indicates that this methodology can be used to determine the 
kinetics o f both aHDL and prepHDL at the same time. However, there is still a 
problem. In this preliminary study, 160 pi plasma was loaded on an agarose gel to 
separate aHDL and prepHDL. The aH D L and prepHDL bands were lai'ge because 
of the big sample size. After extracting aH DL for four times with SDS solution and 
prepHDL for three times, samples contained a large amount o f SDS (48 mg 
in aHDL and 42 mg in prepHDL) and coomassie blue R250 and required a 
relatively large volume o f sample buffer (150 pi) to dissolve. This caused problems 
in the isolation of apoA-I by SDS-PAGE. The sample became viscous after the 
addition of 150 pi sample buffer because of the lai'ge amount of SDS (final 
concentration of SDS was 28% for prepHDL and 32% for aHD L respectively).
110
When these samples were applied to SDS-PAGE, a portion o f sample remained in 
the bottom of the sample vials and another portion adhered to the loading tip. These 
samples required two sample wells, with a maximum capacity o f 60 pi. Thus at least 
20% of the sample was lost at this step. Generally, seven samples could be loaded 
onto the SDS-PAG at the same time. Using this technique, however, the maximum 
number of samples loaded on a gel was 5. At the same time, protein bands became 
quite diffuse and the apoA-I band from prepHDL was large but faint (Figure 47A).
ApoA-I
Figure 47 Comparison o f precipitated and non-precipitated prePHDL separated on SDS-PAGE
A: prepHDL extracted with SDS solution without precipitation, B: after extraction with SDS solution, 
prePHDL was precipitated with ethanol. Non-P: Non-precipitation; P: precipitation. Red arrow 
indicates apoA-1.
The reason for the large band may be because of the large volume but diluted 
samples. Coomassie blue R250 may also interfere with the migrating profile of the 
proteins. To overcome this problem, SDS and coomassie blue R250 had to be 
removed and proteins needed to be purified to improve the separation resolution on 
SDS-PAGE. The combination o f an ethanol precipitation and diethyl ether 
delipidation was investigated as a method to further precipitate and purify the HDL
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proteins from SDS, coomassie blue R250 and lipid. Addition of ethanol to the 
freeze-dried SDS-extracted proteins from agarose gel removed SDS, coomassie blue 
R250 and some lipid. The remaining lipid was removed by diethyl ether. This 
procedure may have resulted in a small amount of protein loss because of incomplete 
precipitation. A previous study suggested 95% of proteins were recovered with this 
method (Poison et a l  2003). However, further loss may occur when discarding the 
supernatant from the vials, because the protein deposits did not tightly adhere to the 
bottom of the vials.
The difference in loss rate between the precipitation and non-precipitation 
procedures was compared by mnning prepHDL (3 vs 3) and aH D L (4 vs 4) samples, 
from a study in which ’^C-leucine was infused to label apoA-I, on SDS-PAGE with 
the subsequent measurement of leucine from apoA-I by GC-MS (Figure 47). Figure 
47A and 47B show the SDS-PAGE migrating profile of proteins from prepHDL 
with and without precipitation after SDS-extraction respectively. A non-precipitation 
sample occupied two lanes due to the large volume of sample buffer added to 
dissolve sample, while a precipitation sample occupied one lane.
To quantify the results, apoA-I bands were excised, hydrolyzed and enrichment 
measured by GC-MS. Table 13 shows the GC-MS results. Compared to the non­
precipitation procedure, average peak areas of leucine from prepHDL and aHDL 
were increased by 107% and 22% in the precipitation procedure, respectively. After 
the precipitation treatment, 7 samples were isolated at the same time on one SDS- 
PAG (5 samples isolated on an SDS-PAG before the precipitation) and therefore the 
SDS-PAGE usage efficiency was improved by 40%.
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N on-precipitation Precipitation
samples 209
m
210
m+1
210/209
m +l/m samples
209
m
210
m+1
210/209
m +l/m
Prep
N1 1669644 153843 0.092
Prep
PI 3977479 352264 0.089
Prep
N2 3746715 349580 0.093
Prep
P2 8946398 835523 0.093
Prep
N3 2576029 239313 0.093
Prep
P3 3604369 333658 0.093
Mean 2664129 247579 Mean 5509415 507148
aHDL
N1 45568962 4168735 0.091
aHDL
PI 72009733 6640894 0.092
aHDL
N2 41635658 3948001 0.095
aHDL
P2 46361966 4405137 0.095
aHD L
N3 40223326 3813687 0.095
aHDL
P3 36294586 3459381 0.095
aHDL
N4 39854581 3781236 0.095
aHDL
P4 65675203 6267645 0.095
Mean 40571188 3847641 Mean 49443918 4710721
Table 13 Comparison o f the effects o f precipitation and non-precipitation on GC-MS
N1-N3 : non-precipitation samples 1 to 3; P I to P4: precipitation samples 1 to 4. 209(m): the peak 
area o f  ^ ^C-leucine derivative (M olecular weight is 209), 210 (m):^^C-leucine derivative (Molecular 
weight is 210). 210 / 209: the ratio o f  the peak ai ea o f  between ‘^ C-leucine derivative and '^C-leucine 
derivative.
The precipitation method also reduced chemical reagents and time consumed by 
running SDS-PAGE. Furthermore, it reduced the chemical waste generated during 
experiments such as silver stain. Thus this method was adopted for the determination 
o f prepHDL and aHDL apoA-I kinetics and the new analytical procedure was 
shown in the following flow chart:
Agarose electrophoresis—>Freeze dry prep and aHDL bands —> SDS extraction 
-^Precipitation^SDS-PAGE -^Hydrolysis lEC—>Derivatization—>GC-MS
4.5 Discussion
HDL is a group of heterogeneous particles and the kinetics of different subclasses 
may be different. Chétiveaux et al (2006) showed that the concentration of prep 
HDL-C and prePHDL apoA-I were increased despite the decreased concentrations of 
plasma apoA-I and HDL-C in patients with type 2 diabetes. aHDL-C and aHDL
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apoA-I concentrations were also decreased. Another study from a Chinese group 
also suggested that the smaller particle size HDL subclasses accumulated in the 
plasma of patients with type 2 diabetes and obesity (Xu et a l  2001a; Xu et a l  
2001b). These results indicate that different HDL subclasses may have different 
roles in the progression of type 2 diabetes and obesity. If  we are to understand the 
physiology of HDL it is important to determine the kinetics of individual HDL 
subclasses rather than treating them as a single group in these patients.
The relatively low concentration of prepHDL and the low turnover o f apoA-I makes 
it difficult to determine the kinetics of apoA-I in these particles. However, in this 
study prepHDL kinetics was measurable after increasing the volume of plasma 
loaded on the first dimensional agarose electrophoresis and then concentrating the 
derivatised sample before GC-MS. This is first time aH DL and prepHDL kinetics 
have been measured with this two dimensional electr ophoresis method. This method 
enabled the separation of prepHDL and aHD L without damaging their integrity.
4.5.1 Effect of sequential ultracentrifugation on HDL particles and apoA-I
As shown in Figure 36 (page 96), when an HDL fraction isolated by sequential 
ultracentrifugation in the density range of 1.063<d<1.21 g/ml was applied to an 
agarose gel, only aHD L was obser*ved. This confirmed the finding of Cheung & 
Albers (1979) that there was no prepHDL recovered in the HDL fraction in the 
density range of 1.063<d<1.21 g/ml.
4.5.2 Temperature control is critical for agarose gel electrophoresis
During the procedure to set up agarose gels, many problems were encountered. 
Because the agarose gel was run at a high voltage, a rise in temperature was the
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biggest problem. It is important to control temperatui*e, because the heat produced 
during electr ophoresis could lead to the syneresis of the gel and affect the migration 
of proteins and particles. Asztalos et al (1993) ran agarose gels in a vertical slab 
cassette and also had heat problems. This was overcome by using a recirculating 
cooler to maintain the temperature at 10°C (Asztalos et al. 1993). In the current 
study, a flat-bed electrophoresis cassette with a water cooling system was used to 
maintain the running buffer at low temperature. The running buffer was changed 
with pre-cooled running buffer during electrophoresis. LE agarose has been reported 
to be important in the isolation of HDL subclasses on agarose gel (Asztalos et al. 
1993). However, it was found that it was crucial to use not only LE agarose, but LE 
agarose with a high gelling point to separate HDL subclasses with horizontal flat-bed 
electrophoresis.
4.5.3 How SDS from sample buffer affects apoA-I separation by SDS-PAGE
In the western blotting experiment shown in Figure 38 (page 98) and 39 (page 100), 
proteins were transferred from gel to membrane by pressure distribution. Because 
this is not a full tr ansfer of proteins from the SDS-PAGE to the membrane as would 
occur with electrophoretic transfer, pressure distribution can provide an identical 
duplicate o f a gel and its membrane. This makes it easy to compare the position of 
proteins in the gel and membrane.
ApoA-I is not only found in HDL particles. It has also been described in TRL 
particles (Velez-Carrasco et al. 1999). Figure 38 (page 98) showed that apoA-I was 
obser-ved in |3-migrating particles as well as the origin and the latter could be derived 
from large TRL particles or may be non-specific binding backgrormd. In the plasma 
sample which was directly run on SDS-PAGE, westeru blotting showed a large
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amount of apoA-I in the upper position with a molecular weight o f around 190 IcDa 
(Figure 39B, yellow aiTow, page 100), however, it is difficult to tell whether this 
apoA-I came from aHD L particles, or a mixture of both aHDL and TRL particles. 
In both plasma (1 dimensional electrophoresis) and aHD L (2 dimensional 
electrophoresis), considerable apoA-I was obseiwed in the position of 31 IcDa (Figure 
39B, pink and red aiTows, page 100), which suggested that single apoA-I molecules 
were isolated from plasma and aHDL. However, two other bands were obseiwed in 
the upper position (Figure 39B, green and blue arrows). This may indicate that SDS- 
PAGE only partially isolated apoA-I from the aHDL particles when there was no 
previous treatment of proteins after the dimensional agarose gel. This result 
indicated that it was necessary to extract proteins from agarose gel before the 2"  ^
dimensional electrophoresis.
No apoA-I was observed in the prepHDL band either in the SDS-PAG stained with 
coomassie blue R250 or after western blotting (Figure 39, page 100). There are three 
possible reasons, i] The coomassie blue R250 staining method is not as sensitive as 
silver staining and ii] the staining and destaining steps in the coomassie blue R250 
procedure may cause protein loss, iii] ApoA-I from prepHDL was undetectable even 
with western blotting and this suggested that a relatively low amount of proteins 
were transferred to the nitiocellulose membrane by pressure distribution from SDS- 
PAG. ApoA-I from aH D L was observed on the western blotting membrane but not 
on the SDS-PAG, which also indicated that the coomassie blue R250 was not 
sensitive enough to determine a small amount of proteins.
To determine the kinetics o f apoA-I from HDL particles, apoA-I needed to be 
excised from the SDS-PAG. However, the results shown in Figure 37 (page 97)
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indicated that apoA-I isolated from 20 pi plasma was not sufficient for GC-MS 
analysis, not only for prepHDL, but also for aHDL. Thus in first dimensional 
electrophoresis, a large amount of sample was needed to be applied to the agarose 
gel. Proteins also needed to be exti*acted from the agarose gel and concentrated 
before loading onto the second dimensional SDS-PAGE, These steps enabled the 
measurement of prepHDL apoA-I isotopic enrichment and may reduce the 
significance of any contamination. The interference of proteins isolated by SDS and 
coomassie blue R250 in extracted HDL samples was avoided and good resolution 
was gained. The preliminary study indicated that after adjusting the plasma volume 
to 160 pi and extracting protein from agarose gel with an SDS exti'action procedure, 
apoA-I kinetics from both aHDL and prepHDL were measurable. However, the 
increase in the sample size loaded on agarose gel also resulted in the increase of 
sample size after extracting proteins from the aHDL and prepHDL bands with SDS 
solution. This meant that each sample needed 2 wells when separated on second 
dimensional SDS-PAGE ie the sample volume was too large to be loaded into a 
single well. To reduce this sample size and remove the extra SDS, treatment of the 
extracted aHDL and prepHDL with ethanol was also necessary before mnning 
second dimensional SDS-PAGE. This avoided the problem of requiring 2 
wells/sample on SDS-PAGE.
4.5.4 Comparison of Idnetics of aHDL and prepHDL separated by FPLC and 2- 
DE
The enrichment curve showed that the ^^C-leucine enrichment (APE) of aHDL and 
prepHDL apoA-I increased with time (Figure 46, page 110). The slope of aHDL and 
prepHDL apoA-I enrichment was different demonstrating that two different
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populations had been separated. This suggests that this methodology can be used to 
determine apoA-I kinetics from aHDL and prepHDL (Figure 46, page 110). The 
relatively small amount of prepHDL in plasma (7-10%) makes it difficult to isolate 
sufficient apoA-I to detennine the kinetics o f prepHDL apoA-I(Asztalos & Schaefer 
2003). By using a relatively large plasma sample size (160 pi plasma), it was 
possible to determine the kinetics of prepHDL apoA-I and at the same time reduce 
the significance of any background noise.
In the preliminaiy study, prepHDL and aHDL FCR was 0.24 pools/day and 0.19 
pools/day respectively. The separation of prep i HDL, prepzHDL and aHDL with 
FPLC was reported by Chetiveaux et al (2002), These authors reported an FCR of 
prep 1 HDL of 0.263 ± 0.085 pools/day (range: 0.142-0.31 pools/day) and aH D L of 
0.112 ± 0.026 pools/day (range: 0.076-0.148 pools/day) respectively in 6 healthy 
subjects. Compared to their results, prepHDL FCR from the cunent study was in the 
mid range of their result while aHDL FCR was slightly higher (Chetiveaux et al. 
2006). Because the preliminary study was in only one subject, it was difficult to 
identify the reason for this difference.
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Chapter 5 Development of methods to determine the 
concentration of aHDL apoA-I and prepHDL apoA-I
5.1 Introduction
Plasma apoA-I concentration and HDL apoA-I concentration are commonly 
determined using immunoturbidimetiic methods (Porsch-Ozcurumez et a l 2001).
Commercial kits are also available to determine apoA-I concentration by Enzyme- 
Linked Immunosorbent Assay (ELISA). In the cuiTent study since apoA-I in 
prepHDL and aHDL was first separated using an agarose gel, it was not possible to 
measure apoA-I concentration directly using these methods.
It has been reported that apoA-I concentration from different HDL subclasses can be 
estimated by western blot of an electrophoresis gel using scanning densitometry |
(Asztalos et al. 1993). The concentration calculation was based on the density ratio 
between different HDL subclasses and total plasma apoA-I. However, the results 
shown in Chapter 4 suggested that after dimensional electrophoresis, if agarose 
gel was directly put on SDS-PAGE, apoA-I may not be completely isolated from the 
HDL particles. Thus it would then affect the accuracy of the results if that gel was 
used to estimate apoA-I concentration (Figure 39, page 100). Therefore, to deternrine j
apoA-I concentration, prepHDL and aH D L proteins first needed to be extracted 
from the agarose gel. As described in Chapter 4, section 4.2.7.4 (page 104), an SDS 
extraction procedure proved to be an effective method to extract prepHDL and 
aHDL from an agarose gel (Figure 43, page 107). However, proteins in an agarose 
gel cannot be completely extracted from the gel, the proportion of proteins extracted 
from agarose can be calculated according to the ratio of SDS solution added to and 
taken out of agarose gel to extiact proteins (refer to Figure 26 and Equation 9, page
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70).
However, there will still be difficulties in detennining apoA-I concentration directly 
after proteins were extracted from aH D L and prepHDL bands with the SDS 
exti'action procedure. In addition to the extraction of proteins, coomassie blue R250 
which is bound to the proteins will also be washed off the agarose gel along with a 
relatively large amount of SDS. Both the coomassie blue R250 and SDS may 
interfere with the determination of the concentration of apoA-I by an 
immunoturbidimetric or ELISA method. As an anionic surfactant, SDS may affect 
the activities of antibodies and enzymes. Coomassie blue R250 may interfere in the 
light absorption in the immunotuibidimetric assay as well as interfere in the antigen 
antibody interaction.
There are two methods which would avoid the interference from coomassie blue 
R250. One option is to remove coomassie blue R250. Coomassie blue R250 itself 
does not dissolve in water unless in the presence of SDS. Coomassie blue R250 and 
SDS could be removed by the addition of solvent to the samples. Either ethanol or 
methanol are solvents for both coomassie blue R250 and SDS. As they precipitate 
proteins to remove both coomassie blue R250 and SDS from samples. However, 
proteins are not 100% precipitated and this makes it unsuitable for quantitative 
analysis. Another option would be to avoid coomassie blue R250 and to use other 
dyes to visualize the lipoproteins in the agarose gel.
In this chapter, various methods investigated for measuring apoA-I concentration are 
described. One method was to separate plasma prestained with Sudan Black B on 
agarose gel avoiding the use of coomassie blue R250. The other two methods 
estimate apoA-I concentiation indirectly without removing SDS and coomassie blue
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R250, including gel scanning o f apoA-I after SDS-PAGE separation and estimation 
of the leucine content of apoA-I using norleucine as internal standard on GC-MS.
5.2 Methods
Plasma was run on an agarose gel as described in Chapter 2 section 2.3.1 (page 66). 
The protein extraction procedure from the agarose gel was the same as described in 
Chapter 2 section 2.3.2 (page 67). SDS-PAGE was run as described in Chapter 2 
section 2.2.8 (page 57).
5.2.1 Prestained plasma with Sudan Black B
The possibility o f prestaining plasma prior to application on agarose gel was 
investigated. Prestaining plasma with Sudan Black B was explored. Sudan Black B 
staining solution was prepared with either ethanol/glycerol (4:1, v:v) or ethylene 
glycol, as described in Chapter 2 section 2.3.3 (page 67).
5.2.2 Determination of the recovery rate of apoA-I with SDS extraction
To estimate prepHDL and aHD L apoA-I plasma concentration, an apoA-I extraction 
recovery rate was required. The SDS extraction recoveiy rate was detennined 
according to the volume ratio of SDS solution added to and that taken out from the 
samples. To calculate the recovery rate, 3 ml SDS solution was added to each sample 
and samples were placed on a shaking table for 2 hours at room temperature. A 
certain amount of equilibrium solution was removed using pipettes and the volume 
of solution taken out was recorded (Figure 41, page 105). Extiactions were repeated 
and each time the volume taken out was recorded. PrepHDL was extracted three 
times and aHD L was extracted four times. The value of volumes taken out was used 
for the calculation o f extraction recoveiy rate using Equation 9 (refer to Figure 26,
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page 70).
5.3 Results
5.3.1 Prestaining plasma with Sudan Black B
Sharper bands were observed in the plasma stained by Sudan Black B prepared with 
ethylene glycol than that prepared with ethanol/glycerol (Figure 48A). Hence plasma 
was prestained with Sudan Black B prepared with ethylene glycol in later 
experiments. However, the results showed that the prep band was not always 
observed after the electrophoretic separation and only a-m igrating (containing 
aHDL) and p-migrating bands were observed on most gels (Figure 48).
PLA PLB
Ethylene Ethanol’
■
igratinga  m
Figure 48 Comparison o f Sudan Black B staining method on agarose gel
A: Comparison o f two different Sudan Black staining methods. Ethylene: Sudan Black B was 
prepared with ethylene glycol; Ethanol: Sudan Black B staining solution was prepared with 
ethanol/glycerol mixture. B: Plasma was prestained with Sudan Black B prepared with ethylene 
glycol. A faint preP band was observed, the red arrow indicates the position o f preP band. C: 
Migrating profile o f prestained plasma from 2 subjects. Plasma was prestained with Sudan Black B 
prepared with ethylene glycol. PL: plasma. PLA: Masma from subject A; PLB: Plasma from subject 
B. Blue arrows indicate the position o f P migrating bands; pink arrows indicate the position o f 
a  migrating bands.
PrepHDL was observed as a very faint band in some subjects (Figure 48B). 
Different subjects' plasma showed different migrating profiles (Figure 48C). These 
results indicated that prestained plasma could not be used to identify the position of
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prepHDL but only aHDL. Because Sudan Black B only stains lipid but not proteins, 
different subjects may have different lipid profiles resulting in different migrating 
profiles for prestained plasma.
5.3.2 Recovery rate with SDS extraction
Table 14 shows the calculated recovery rates for 11 samples o f both aHDL and 
prepHDL (Equation 9, page 70). A mean±SEM of 99.3+0.11% proteins could be 
recovered from prepHDL and a mean+SEM of 96.57+0.87% proteins recovered 
from aHDL with 3 or 4 SDS extractions respectively.
Percentage recoveiy rateo ample s t^ n 1 1  j prepHDL (3 washes) aHD L (4 washes)
1 99.6 95.0
2 99.6 92.4
3 98.6 92.1
4 99.9 96.2
5 99.2 93.7
6 99.4 98.7
7 99.1 99.4
8 99.4 98.6
9 99.4 97.5
10 98.7 98.8
11 99.6 99.9
Mean+SEM 99.3+0.1 96.6+0.9
Table 14 Recovery rate o f SDS washing procedure
PrepHDL bands were exfracted with SDS solution three times and aH D L bands were extracted foui- 
times.
5.3.3 Development of methods to quantitate apoA-I concentration
The amount of SDS added was reduced in extracted protein samples by using 0.2% 
SDS solution instead of 1% SDS solution in the second and following protein 
extraction steps. Two methods were investigated to determine the apoA-I 
concentiation in prepHDL and aHDL. One method was based on using a Imown
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amount o f noiieucine as an internal standar d to calculate the amount o f leucine apoB 
according to the leucine/norleucine ratio determined by GC-MS (Maugeais et al. 
2001; Beghin et al. 2000). Another method was based on gel scanning by 
densitometer.
5.3.3.1 Quantification o f  apoA-I concentration using norleucine as an internal 
standard on GC-MS
5.3.3.1.1 Leucine and norleucine standard curve
A leucine and norleucine concentration calibration standard curve was prepai'ed as 
shown in Table 15. The amount o f leucine in each sample varied and that of 
norleucine was fixed (8 p,g).
Samples (n=13) leu (|ig) norleu (p,g) leu/nor
1 0 8 0
2 1.5 8 0.19
3 3 8 0.38
4 4.5 8 0.56
5 7.5 8 0.94
6 10.5 8 1.31
7 15 8 1.88
8 20 8 2.50
9 25 8 3.13
10 30 8 3.75
11 35 8 4.38
12 40 8 5.00
13 45 8 5.63
Table 15 Preparation o f Standard curve o f leucine and norleucine for concentration 
measurement
The standard curve was derivatised with TFA/TFAA (1:1, v:v) as described in 
Chapter 2 section 2.2.12 ( page 61) and the leucine and norleucine peak area was 
measured by GC-MS. The peak area ratio of leucine/norelucine was used to estimate 
the ratio o f their relative quantities.
Figure 49 shows the standard curve o f leucine and norleucine for calculation o f 
leucine concentration. The theoretical amount o f leucine was plotted against the
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measured amount of leucine. A good linear relationship (r^=0.9938) was achieved 
with a slope of 1.02. The CV was 3.3%. This standard curve indicates that it is 
possible to use the ratio of leucine and norleucine peak areas from GC-MS to 
measure leucine concentration. Thus apoA-1 concentration of apoA-I can be 
calculated using Equation 12-14 (Chapter 2, section 2.4, page 71).
4.5
y = 1.02X + 0.0382
O)^  3.5 = 0.9938
2.5
0.5
0 0.5 1 2.5 31.5 2 3.5 4.5 54
Theoretical leucine (gg)
Figure 49 Standard curve o f leucine and norleucine concentration
Results are presented as Mean ±SEM (n=5).
5.3.3.1.2 Comparison o f pure apoA-I standard concentration to that estimated bv 
leucine and norleucine ratio
To further confirm whether this method could be used to calculate the concentration 
of apoA-I, pure apoA-I standards were prepared and isolated on 4-10% 
discontinuous SDS-PAGE (Table 15). After the gel silver stained, apoA-I bands 
were cut and hydrolyzed with 1 ml 6 M HCl at 120°C for 24 hours. At this step, 0.8 
pg norleucine was added to each hydrolysis vial before heating the vials. After 
hydrolysis, the hydrolysate amino acids were purified by lEC. Standards were 
derivatised as described previously in section 2.2.12 (page 61) and analyzed by GC- 
MS.
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sample number apoA-I (pg) theoretical leucine (pg) norleucine (pg)
1 2.15 0.32 0.8
2 4.3 0.64 0.8
3 6.45 0.96 0.8
4 8.6 1.29 0.8
5 10.75 1.61 0.8
6 12.9 1.93 0.8
7 15.05 2.25 0.8
8 17.2 2.57 0.8
9 19.35 Z89 0.8
10 21.5 3.22 0.8
11 23.65 3.54 0.8
12 25.8 3.86 0.8
Table 16 Preparation o f apoA-I standard curve to estimate apoA-I concentration by leucine and 
norleucine ratio.
The GC-MS results indicated that a good linear relationship was achieved (r^=0.97) 
but with a low recovery of apoA-I (slope=0.4498) indicating loss of about 50% of 
the samples (Figure 50).
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Figure 50 Standard curve o f apoA-I loaded on SDS-PAGE.
Norleucine was used as an internal standard to estimate the amount o f apoA-1 after GC-MS analysis.
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5.3.3.2 Measurement o f  apoA-l concentration by scanning densitometry o f  SDS- 
PAGs
5.2.3.2.1 Preparation of apoA-I standard samples for gel scanning
Scanning the SDS-PAG with a densitometer (GS800, Bio-Rad Laboratories, 
Richmond, CA, USA) was investigated as a method to determine apoA-I 
concentration in prepHDL and aH D L particles. An apoA-I standard calibration 
curve was designed for this method to estimate the concentration of apoA-I. Two 
groups of standards were prepared to cover the concentration range of both 
prepHDL and aHDL which were run on 2 gels. Table 17 shows the preparation of 
pure apoA-I standard samples for two gels. ApoA-I samples were made up in a 
volume of 20 pi and the final concentration was from 0.1075 to 1.505 pg/pl. Silver 
and coomassie blue R250 staining methods were compared to investigate the 
possibility of using gel scanning method to estimate apoA-I concentration.
SDS-PAGE sample no apoA-I pg Volume pi apoA-I 
concentration pg/pl
G ell 1 2.15 20 0.1075
2 4.3 20 0.215
3 6.45 20 0.3225
4 8.6 20 0.43
5 10.75 20 0.5375
6 12.9 20 0.645
7 15.05 20 0.7525
Gel 2 8 17.2 20 0.86
9 19.35 20 0.9675
10 21.5 20 1.075
11 23.65 20 1.1825
12 25.8 20 1.29
13 27.95 20 1.3975
14 30.1 20 1.505
Table 17 Preparation o f apoA-I standard samples for SDS-PAGE
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5.2.3.2.2 SDS-PAGE stained with silver stained kit
ApoA-I samples were loaded on 4-10% discontinuous SDS-PAGE and isolated as 
described in section 2,2.8 (page 57). SDS-PAGs were scanned with a densitometer 
after staining with silver stain. Scanned images were analyzed by Quantity One 4.6.3 
(1-D analysis software, Bio-Rad Laboratories, Richmond, CA, USA). Figure 51 
shows the gels with the low and high concentration range (gel 1 and gel 2) scanned 
with a densitometer after staining. The concentration of the apoA-I on the gel 
increased from left to right according to Table 17.
std
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Figure 51 Pure apoA-I separation on SDS-PAGE stained with silver
A: Gel 1, B: Gel 2. The image was scanned by densitometer. SDS-PAG A and B were loaded with the 
same amount o f sample in the sequence shown in Table 17. The silver stain background was different 
between A and B. The image was scanned by densitometer.
Figure 52 was generated by plotting adjusted volume of optical density (OD)*mm^ 
(data generated by the software Quantity One) against the concentration of apoA-I. 
Figure 52A shows results from gel 1 with the lower concentration range which had a 
slope of 0.1031 and Figure 52B showed results from gel 2 with high concentration 
range which had a slope of 0.1615. The different slope of the two curves made it 
difficult to use it as calibration curve. The main cause is that there is not a linear 
increase in staining with increasing protein concentration. Conversely, the stained
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band became pale yellow and transparent when a large quantity of proteins was 
loaded. Because of the higher sensitivity of the silver stain and its nonspecific stain 
ability, it results in a large and uneven background. This will lead to an 
overestimation in the concentration of an unknown sample. These two standards
were repeated
18
16
14
'ôî 12
< 10
Q. 8<
6
4
2
0
y = 0.1031x-1.7169
R‘  = 0.9744
♦
25 50 75 100 125
Adj volume OD*mm^
150 175
B
05
<a<
32
30
28
26
24
22
20
18
16
y = 0.1615x-22.603
= 0.9572
♦
200 225 250 275
Adj volume OD*mm
300
2
325 350
Figure 52 The relationship between adjusted volume o f OD*mm^ o f apoA-I bands and apoA-I 
concentration
A; Gel 1 with low concentration range which covers the pre(5HDL apoA-I concentration range. B: Gel 
2 with a high concentration range which covers the aH D L apoA-I concentration range. OD: optical 
density.
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5.2.3.2.3 SDS-PAGE stained with coomassie blue R250
An alternative staining method using coomassie blue R250 instead of silver stain 
was investigated. Compared to the silver stain, the coomassie blue R250 stain was 
less sensitive with no non-specific background staining. Figure 53 shows the 
densitometer scan of apoA-I in the low concentration range stained with coomassie 
blue R250 after separation on SDS-PAGE. The adjusted volume (OD*mm^) was 
plotted against the amount of apoA-I (Figure 54).
Figure 53 ApoA-I was separated on SDS-PAGE stained with coomassie blue R250
The image was scanned by a densitometer.
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Figure 54 The relationship between the OD*mm^ and the amount o f apoA-I
ApoA-I standard samples was separated on SDS-PAGE and stained with coomassie blue R250. OD: 
optical density.
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This apoA-I standaid curve was used to calibrate the pre|3HDL and aHDL apoA-I 
concentration from a single subject. Thi*ee different dilutions of prepHDL and 
aHDL samples were loaded onto a SDS-PAG and the concentration of apoA-I fr'om 
prePHDL and aH DL calculated using the standard curve shown in Table 18. They 
were 0.2Ü0.003 mg/ml and 1.56±0.031 mg/ml respectively. Total apoA-I 
concentration was therefore 1.77 mg/ml. When calculated as a percentage, prepHDL 
apoA-I was 11.7±0.2% and aHD L apoA-I was 88.3±0.2%. However, the total 
plasma concentration apoA-I o f this subject was 1.32 mg/ml when it was measured 
by immunoturbidimeti'ic method using an automated analyser ABX Mira Plus 
(Chapter 2, section 2.2.5, page 55). Thus apoA-I concentration may be overestimated 
by this methodology.
Samples
(n=3)
prepHDL 
apoA-I (mg/ml)
aHDL apoA-I 
(mg/ml) prepHDL% aHDL%
1 0.21 1.63 11.3 88.7
2 0.20 1.53 11.7 88.3
3 0.21 1.54 12.1 87.9
Mean±SEM 0.21±0.003 1.56±0.031 11.7±0.2 88.3±0.2
CV Z3%& 3.5% 3 J% 0.4%
Table 18 PrePHDL and aH D L  concentration estimated by densitometry
5.4 Discussion
It is technically difficult to determine the concentration of apoA-I in prepHDL and 
aHDL directly. As described in the introduction most research studies which have 
quantitated prepHDL and aHD L apoA-I used a 2-DE (agarose electrophoresis + 
non-denatured PAGE) combined with an immunodetection technique. The relative 
ratio o f different HDL subclasses were calculated, ie the percentage of prepHDL 
apoA-I was calculated according to the density ratios of prepHDL apoA-I to total
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apoA-I (Asztalos & Schaefer 2003). The concentration was then calculated from the 
total plasma apoA-I concentration measured by a single radial immunodiffusion 
method (Xu & Fu 2003; Yang et a l 2005). One study measured prepiHDL apoA-I 
concentration by a sandwich enzyme immunoassay (Miyazaki et a l  2000). However, 
this method was not suitable to determine the total prepHDL apoA-I concentration 
since a specific monoclonal prep i HDL antibody was used in the study by Miyazaki 
et al (2000). Chetiveaux et al (2004) used FPLC to separate prepiHDL and aHDL to 
measure apoA-I kinetics. They were unable to measure prepiHDL and aHDL apoA- 
I concentration directly, as 10 of the fractions eluted from FPLC contained both 
prePiHDL and aH D L particles (Chetiveaux et a l  2004). The percentages of 
prePiHDL apoA-I and aH D L apoA-I were assumed to be 11% and 89% and were 
used to estimate the apoA-I concentration in prep iHDL and aH D L in healthy people 
according to published data (Chetiveaux et a l  2004).
In the current study, SDS and coomassie blue R250 were inti’oduced into the samples 
and would interfere with any apoA-I assay. Alternative methods were investigated to 
measure apoA-I concentration.
5.4.1 Prestaining plasma with Sudan Black B
Several lipids including phospholipids, neutral fats and sterols are stained intensely 
by Sudan Black B. Prestained plasma is generally used to detennine abnormal 
lipoprotein profiles. However, the results indicated that prepHDL was not always 
identified by this method on the agarose gel after electiophoresis. PrepHDL is a 
lipid-poor lipoprotein and it could not be stained or was very poorly stained by 
Sudan Black B. Therefore, it was difficult to identify the prePHDL itself with Sudan
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Black staining. However, prepHDL has the same migrating position as VLDL (Biere 
et a l  1996). Theoretically, VLDL could be stained since 90% of its components are 
lipid. According to the VLDL position, prepHDL can be identified. However, the 
results confirmed that prepHDL was not always obseiwed after separation of plasma 
prestained with Sudan Black on agarose gel. The possible reason for the different 
migrating profiles between subjects may be because of the different characteristics of 
the subjects and may also be induced by the prestaining procedure itself. Ethylene 
glycol was used as a solvent to dissolve Sudan Black B and it may result in some 
delipidation of VLDL.
5.4.2 Estimation of apoA-I concentration using norleucine as an internal 
standard
Norleucine is an isomer of both leucine and isoleucine not found in proteins. 
Therefore, norleucine can be used as an internal standard to estimate protein 
concentiation according to the amount of leucine in the protein. Studies have 
suggested that apoB concentration can be estimated with this method (Maugeais et 
a l  2001; Beghin et a l 2000). In the study by Beghin et al (2000), norleucine was 
added to VLDL and LDL apoB which was precipitated by isopropanol and then 
directly hydrolyzed using 6 M HCl. The CV for measuring apoB concentration with 
this method was between 3.6 and 9.8%. In cunent study apoA-I was isolated by 
SDS-PAGE first and then the excised apoA-I band was hydrolyzed by 6 M HCl. The 
application of this method showed the amount of standard apoA-I was seriously 
underestimated. Only 44.98% of the apoA-I loaded onto the gel was recovered.
There are two possible causes which could lead to such a great difference between 
measured apoA-I and theoretical apoA-I. The Toss’ of apoA-I occurring during
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SDS-PAGE isolation of apoA-I may contribute to the underestimation. Figure 51 
(page 128) shows that w ith silver staining pure apoA-I (purity >85%) had tliree extra 
bands after sepaiating on SDS-PAGE. Self-association of apoA-I in aqueous solution 
may lead to formation o f dimers and tetramers. Thus the extra bands may include 
apoA-I dimers or tetramers. Only the apoA-I monomer was excised from SDS-PAG 
and hydrolyzed for GC-MS analysis in this study which may not include all the 
apoA-I loaded on the gel.
Another possible reason was the loss of leucine during the purification of 
hydrolysates with lEC. The analytical procedure of this method using norleucine as 
internal standard to calculate apoA-I concentration includes several steps shown in 
the following flow chart:
SDS-PAGE-^Hydrolysis—>IEC^Derivatization—^ GC-MS 
Norleucine was added at the hydrolysis step. A portion of hydrolysate would be lost 
during the transfer of hydrolysate to the lEC column, however, leucine and 
norleucine would be lost in equal ratios. Therefore, it should not result in a great 
difference in the theoretical and measured amount of apoA-I. The slightly different 
structure between amino acids can result in a different pK.
CHs NHg B
Figure 55 Structures o f Leucine and Noiieucine.
A: L-Leuciiie B: L-Noiieucine (Buiiingame & Can 1996)
C OH
NH
The structural difference between leucine and norleucine may cause them to have 
different pKs (Figur*e 55). Leucine pKz is 9.6 and isoleucine pKi is 9.7. Therefore,
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when the hydrolysates were eluted through the lEC column, leucine would be 
washed out first when the pH was changed in the mobile phase. In the current 
protocol, after hydrolysate was added to the prewashed column, the column was 
washed with water until the pH was 6.5. Since the isoelectric point (PI, 
PI=(pKi+pK 2)/2 ) of leucine is 6 , a small amount of leucine may be lost before the 
addition of ammonia.
5.4.3 Estimation of apoA-I concentration with scanning densitometry
5.4.3.1 SDS-PAGE stained with silver
An apoA-I standard curve was divided into two sets of samples and separated on two 
SDS-PAGs stained with silver. When the density and the amount of apoA-I were 
plotted after scanning with a densitometer, the two sets o f standard samples were not 
able to achieve the same slope (Figure 52 A and B, page 129). This suggested that 
silver staining may not be a suitable method to stain the gel. Silver staining is a veiy 
sensitive staining method to visualize proteins on SDS-PAG, however, it has a non­
specific staining and a large background is easily generated. Quantify one (the 
software used to analyze the scanned gel) is able to subtiact the mean background 
density when calculating the proteins concentration from the band densities on the 
gel. However, when the background density is uneven, it may not be accurate to 
subtiact a mean background density to calculate sample densities. Another problem 
which occurred during silver staining was that a large protein sample size resulted in 
a pale yellow and half-transparent band, and as a consequence the density did not 
reflect the protein concentiation.
5.4.3.2 SDS-PAGE stained with coomassie blue R250
Compared to silver staining, the data from the gel stained with coomassie blue R250
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showed a relatively better standard calibration cm^ve, because coomassie blue R250 
staining has veiy little background stain. However, the coomassie blue R250 staining 
method has its own unavoidable wealcness as well. It is not a very sensitive staining 
method and not capable of visualizing small amount of proteins, while a prolonged 
staining time and destaining time may result in the loss of proteins.
To overcome the side effects of protein loss during the long staining and destaining 
procedures, the SDS-PAGs of the standard apoA-I used for calibration and the 
samples with unknown apoA-I concentration should be stained and destained for 
equal time. Otheiwise, standard apoA-I samples need to be separated on the same gel 
with the samples o f unknown apoA-I concentration. Consequently, fewer standard 
apoA-I samples could be applied on a single individual gel and the precision of the 
calibration cuiwe would be reduced. In addition, more gels and standard apoA-I 
samples would be required to quantify the concentration of pre(3HDL and aHDL 
apoA-I in plasma.
Due to the lower sensitivity o f coomassie blue R250 staining, it may not be accurate 
to calculate small amoimts of proteins according to the standard calibration curve. 
Results fiom the current study indicated that it led to an overestimation of apoA-I 
using the standard calibration cuiwe. However the percentage of apoA-I from 
prepHDL and aHD L (11.7% and 88.3%) detennined by this method was similar to 
the study by Xu & Fu (2003) which reported that prepHDL and aFIDL was 10.6% 
and 89.7% respectively in healthy subjects. Hence, the coomassie blue R250 staining 
method may be suitable to estimate the percentage of apoA-I in prepHDL and 
aHDL, but not suitable to estimate tlie concentiation of apoA-I.
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5.4.4 Further work
Ishida et al (1987) set up a method to estimate prepHDL and aHD L apoA-I 
concentration by solid phase radioimmunoassay following electrophoresis. In this 
method proteins were transfeiTed from agarose to nitrocellulose without using 
methanol or detergent SDS (Ishida et a l  1987). A better method to determine the 
concentiation of apoA-I prepHDL and aH D L may be to scan a western blot of 
agarose gel directly. This will avoid the use of radioactive radioimmunoassay. 
Western blotting is a veiy sensitive and specific method for the detection of apoA-I. 
In addition, a relatively low background could be achieved. Thus validation can be 
determined by western blotting after agarose gel which then can be scanned by 
densitometer. In this method, the coomassie blue R250 staining of agarose gel and 
the protein extiaction step would be omitted and it would be faster, more effective 
and more specific.
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Chapter 6 PrepHDL and aH DL kinetics in healthy subjects
6.1 Subjects and methodology
Foul* subjects (3F+1M) recruited from students and staff in the Diabetes and 
Endocrinology Unit, PGMS, University o f Suii'ey were recruited. The clinical 
protocol is described in Chapter 2, section 2.1 (page 52). Blood samples were talcen 
dui’ing an infusion of ^^C-leucine at baseline and then evei*y hour* for 9 hours. The 
various methods involved in the analytical proceduie have been described in Chapter 
2 Methodology. These methods include separation of prePHDL and aHD L by 2-DE, 
separation of HDLz and HDL3 by ultracentrifugation, isolation o f apoA-I by SDS- 
PAGE, hydrolysis o f apoA-I w ith 6  M HCl, puiiflcation o f amino acids with lEC 
and isotopic emichment measurement by GC-MS. The study protocol was approved 
by the West Kent Local Reseai'ch Ethics Committee. All the subjects signed a written 
consent form.
6.2 Results:
6.2.1 Subject characteristics and lipid profile
Table 19 shows the subjects characteristics. Subject 1 and 3 were borderline 
overweight (BMI>25) and subject 2 had a borderline high fasting insulin 
concentration (fasting insulin level < 15 mU/L is normal, 15 to 20 mU/L is 
borderline high and > 20 mU/L is high) (Valentin Fuster et a l 2004).
Subjects (n=4) S-1 S-2 S-3 S-4 M ean± SEM
Age 30 33 41 53 39.3±5.1
Gender F F M F
BW (kg) 78.9 58 85.6 54 69.2±7.7
Height (cm) 175.5 161 182 162.6 170.3±45.1
BMI (kg/m^) 25.6 22.4 25.8 20.4 23.6 ±1 .3
Insulin (mU/L) 8.5 15.6 13.1 6 . 2 10.9 ±2.1
Table 19 Subject characteristics
S-1: subject 1; S-2: subject 2; S-3: subject 3; S-4: subject 4; BW: body weight; BMI: body mass 
index.
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Table 20 shows the lipid profile o f the subjects. All four subjects had normal lipid 
levels.
S-1 S-2 S-3 S-4 M eaniSEM
PL-TG (mmol/L) 0.50 0.69 0.65 0.63 0.62±0.04
PL-C (mmol/L) 4.15 3.69 4.71 4.58 4.28±0.23
HDLi-TG (mmol/L) 0.04 0.07 0.04 0.06 0.05±0.01
HDL2-C (mmol/L) 0.67 0.71 0.72 1 . 1 1 0.81±0.10
HDL3-TG (mmol/L) 0.014 0.038 0 . 0 1 2 0.017 0 .0 2 ± 0 . 0 1
HDL3-C (mmol/L) 0.27 0.45 0.32 0.41 0.36±0.04
HDL-TG (mmol/L) 0.06 0 . 1 0 0.05 0.08 0.07±0.01
HDL-C (mmol/L) 0.95 1.16 1.05 1.52 1.17±0.13
PL-apoA-I (mg/ml) 1.33 1.32 1.35 1.73 1.43±0.10
HDL2 apoA-I (mg/ml) 1.03 0.77 0.31 0.74 0.71±0.15
HDL3 apoA-I (mg/ml) 0.45 0.60 0.48 0.51 0.51±0.03
Table 20 Lipid profile and apoA-I concentration o f the subjects
S-1: subject 1; S-2: subject 2; S-3: subject 3; S-4: subject 4PL: plasma; TG: triglyceride;
C: cholesterol. PL-C: plasma choleterol.
6.2.2 Isotopic enrichment, PR and FCR of apoA-I
Figure 56 shows the a-KICAPE from 4 subjects. Only the plateau o f a-KICAPE was 
used to calculate apoA-I FCR, thus samples were not measured at 1 and 2 hours.
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Figure 56 a-ketoisocaproate (a-K IC) enrichment
Results are presented as Mean± SEM (n=4). APE: Atom percent excess.
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PrepHDL and aHDL apoA-I enrichment (APE) was determined at baseline and at 
timed intervals for 9 hours as shown in Figure 57 (n=4). PrepHDL and aHDL apoA- 
I enrichment from each individual subject is included in appendix II (Figure A1-A4, 
page 180-181).
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Figure 57 Isotopic enrichment o f apoA-I from prePHDL and aH D L
Results are presented as Mean± SEM (n=4). APE: atom percent excess; Blue diamond (♦): prePHDL; 
Pink square (■): aHDL.
HDLi and HDL] apoA-I enrichment (APE) was determined at baseline and at timed 
intervals for 9 hours as shown in Figure 58. HDLi and HDL] apoA-I enrichment 
from each individual subject is included in appendix II (Figure A5-A8, page 182- 
183).
The FSR of HDL apoA-1 was estimated using a regression model and kinetic 
analysis of tracer-to-tracee ratios achieved by fitting a regression line to the APE of 
apoA-I vs time (hour) data. FSR was calculated by using the slope of the enrichment 
curve divided by the a-KIC APE plateau (Chapter 2, section 2.4, Equation 2, page 
69). In the fasting study, subjects are in steady state and the FSR is equal to FCR.
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The apoA-I PR was then calculated (Chapter 2, section 2.4 Equation 3. page 69). 
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Figure 58 Isotopic enrichment o f apoA-I from HDL% and HDL3
Results are presented as Mean ±SEM (n=4). APE: atom percent excess; Green triangle (A ); HDL 2 ; 
light blue cross (x): HDL3.
Table 21 shows aHDL and prePHDL FCR. A paired-sample t-test was conducted to 
evaluate the variation of prepHDL FCR and aHDL FCR. There was a statistically 
significant difference between prepHDL and aHDL FCR (P=0.039).
Subjects
(n=4)
aH D L  FCR 
(pools/day)
prepH D L FCR 
(pools/day)
S-1 0.160 0 . 2 0 1
S-2 0.153 0.219
S-3 0.187 0.216
S-4 0.107 0.124
M eaniSE M 0.152±0.017 0.190±0.022
P 0.039
Table 21 aH D L and prePHDL FCR
S-1: subject 1; S-2: subject 2; S-3: subject 3; S-4: subject 4; P\ two-tailed T-test; FCR: factional 
clearance rate.
PrepHDL and aHDL apoA-I PR could not be calculated as the method development 
for measuring their apoA-I content was unsuccessful. Table 22 shows PR and FCR
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of HDL2 and HDL3 , A paired-sample t-test showed a statistically significant 
difference between HDL% and HDL3 FCR (P=0.003) but no significant difference 
between HDL2  and HDL3 PR (P=0.203).
Subjects
(n=4)
FCR (pools/day) PR (mg/kg/day)
HDL2 HDL3 HDLz HDL3
S-1 0.166 0.152 5.235 2.348
S-2 0.164 0.141 4.909 3.279
S-3 0 . 2 0 2 0.183 2.625 3.650
S-4 0.116 0 . 1 0 1 3.509 2.075
M eaniSEM 0.162±0.018 0.144±0.017 4.0693=0.610 2.838±0.374
P 0.003 0.203
Table 22 Production rate and fraction clearance rate o f HDL2 and HDL3
S-1: subject 1; S-2: subject 2; S-3: subject 3; S-4: subject 4; FCR: factional clearance rate; PR: 
production rate; P\ two-tailed T-test.
6,3 Discussion
6,3.1 Comparison of prepHDL and aHDL apoA-I metabolism measured 
following separation by 2-DE and FPLC technique
The existence of prepHDL was first reported by Kunitake et al (1985). The majority 
of its mass (90%) was reported to be protein and it was referred to as lipid-poor 
apoA-I (Kunitalce et a l 1985). PrepHDL contains both prePiHDL and prep2 HDL 
subclasses (Figure 7, page 22) (Asztalos et a l 2005). PrepiHDL is thought to be 
involved in the initial step o f HDL metabolism, however, it does not only contain 
newly synthesized apoA-I but is also generated by the catabolism of HDL2  (Miida et 
a l 2000; BaiTans et a l 1994; Guendouzi et a l 1999).
In this project, 4 healthy subjects were recruited for the study o f apoA-I kinetics 
from prepHDL and aH DL isolated by agarose electrophoresis. Isotopic enricliment 
of apoA-I from HDL2  and HDL3 separated by sequential ultracentrifugation was also 
measured. An additional subject was recruited for a pilot study to confirm the
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feasibility of 2-DE to detennine the kinetics of apoA-I from prepHDL and aHDL. 
The kinetic data of prepHDL and aH D L from these 5 subjects indicates that 
prepHDL and aHDL apoA-I kinetics is measurable using this novel 2-DE technique. 
The results from 5 subjects showed aHD L apoA-I FCR of 0.107-0.19 pools/day and 
prepHDL apoA-I FCR of 0.124-0.247 pools/day.
In the cuiTent study, one of the 4 patients was very different from the other subjects 
(S-4) with a high HDL-C and apoA-I concentration and a relatively low apoA-I FCR. 
This may due to specific characteristics and lifestyle of the subject. It is well known 
that regular exercise can result in an increase in HDL-C (Hagberg et ah 1999). 
Dietary habit also affects the level of HDL-C. An increase in the consumption of fish, 
vegetables, fr uits and olive oil is associated with an increase of HDL-C while high 
carbohydrate consumption is associated with a reduced HDL-C level (Toth 2005).
The relatively low concentration of prepHDL in plasma makes it technically difficult 
to isolate prepHDL and detennine its kinetics. Thus there are only a few published 
papers describing prepHDL kinetic data. All the published articles reporting 
prepHDL and aHDL kinetics are from Chetiveaux et al (2002, 2004, 2006), who 
separated prepiHDL and aH D L from both healthy subjects and patients with type 2 
diabetes by FPLC. Compared to the separation by FPLC, the 2-DE used in this study 
allowed aHD L and prepHDL to be separated directly from plasma and decreased 
any possible exchange between HDL subclasses which may have occuned when 
samples were processed in buffers duiing isolation of HDL subclasses by FPLC.
The separation of HDL subclasses with FPLC was not complete and an overlap 
between aHDL and prepiHDL occurred (Figure 59) (Chetiveaux et a l  2002). In the
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study by Chetiveaux et al (2004) prePiHDL and aHDL were not completely 
separated. To maintain the purity of the HDL subclasses, 10 fractions containing 
both prePiHDL and aH DL (2 ml) were excluded from the kinetic study. However, 
because o f incomplete separation o f prepiHDL and aHDL, it was not possible to 
quantitate apoA-I from these two subclasses directly with this methodology. 
Chetiveaux et al (2006) considered that prepiHDL apoA-I was 12% in healthy 
subjects and aHDL apoA-I was 8 8 % of total apoA-I according to the published 
articles and used this to estimate the concentration apoA-I and the PR of prepiHDL 
and aHDL. In type 2 diabetics they assumed that prePiHDL apoA-I was 18% and 
aH D L apoA-I was 82% also according to the published data (Chetiveaux et al. 
2006). Using this ratio to calculate apoA-I concentration in prePiHDL and aHDL 
will give rise to erroneous results since this ratio can vary between individuals. In a 
study of HDL subclasses in type 2 diabetes (n=38), prepiHDL was 10.07±2.81% 
compared to 6.11±1.45% in healthy control subjects (n=38) (Xu et al. 2001a).
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Figure 59 The separation o f prePiHDL and aH D L  with FPLC
ApoA-I containing particles were separated on superdex 200 HR column fractions horn whole plasma. 
Three peaks were observed. The frr'st peak represents a large particle with a molecular weight o f 
larger than 500 kD a (preP 2 HDL), the second peak is aH D L with a molecular weight o f 100-500 kDa 
and the third pealc is prep,HD L with a molecular weight o f 40-60 kDa (Chetiveaux et al. 2002).
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Plasma samples were diluted with an EDTA solution in a liquid system to separate 
prepi and ocHDL with FPLC at room temperature (Chetiveaux et a l  2002). It is 
difficult to be sui'e there was no exchange of lipid and proteins between HDL 
subclasses in the presence o f plasma enzymes. A diluted solution may also lead to 
the dissociation o f apoA-I from aH D L paiticles because o f the instability o f larger 
HDL paiticles. Studies also show that apoA-I will self associate when it is free in 
aqueous solution (Vitello & Scanu 1976; Massey et a l 1981). This self-association 
without the existence of lipid may stabilise the lipid-free form o f apoA-I (Chau et a l
2006). This will result in a slower rate for apoA-I to re-associate with lipid and 
contribute to an overestimation of the amount of prePiHDL apoA-I and 
underestimation o f aH DL apoA-I.
Table 23 shows the kinetic data of prep i HDL and aHDL separated by FPLC from 
healthy control subjects (Chetiveaux et a l  2006). aHDL FCR (0.076-0.121 
pools/day) was lower and prePiHDL FCR (0.142-0.31 pools/day) was slightly higher 
than FCR of aHDL (0.107-0.19 pools/day) and prePHDL (0.124-0.247 pools/day) 
measmed in cmi’ent study.
Apo A -I F C R  
prep] H D L  
k(0,10) d"*
Apo A -I F C R  
a H D L  
k(0,20) d“‘
Pool size 
prep] H D L  
mg kg“^
A PR
prep] H D L  
mg kg"^ d"^
Pool size 
a H D L  
m g kg"^
A PR  
a H D L  
mg kg“* d“^
Control subjects
SI 0-310 ± 0 -066 0-076 ± 0 -0 0 6 8-11 5-31 65-55 234-19
S2 0-367 ± 0-288 0-088 ±0-011 7-38 5-14 49-05 483-28
S3 0-269 ± 0 -024 0-148 ± 0-007 9-84 11-10 60-00 272-10
S4 0-228 ± 0-204 0-117 ± 0 -036 3-87 6-71 55-44 356-66
S5 0-142 ± 0-082 0-121 ± 0 -027 5-41 6-56 50-34 189-54
86 NI* 0-120 ± 0 -264 11-73 11-12 56-40 844-75
M ean 0-263 0-112^ 7-72 7-65 56-13 396-75
(SD) (0-085) (0-026) (2-86) (2-75) (6-13) (242-78)
Table 23 The Idnetic data o f  prepiHDL and aH D L  apoA-I in healthy control subjects separated 
by FPLC
Pink rectangle highlights prepiHDL APR, Blue rectangle highlights aH D L  APR. FCR: fractional 
clearance rate, APR: absolute production rate (Chetiveaux et a l  2006). NI: not identifiable.
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W ith 2-DE separation, aH DL and pre|3HDL were completely separated and it was 
unlikely for aH DL to be contaminated by prepHDL. The lower FCR of aHDL 
separated by FPLC may be because of a loss of apoA-I from larger HDL particles 
which would lead to an overestimation of prepiHDL FCR.
The difference in FCR between prepHDL (cuiTent study) and prepiHDL 
(Chetiveaux et al study, 2006) may also be due to a difference in the composition of 
the HDL subclasses, because prepHDL contains both prePiHDL and prep2HDL. 
PrePzHDL apoA-I kinetics was not studied in their study. However, it is also 
possible that the difference between the results may just be a reflection of the 
different characteristics o f the subjects studied. The numbers of subjects in both 
studies were very low.
The PR value (refeiTed to as APR in Table 23) of prePiHDL and aH D L separated by 
FPLC (Table 23) were not in line with reports in literature. Prep,HDL apoA-I PR 
ranged from 5.14 to 11.12 mg/lcg/day with a mean of 7.65mg/kg/day and the PR of 
aHDL apoA-I ranged from 189.54 mg/kg/day to 844.75 mg/kg/day with a mean of 
396.75 mg/kg/day (Table 23, pink rectangle and blue rectangle). Ooi et al (2006) 
compared the kinetics of total plasma HDL apo A-I in healthy subjects measured 
using both radioactive and stable isotopes taken from 29 articles published between 
1978 and 2004. The mean total apoA-I PR was 12.1±0.67 mg/kg/day and the 95% 
confidence inteiwal was 10.7 to 13.4 mg/kg/day. The mean PR of total apoA-I was 
32 times less than the PR of aH D L measured by Cletiveaux et al (2006) and 
prePHDL was 0.67% of the mean PR of total apo A-I (Table 23). The pool size of 
apoA-I was in the noiinal range.
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The possible reason for this great difference in PR may be due to a calculation error. 
Based on equation 3 (Chapter 2, section 2.4, page 69), using the data of the FCR and 
apoA-I pool size reported by Chetiveaux et al (2006), the PR was recalculated and 
the results aie shown in Table 24. The recalculated PR of prePiHDL and aHDL 
seem to be more closer to that described by Ooi et al (2006).
Control subjects (n=6) PreP, PR (mg/kg/day) aH DL PR (mg/kg/day)
SI 2.51 4.98
S2 2.71 4.32
S3 2.65 8.88
S4 0.88 6.49
S5 0.77 6.09
S6 NI 6.77
M eaniSD 1 .9 4 =0 . 9 9 6.254=1.59
Table 24 Recalculation o f absolute production rate o f prePiHDL and aH D L from healthy 
control subjects reported by Chetiveaux et al, 2006
The PR o f pre|3HDL and aH D L  was calculated based on the apoA-I FCR and pool sizes reported by 
Chetiveaux et al (2006). PR: Absolute production rate, NI: not identifiable.
6.3.2 Kinetic study of H D L 2 and H DL 3
This kinetic study with fom- healthy subjects of mixed gender, age and BMI showed 
that there was a significant difference between HDL2 and HDL3 apo A-I FCR but not 
in HDL2 and HDL3 apoA-I PR. Based on particle size, HDL2  can be further divided 
into HDL2b and HDL2 a, while HDL3 can be divided into HDL3a, HDL3b and HDLsc 
(Figure 6 , page 20), Pathological conditions such as diabetes, obesity and CHD are 
associated with reduced HDL2 a, HDL2 b concentration and increased HDL3a (Xu et a l 
2001a; Xu et a l 2001b). Compared to healthy control subjects, HDL3a was increased 
by 32.3%, while HDL2b and HDL2 a were decreased by 41.3% and 18.9% in the 
patients with type 2 diabetes (Xu et a l 2001a). Based on the migrating profile on a 
non-denaturing 2 dimensional electrophoresis (agarose-PAGE), aHDL can be 
fui'ther divided into a-1 HDL, a-2  HDL and a-3 HDL (Figure 7, page 22). Wlien
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comparing with particle size, a-1 HDL is equivalent to HDL%, a-2  HDL contains 
HDLsa and HDLsb, while a-3 HDL contains HDL^c. Another group has shown that 
in patients with CHD the level of a-1 HDL (HDL2) was decreased by 39% and that 
of a-2  HDL was decreased by 9% compared to the healthy control subjects 
(Asztalos et a l  2004). The changes in concentiation o f the different aHDL 
subclasses suggest that the HDL subclass pattern is altered in pathological conditions. 
This phenomenon can be either caused by the increased catabolism of large HDL 
particles or the impairment in small HDL maturation. Thus a kinetic study is 
essential to investigate the underlying mechanisms. All studies to date have shown 
no detectable difference in HDL2  and HDL3 apo A-I kinetics in healthy subjects, 
postmenopausal women and patients with type 2 diabetes (Prenais et a l  1997; Walsh 
et a l  1994). HDL2 and HDL3 can be both downstream or upstream products 
interconverting between each other. One explanation for the similarity in HDL2 and 
HDL3 apoA-I kinetics is that there is a veiy fast interconversion between them.
Unlike previous studies, the data in this study suggest that HDL2 and HDL3 apoA-I 
kinetic metabolism is significantly different in healthy subjects. Comparing the 
analysis procedures used in cuiTent project to those used in the study by Prenais et al 
(1997) the only difference was the ultracentiifugation step. In the study by Prenais et 
al (1997), HDL2  and HDL3 were separated by gradient ultiacentiifugation at 40000 
rpm at 10°C for 24 hours. Unfortunately, the x g value was not published. In the 
current study HDL2 and HDL3 were separated by sequential ultracenti’ifugation at 
40000 rpm (172301 x g) for 48 hours for each fraction at 4°C. It was difficult to 
detennine how centrifugal force may affect HDL2 and HDL3 separation with these 
two methods because of the different types of centiifuges and rotors that were used.
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These may affect the amount of dissociation of apoA-I from HDL2 and HDL3 and 
cause exchange between HDL2 and HDL3 (Kunitake & Kane 1982). After gradient 
ultiacentrifugation, samples fonu a density gradient in a single tube with different 
lipoproteins in different density ranges. It is difficult to remove several different 
fractions without disturbing any other fractions and it is hard to exactly identify the 
density range of each fraction without any visible marker. This may cause mixing of 
HDL2 and HDL3 after ultracentrifugation. In contrast, in sequential 
ultracentrifugation, lipoprotein fractions were removed after each ultracentiifugation 
step and there was unlikely to be any m ixing of lipoproteins.
In the study by Walsh et al (1994), after separation by centrifugation at 4°C, plasma 
was stored at -80°C before sequential ultracentiifugation. The storage time of plasma 
at -80°C was not reported. HDL2 and HDL3 were separated at 25,000 ipm (85925 x g) 
at 10°C with a Beclauan type 25 rotor for 24 and 30 hours respectively (Walsh et a l  
1994). Compared to the cuirent study, sequential ultracentrifugation was also used, 
however, differences existed between rotor types, ultracentrifugation speeds 
(different relative centrifugal force), centrifugation time as well as centiifugation 
temperature which may have affected the separation profile of HDL2 and HDL3 . 
Freezing and thawing may also affect HDL2 and HDL3 particle integrity and cause 
the exchange of apoA-I.
However the divergence between the results may also be because of different 
characteristics of subjects and the small population size and clinical study protocol. 
Thus further studies are needed to confinu this finding in both healthy subjects and 
patients with diabetes or obesity who may have a greater shift in the concentiation of 
the HDL subclasses.
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6.3.3 The relationship of prepHDL, aHDL, HDL2 and HDL3
Comparison o f HDL apoA-I FCR in different subclasses showed that prepHDL 
apoA-I FCR was highest (0.19±0.022 pools/day), followed by HDL2 apoA-I FCR 
(0.162±0.018 pools/day), aH D L apoA-I (0.152±0.017 pools/day) and HDL3 apoA-I 
(0.144±0.017 pools/day). aH D L contains both HDL2 and HDL3 , therefore it is 
unsuiprising that aHD L FCR was intermediate between HDL2 and HDL3 apoA-I 
FCR. Excluding aHDL, the apoA-I FCR comparison sequence was pre^HDL >
HDL2 > HDL3 . It is well loiown that the maturation progress of HDL is pre^HDL —>
HDL3 —) HDL2 . In the fasting state, FCR is equal to FSR. I f  HDL3 was the only 
precursor for HDL2 , HDL3 FSR would theoretically be expected to be greater or 
equal to HDL2 FSR. However, HDL2 FCR was found to be greater than HDL3 FCR.
This suggests that HDL2 may not only be foiined from HDL3 but also from 
prePHDL. This may be the first kinetic evidence which shows that lipid-poor 
prepHDL is able to incorporate with smaller HDL3 to form larger HDL2 particles. It 
is loiown that different HDL subclass particles may contain different numbers of 
apoA-I molecules. However, in this kinetic study, HDL subclasses were separated as 
individual groups, not as individual HDL particles, thus the difference in the number 
of apoA-I molecules between HDL subclasses would not affect the calculation of I
FCR.
It has been proposed that the formation of prePiHDL is the initial step of RCT and 
thus plays an important role in the HDL metabolic pathway. Some researchers have 
suggested that the HDL metabolic pathway follows the route: prep 1 HDL —> 
preP2HDL —>HDL3 —> HDL2 (Xu & Fu 2003; Asztalos et a l  2004). Conversely, an 
in vitro study indicated that prepiHDL was generated from TG-rich HDL2 with the
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action o f HL (Barrans et a l 1994; Guendouzi et a l 1999). One study also showed 
that treatment o f hypertriglyceridemic patients with fibrates increased prePiHDL and 
decreased HDL2 (M iida et a l 2000). The dramatic increase in HL by 24% after 
treatment with fibrates suggested that HDL2  was hydi'olysed by HL to form prePi. 
These studies suggested that prepiHDL was a remnant of HDL2  generated after 
hydrolysis o f HDL2 rather than nascent HDL. PrepiHDL may be remodelled and 
become a large HDL paiticle again.
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Figure 60 Possible model o f HDL metabolism
Figure 60 shows a possible model o f HDL Idnetics. Because of a short study time (9 
hours), compared to a slow turnover rate o f apoA-I, the kinetic data could not be 
used to develop a mathematical model.
151
Chapter 7 Conclusion
Over the last decade, more and more studies have indicated that lipoproteins 
including HDL in the plasma are more than lipid transporters and their 
concentiations, size and components are related to the fonnation and progression of 
cardiovascular disease. The stiucture, sequence and molecular properties of apoA-I 
have been well studied. This knowledge has allowed investigations of its functions, 
as well as the measurement of HDL kinetics. HDL are a group o f heterogeneous 
particles with different compositions and properties where different HDL subclasses 
may play different roles in the RCT pathway. It has been shown in patients with type 
2 diabetes, CHD, hyperlipidaemia and obesity that there is a shift from larger HDL2 
particles to smaller HDL3 and prepHDL particles resulting in the accumulation of 
smaller HDL particles (Asztalos et a l  2000; Xu & Fu 2003; Xu et a l 2001a). 
Researchers have started to investigate the function and metabolism of individual 
HDL subclasses. PrepHDL is an essential step of RCT and a study of its kinetics 
may help to identify why there is an increase in its concentration in pathological 
conditions such as type 2 diabetes and hypercholesterolemia (Miida et a l 1998),
In this project, the aim was to develop a method to deteiinine HDL subclass kinetics 
with stable isotope technology. A novel method was developed and optimised to 
detenuine prepHDL and aH D L kinetics with stable isotope techniques. This 
consisted of a dimensional agarose gel electiophoresis followed by a 2 "*^ 
dimensional SDS-PAGE. This technique was capable of separating prepHDL and 
aHDL providing less likelihood o f disturbing the integrity of particles. ApoA-I was 
labelled with ^^C-leucine and the isotopic enrichment was detenuined by GC-MS. 
This methodology showed that prepHDL and aHDL kinetics could be measured
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with this experimental procedme, HDL2 and HDL3 FCR were also measured and 
shown to be significantly different in a group of four healthy subjects. This is the 
first time that prepHDL and aH D L apoA-I kinetics have been measured with this 
technique.
7.1 Limitations of this project
However, there were a few limitations with this project.
1) The clinical study was designed as a 9 hour study with the administiation of a 
primed constant infusion of L -[l-’'C]-leucine. This was short compared to the 
relatively slow turnover rate of apoA-I (mean residence time is around 5 days). 
Consequently it caused technical difficulties in the development of a metabolic 
model to calculate inter-conversion rate between HDL subclasses.
2) The analysis procedure was time consuming. It took at least 5 weeks to analyze 
samples from a study in a single subject. The analysis protocol is complicated 
with multiple methodologies, and errors which can be generated at any step. 
Only the first two steps of electiophoresis and last step of GC-MS can generate 
visible results from gels and GC-MS peaks. Any errors made in all the other 
steps including SDS extinction, delipidation, hydrolysis, lEC, freeze diying and 
derivatisation will not be detectable. Thus the study needs to be cautiously 
designed to minimize en'ors and carried out by a skilled experimenter. This 
methodology can be improved by increasing sampling time points in the clinical 
protocol from eveiy 1 hour to eveiy half hour in the last 3 hours of the study. 
This will make the enrichment curve smoother and more reliable. With a 10 
sample protocol, the slope o f enrichment cuiwe will be highly affected by one 
missing point close to the end of the study. To overcome these problems, a new
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clinical protocol is required with a longer study time, an increase in stable 
isotope infusion time and an increase in the number of sampling points close to 
the end of the study.
3) It is technically difficult to determine the concentration o f apoA-I directly from 
prepHDL and aH D L separated by agarose electiophoresis and both gel scanning 
and using norleucine as an internal reference failed to estimate apoA-I 
concenti'ation accurately. However, a direct transfer of lipoproteins fr om agarose 
gel to nitrocellulose followed by immuno-detection may be able to determine 
apoA-I concentration.
4) Because albumin has the same migrating position as aH DL and the amount of 
albumin in plasma is high (the concenti'ation of albumin in a healthy subject is 
around 30 mg/ml, which is 15 to 20 times higher than apoA-I) there was always 
a large a-migrating band. When aH D L was excised from agarose gel, a large 
amount of albumin was included and was extracted together with aHDL. This 
meant that aH D L extraction required much more SDS solution than prepHDL 
for the extraction. In the second dimensional electrophoresis, the large amount of 
albumin could also spread between lanes on SDS-PAGE. Fortunately, owing to a 
large difference in molecular weights between albumin ( 6 6  kDa) and apoA-I 
(28.1 kDa), albumin did not affect the migrating profile of apoA-I.
7.2 Future studies:
7.2.1 New clinical protocols
Further studies are required to set up a new clinical protocol to develop a metabolic 
model to reveal the relationship between HDL subclasses. This requires a longer 
study time and stable isotope infusion time. The following is a proposed design of a
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clinical protocol for a 24 hour infusion study. This would require subjects to remain 
in a clinical research centre overnight (Figure 61).
Intravenous bolus 
ofi^C Leucine 
(Irag/kg)
Constant infusion o f *’C-Leucine (ling/kg/h) for 24 hours
Sample for a-KIC
-12 fasting 0 10 12 14 16 18 20 22 24 hours
Baseline sample
f t  t  t  t  t  t  I t  t  t  t  t  t  1 1  t  t  t  t  t  1 1  t
Blood sanq)ling time points for leucine enrichment
Study time plan
I
20:00 fasting 8:00 10:00 12:00 14:00 16:00 18:00 20:00 22:00 0:00 2:00 4:00 6:00 8:00 Time 
PM AM PM Meal AM Breakfast
Figure 61 Proposed clinical protocol for a 24 hour infusion study.
After fasting overnight for 12 hours, the subject would start a 24 hour study with a 
primed constant infusion o f L -[l-’^C]-leucine in the morning at 8:00 AM. Blood 
samples would be taken at baseline and every hour throughout the study and samples 
for a-KIC would be taken at 0, 1, 2, 4, 6 , 7, 8  and 9 hours. Subjects would be given a 
low fat meal during the study which would be then less likely to affect HDL kinetics 
as a low fat diet would minimize the secretion of chylomicrons with which apoA-I 
synthesized by intestine is secreted into the circulation (Velez-Carrasco et al. 1999). 
The subject would stay in the clinical research centre overnight. After the study, the 
subject would be given breakfast and sent home. Subjects would come back in the 
morning of the following 3 days with additional fasting blood samples taken at 48, 
72 and 96 hours.
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A bolus injection protocol can also be investigated. In this protocol subjects would 
be required to fast overnight and a bolus L-[l-'^C]-leucine 60 |u,mol/kg (7.93 mg/kg) 
would be administered at 8  am (Fisher et a l  1995). A similar study protocol was 
used by Fisher et al (1995) to measure HDL apoA-I kinetics using leucine as 
isotopic tracer. Blood samples would be taken hourly for 12 hours and the subject 
would come back in the morning of the following 4 days for additional fasting blood 
samples at 24, 48, 72 and 96 hours.
7.2.2 Improvement of aHDL separation resolution by removing albumin
Methods to remove albumin from plasma which do not affect prepHDL and aHDL 
integrity should be investigated. There are two steps during which albumin can be 
removed. One is before agarose gel electiophoresis and the other is after agarose gel 
electrophoresis. There are commercially available products that can remove albumin 
from plasma with an albumin antibody or by using size exclusion chromatography. 
However, using these methods, plasma samples needs to be diluted therefore 
prepHDL concenti’ation could be affected. Thus sample preparation may lead to lipid 
free apoA-I associating with each other and stabilising in the lipid-free foi*m 
resulting in ineversible dissociation of apoA-I from larger HDL particles in an 
aqueous environment (Vitello & Scanu 1976; Massey et a l 1981). Another option is 
to remove albumin after aHDL is extracted from the agarose gel with an albumin 
antibody or by using size exclusion chromatography. The exchange between aHDL 
and prePHDL can be avoided and contamination sources such as SDS and coomassie 
blue R250 are also removed together. As a consequence, a better separation of 
proteins would be achieved on SDS-PAGE. However, this would not help to 
improve the extraction of aHDL.
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7.2.3 A pplication of this technique
The heterogeneous characteristics of HDL make its metabolism complicated. The 
interconversions between HDL subclasses are not unidirectional but bidirectional or 
multidirectional. HDL are well Icnown to have an important role preventing 
atherosclerosis and HDL-C is inversely associated with CVD risk. Increasing the 
total level o f HDL is regarded as a potential therapeutic target to prevent CVD. 
However, the failed tiial of CETP inhibitor torcetiapib challenged the concept that a 
higher HDL-C would necessarily result in less heart disease risk (Moyad & Merrick
2007). Although, the mortality increase in the torcetiapib trial may have been 
because of the dm g’s effect to increase patient blood pressure, it also suggested the 
total level of HDL itself may not be the only essential factor in preventing CVD. A 
high concentration of HDL does not result in a high quality of cardiovascular 
protection. The biological functionality of the individual HDL subclasses may be the 
key determinant of their cardiovascular protective properties. Thus the study of lipid 
and protein metabolism in the HDL subclasses is important so as to identify their 
metabolic roles in preventing CVD.
The composition, stmcture and properties of individual HDL subclass particles are 
various and may underlie their different physiological functions. It is a big challenge 
to identify which are the deteiminants of HDL’s cardiovascular protective effect. 
Each individual HDL subclass is an important component in the HDL metabolic 
pathway and any impairment of any HDL subclass may result in a malfunction of the 
pathway. The impairaient in HDL metabolic pathway may be directly related to the 
fonnation and progression o f atherosclerosis. The process o f HDL maturity and 
remodelling is also regulated by cell membrane transporters A BCAl, membrane 
receptor SR-BI and plasma factors such as LCAT, PLTP, CETP, HL and LPL.
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Impairment and deficiency o f these enzymes and proteins may also lead to abnormal 
HDL biological activity and an increase in the incidence and prevalence of CVD and 
cause other diseases such as fish eye disease.
Combining the 2-DE methodology developed in this thesis and sequential 
ultracentiifugation, prepHDL, aH DL and HDL2 and HDL3 metabolism can be 
studied in vivo. This methodology can be used to analyze and compare the 
differences in HDL kinetics in patients with metabolic diseases and the healthy 
population and gain a greater understanding of HDL metabolism.
Evidence shows that HDL-C is inversely related to CVD risk. Thus a greater 
understanding of HDL metabolism could enable identification of potential therapies 
and the development of novel drugs. The methodology could be used to analyze and 
compare the kinetic differences between prepHDL, aHDL, HDL2  and HDL3 in 
patients before and after administiation of HDL-C raising drugs and before and after 
modification of lifestyle. Such studies would reveal the mechanisms by which drugs 
and lifestyle modification raise HDL-C.
158
Reference List
Acton SL, Scherer PE, Lodish HF & Krieger M 1994 Expression cloning of SR-BI, a CD36-related 
class B scavenger receptor. J  B iol.Chem . 269 21003-21009.
Aiello RJ, Brees D & Francone OL 2003 A BCAl-deficient mice: insights into the role of monocyte 
lipid efflux in HDL formation and inflammation. A rterioscler.Throm b.V asc.B iol. 23 972-980.
Ajees AA, Anantharamaiah GM, Mishi’a VK, Hussain MM & M mthy HM 2006 Crystal structure of 
human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases. 
Proc.N atl.Acad.ScLU .S.A  103 2126-2131.
Alam S, Stolinski M, Pentecost C, Boroujerdi MA, Jones RH, Sonksen PH  & Umpleby AM 2004 The 
effect o f a six-month exercise program on very low-density lipoprotein apolipoprotein B secretion in 
type 2 diabetes. J.C lin .E ndocnno l.M etab  89 688-694.
Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC & Schaefer EJ 2004 High- 
density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants 
of the Framingham Offspring Study. A rterioscler.Throm b.V asc.B io l 24 2181-2187.
Asztalos BF, de la Llera-Moya M, Dallai GE, Horvath KV, Schaefer EJ & Rothblat GH 2005 
Differential effects of HDL subpopulations on cellular A BC A l- and SR-BI-mediated cholesterol 
efflux. J  L ip id  Res. 46 2246-2253.
Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV & Schaefer EJ 2000 
Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. 
A rterioscler.T hrom b.V asc.B io l 202670-2676.
Asztalos BF & Schaefer EJ 2003 High-density lipoprotein subpopulations in pathologic conditions 
A m .J .C ard io l 91 12E-17E.
Asztalos BF, Sloop CH, W ong L & Roheim PS 1993 Two-dimensional electrophoresis o f plasma 
lipoproteins: recognition of new apo A-I-containing subpopulations Biochim .B iophys.Acta  1169 291- 
300.
Barrans A, Collet X, Barbaras R, Jaspard B, Manent J, Vieu C, Chap H & Perret B 1994 Hepatic 
lipase induces the formation of pre-beta 1 high density lipoprotein (HDL) from triacylglycerol-rich 
HDL2. A study comparing liver perfusion to in vitro incubation with lipases. J .B io lC hem . 269 
11572-11577.
Barter P  & Rye KA 2007 C ETP inhibition  - w here now ? A handbook fo r  clinicians.
Barter P  & Rye KA 2005 H igh density lipoprotein cholesterol: the new  target-a handbook fo r  
clinicians.
Barter PJ 2002 Hugh Sinclair lecture: the regulation and remodelling of HDL by plasma factors. 
A theroscler.Suppl 3 39-47.
Barter PJ, Nicholls S, Rye KA, Ananthar amaiah GM, Navab M & Fogelman AM 2004 
Antiinflammatory properties of HDL. Circ.Res. 95 764-772.
Barter PJ & Rye KA 1996 High density lipoproteins and coronary heart disease. A therosclerosis 121 
1- 12 .
Batista MC, Welty FK, Diffenderfer MR, Sarnak MJ, Schaefer EJ, Lamon-Fava S, Asztalos BF, 
Dolnikowski GG, Brousseau M E & M arsh JB 2004 Apolipoprotein A-I, B-lOO, and B-48 metabolism 
in subjects with chronic kidney disease, obesity, and the metabolic syndrome. M etabolism  53 1255- 
1261.
159
Beghin L, Duhal N, Poulain P, Hauw P, Lacroix B, Lecerf JM, Bonté JP, Fruchart JC & Luc G 2000 
Measurement o f apolipoprotein B concentration in plasma lipoproteins by combining selective 
precipitation and mass spectrometry, J  Lipid Res. 41 1172-1176.
Bekaert ED, Alaupovic P, Knight-Gibson C, Norum RA, Laux M J & yrault-Jarrier M 1992 Isolation 
and partial characterization of lipoprotein A-II (LP-A-II) particles of human plasma. 
Biochim.Biophys.Acta 1126 105-113.
Betteridge DJ 1999 Lipoproteins in Health and Disease. New York; Oxford University Press.
Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE & Selkoe DJ 1996 Amyloid beta- 
peptide is transported on lipoproteins and albumin in human plasma J.BiolChem . 271 32916-32922.
Blanche PJ, Gong EL, Forte TM  & Nichols AV 1981 Characterization o f human high-density 
lipoproteins by gradient gel electrophoresis Biochim.Biophys.Acta 665 408-419.
Blanco-Vaca F, Escola-Gil JC, Martin-Campos JM & Juive J 2001 Role of apo A-II in lipid 
metabolism and atherosclerosis; advances in the study o f an enigmatic protein. J.Lipid Res. 42 1727- 
1739.
Blue ML, Williams DL, Zucker S, Khan SA & Blum CB 1983 Apolipoprotein E synthesis in human 
kidney, adrenal gland, and liver. Proc.Natl.Acad.Scl U.S.A 80 283-287.
Bolanos-Garcia VM & Miguel RN 2003 On the structure and function of apolipoproteins: more than a 
family o f lipid-binding proteins. Prog.Biophys.Mol.Biol 83 47-68.
Brewer HB, Jr., Lux SE, Ronan R & John KM 1972 Amino acid sequence of human apoLp-GIn-II 
(apoA-II), an apolipoprotein isolated from the high-density lipoprotein complex. 
Proc.NatlAcad.ScLU.S.A  69 1304-1308.
Brown ML, Inazu A, Hesler CB, Agellon LB, Mann C, W hitlock ME, Marcel YL, Milne RW, 
Koizumi J, Mabuchi H & . 1989 Molecular basis o f lipid transfer protein deficiency in a family with 
increased high-density lipoproteins Nature 342 448-451.
Bu X, W arden CH, Xia YR, De MC, Puppione DL, Teruya S, Lokensgard B, Daneshmand S, Brown 
J, Gray RJ & . 1994 Linkage analysis o f the genetic determinants of high density lipoprotein 
concentrations and composition; evidence for involvement o f tlie apolipoprotein A-II and cholesteryl 
ester transfer protein loci. H um .G enel 93 639-648.
Burlingame AL & Carr SA 1996 Identifying unexpected protein modifications. In Mass Spectrometry 
in the Biological Sciences, pp 333-350. Humana Press.
Busch SJ, Barnhart RL, Martin GA, Fitzgerald MC, Yates MT, Mao SJ, Thomas CE & Jackson RL 
1994 Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic 
cholesterol in cholesterol-fed transgenic mic& J.BiolChem . 269 16376-16382.
Castro GR & Fielding CJ 1988 Early incorporation of cell-derived cholesterol into pre-beta-migrating 
high-density lipoprotein. Biochemistry 27 25-29.
Chapman MJ, Assmann G, Fruchart JC, Shepherd J & Sirtori C 2004 Raising high-density lipoprotein 
cholesterol with reduction of cardiovascular risk; the role o f nicotinic a c id -a  position paper 
developed by the European Consensus Panel on HDL-C Curr.Med.Res.Opin. 20 1253-1268.
Chau P, Nakamura Y, Fielding CJ & Fielding PE 2006 Mechanism of prebeta-HDL formation and 
activation. Biochemistiy 45 3981-3987.
Chetiveaux M, Lalanne F, Lambert G, Zair Y, Ouguerram K & K iem pf M  2006 Kinetics of prebeta 1 
HDL and alphaHDL in type II diabetic patients. Eur.J.Clin.Invest 36 29-34.
160
Chetiveaux M, Nazih H, Ferchaud-Roucher V, Lambert G, Zair Y, Masson M, Ouguerram K, 
Bouhours D & K iem pf M  2002 The differential apoA-I enrichment o f prebeta 1 and alphaHDL is 
detectable by gel filtration separation. J.Lipid Res. 43 1986-1993.
Chetiveaux M, Ouguerram K, Zair Y, Maugere P, Falconi I, Nazih H & K iem pf M  2004 New model 
for kinetic studies of HDL metabolism in humans. Eur.J.Clin.In.vest 34 262-267.
Cheung MC & Albers JJ 1984 Characterization o f lipoprotein particles isolated by immunoaffinity 
chromatography. Particles containing A-I and A-II and particles containing A-I but no A-II 
J.BiolChem . 259 12201-12209.
Cheung MC & Albers JJ 1979 Distribution of cholesterol and apolipoprotein A-I and A-II in human 
high density lipoprotein subfractions separated by CsCl equilibrium gradient centrifugation: evidence 
for HDL subpopulations with differing A-FA-II molar ratios J.Lipid Res. 20 200-207.
Cheung MC & Albers JJ 1982 Distribution of high density lipoprotein particles with different 
apoprotein composition: particles with A-I and A-II and particles with A-I but no A-II. J.Lipid Res. 23 
747-753.
Cheung MC & W olf AC 1988 Differential effect of ultr acentrifugation on apolipoprotein A-I- 
containing lipoprotein subpopulations. J Lipid Res. 29 15-25.
Christoffersen C, Jauhiainen M, Moser M, Porse B, Ehnholm C, Boesl M, Dahlback B & Nielsen LB 
2008 Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low 
density lipoprotein receptor knock-out mice. J.BiolChem . 283 1839-1847.
Christoffersen C, Nielsen LB, Axler O, Andersson A, Johnsen AH & Dahlback B 2006 Isolation and 
characterization of human apolipoprotein M-containing lipoproteins. J.Lipid Res. 47 1833-1843.
Cobelli C, Toffolo G & Foster DM 1992 Tracer-to-tracee ratio for analysis o f stable isotope tr acer 
data: link with radioactive kinetic formalism. Am .J Physiol 262 E968-E975.
Cohn JS, Tremblay M, Amiot M, Bouthillier D, Roy M, Genest J, Jr. & Davignon J 1996 Plasma 
concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic 
and hyperlipidémie subjects. Arterioscler.Thromb.Vasc.Biol 16 149-159.
Cuchel M & Rader DJ 2006 Macrophage reverse cholesterol transport: key to the regression of 
atherosclerosis? Circulation 113 2548-2555.
Demant T, Carlson LA, Holmquist L, Karpe F, Nilsson-Ehle P, Packard CJ & Shepherd J 1988 
Lipoprotein metabolism in hepatic lipase deficiency: studies on the turnover o f apolipoprotein B and 
on the effect o f hepatic lipase on high density lipoprotein J.Lipid Res. 29 1603-1611.
Duan J, Dahlback B & Villoutreix BO 2001 Proposed lipocalin fold for apolipoprotein M based on 
bioinformatics and site-directed mutagenesis FEBS L ett 499 127-132.
Dwyer KP, Barrett PH, Chan D, Foo JI, W atts GF & Croft KD 2002 Oxazolinone derivative of 
leucine for GC-MS: a sensitive and robust method for stable isotope kinetic studies of lipoproteins. 
J.Lipid Res. 43 344-349.
Eisenberg S 1984 High density lipoprotein metabolism. J.Lipid Res. 25 1017-1058.
Feingold KR, Shigenaga JK, Chui LG, M oser A, Khovidhunkit W  & Grunfeld C 2008 Infection and 
inflammation decrease apolipoprotein M  expression. Atherosclerosis 199 19-26.
Fielding CJ & Fielding PE 1995 Molecular physiology of reverse cholesterol transport J.Lipid Res. 36 
211-228,
161
Fisher WR, Venkatakrishnan V, Zech LA, Hall CM, K ilgore LL, Stacpoole PW , Diffenderfer MR, 
Friday KE, Sumner AE & Marsh JB 1995 Kinetic evidence for both a fast and a slow secretory 
pathway for apolipoprotein A-I in humans. J.Lipid Res. 36 1618-1628.
Ford GC, Cheng KN & Halliday D 1985 Analysis o f (l-13C)leucine and (13C)KIC in plasma by 
capillary gas chromatography/mass spectrometry in protein turnover studies Biomed.Mass Spectrom. 
12 432-436.
Frank PG & Marcel YL 2000 Apolipoprotein A-I; sti'ucture-function relationships. J.Lipid Res. 41 
853-872.
Frayn K 2003 Metabolic Regulation- a human perspetive. Blackwell.
Frenais R, Ouguerram K, Maugeais C, M ahot P, Maugere P, Krempf M  & Magot T  1997 High 
density lipoprotein apolipoprotein AI kinetics in NIDDM: a stable isotope study. Diabetologia  40 
578-583.
Garza, C. Interpretation of Advanced CVD Markers: LDL-C, ApoB, and LDL-S3GGE Subclasses. 
In ternet. 2009. Ref Type: Electronic Citation
Gorg A, W eiss W & Dunn MJ 2004 Current two-dimensional electrophoresis technology for 
proteomics. Proteomics. 4 3665-3685.
Grundy SM 1990 Cholesterol and Atherosclerosis: Diagnosis and Treatment. Mosby.
Guendouzi K, Jaspard B, Barbaras R, Motta C, Vieu C, Marcel Y, Chap H, Perret B & Collet X 1999 
Biochemical and physical properties o f remnant-HDL2 and of pre beta 1-HDL produced by hepatic 
lipase. Biochemistry 38 2762-2768.
Hagberg JM, Ferrell RE, Katzel LI, Dengel DR, Sorkin JD & Goldberg AP 1999 Apolipoprotein E 
genotype and exercise training-induced increases in plasma high-density lipoprotein (HDL)- and 
HDL2-cholesterol levels in overweight men. Metabolism  48 943-945.
Hirata K, Dichek HL, Cioffi JA, Choi SY, Leeper NJ, Quintana L, Kronmal GS, Cooper AD & 
Quertermous T  1999 Cloning of a unique lipase from endothelial cells extends the lipase gene family 
7 274 14170-14175.
Huang XS, Zhao SP, Hu M & Luo YP 2007 Apolipoprotein M likely extends its anti-atherogenesis 
via anti-inflammation Med.Hypotheses 69 136-140.
Huang Y, von EA, Wu S, M aeda N & Assmann G 1994 A plasma lipoprotein containing only 
apolipoprotein E and with gamma mobility on electrophoresis releases cholesterol from cells. 
Proc.Natl.Acad.Sci.U.S.A  91 1834-1838.
Hurt E, Bondjers G & Camejo G 1990 Interaction of LDL with human arterial proteoglycans 
stimulates its uptake by human monocyte-derived macrophages. J Lipid Res. 31 443-454.
Hurt-Camejo E, Camejo G, Rosengren B, Lopez F, Ahlstrom C, Fager G & Bondjers G 1992 Effect 
of arterial proteoglycans and glycosaminoglycans on low density lipoprotein oxidation and its uptake 
by human macrophages and arterial smooth muscle cells. Arterioscler.Thromb. 12 569-583.
Huuskonen J, Olkkonen VM, Jauhiainen M  & Ehnholm C 2001 The impact o f phospholipid transfer 
protein (PLTP) on HDL metabolism. Atherosclerosis 155 269-281.
Ikewaki K, Rader DJ, Schaefer JR, Fairwell T, Zech LA & Brewer HB, Jr. 1993 Evaluation of apoA-I 
kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods 
J.Lipid Res. 34 2207-2215.
162
Ishida BY, Frolich J & Fielding CJ 1987 Prebeta-m igrating high density lipoprotein: quantitation in 
normal and hyperlipidémie plasma by solid phase radioimmunoassay follow ing electrophoretic 
transfer. J.Lipid Res. 28 778-786.
Jauhiainen M, Metso J, Pahlman R, Blomqvist S, Van TA  & Ehnholm C 1993 Human plasma 
phospholipid transfer protein causes high density lipoprotein conversion J.BiolChem . 268 4032-4036.
Jaye M, Lynch KJ, Krawiec J, M archadier D, Maugeais C, Doan K, South V, Amin D, Perrone M & 
Rader DJ 1999 A novel endothelial-derived lipase that modulates HDL metabolism Nat.Genet. 21 
424-428.
Ji Y, Jian B, W ang N, Sun Y, Moya ML, Phillips MC, Rothblat GH, Swaney JB & Tall AR 1997 
Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J  
BiolChem . 27220982-20985.
Jin W, Millar JS, Broedl U, Glick JM  & Rader DJ 2003 Inhibition of endothelial lipase causes 
increased HDL cholesterol levels in vivo. J  Clin.Invest 111 357-362.
Karpe F  & Hamsten A 1994 Determination of apolipoproteins B-48 and B-lOO in triglyceride-rich 
lipoproteins by analytical SDS-PAGE. J  Lipid Res. 35 1311-1317.
Klerkx AH, El HK, van der Steeg WA, Boekholdt SM, Stroes ES, Kastelein JJ & Kuivenhoven JA 
2006 Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein 
cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis. 
Arterioscler.Thromb.Vasc.Biol 26 706-715.
Kontush A, Chantepie S & Chapman M J 2003 Small, dense HDL particles exert potent protection of 
atherogenic LDL against oxidative stress. Arterioscler.Thromb.Vasc.Biol 23 1881-1888.
Kontush A & Chapman M J 2006 Antiatherogenic small, dense H D L-guardian angel o f the arterial 
waWl Nat.Clin.PraclCardiovasc.Med. 3 144-153.
Koppaka V 2001 Structural studies of discoidal lipoprotein A-I. Cell Mol.Life S c l  58 885-893,
Kostner K 2002 Beyond LDL-Cholesterol: New treatments Raising HDL-CholesteroI or Enhancing 
REverse Choleserol Transport. J Kardiol 9(7-8) 238-331.
Krimbou L, Marc il M, Chiba H & Genest J, Jr. 2003 Structural and functional properties of human 
plasma high density-sized lipoprotein containing only apoE particles. J.Lipid Res. 44 884-892.
Kr imbou L, Tremblay M, Davignon J & Cohn JS 1997 Characterization of human plasma 
apolipoprotein E-containing lipoproteins in the high density lipoprotein size range: focus on pre­
beta 1-LpE, pre-beta2-LpE, and alpha-LpE. J.Lipid Res. 38 35-48.
Kumar MS, Carson M, Hussain MM & Murthy HM 2002 Structures o f apolipoprotein A-II and a 
lipid-surrogate complex provide insights into apolipoprotein-Upid interactions. Biochemistry 41 
11681-11691.
Kunitake ST & Kane JP 1982 Factors affecting the integrity of high density lipoproteins in tire 
ultracentrifuge. J  Lipid Res. 23 936-940.
Kunitake ST, La Sala KJ & Kane JP 1985 Apolipoprotein A-I-containing lipoproteins with pre-beta 
electrophoretic mobility. J.Lipid Res. 26 549-555.
Kurien BT & Scofield RH 2006 Western blotting. Methods 38 283-293.
Lewis GF & Rader DJ 2005 New insights into the regulation of HDL metabolism and reverse 
cholesterol tiansport. Circ.Res. 96 1221-1232.
163
Lusk LT, W alker LF, DuBien LH & Getz GS 1979 Isolation and partial characterization of high- 
density lipoprotein H D Ll from rat plasma by gradient centrifugation 
1. Biochem J. 183 83-90.
Mahley RW, Innerarity TL, Rail SC, Jr. & W eisgraber KH 1984 Plasma lipoproteins: apolipoprotein 
structure and function. J.Lipid Res. 25 1277-1294.
Marathe GK, Harrison KA, Roberts LJ, M onow  JD, Murphy RC, Tjoelker LW, Prescott SM, 
Zimmerman GA & McIntyre TM  2001 Identification of platelet-activating factor as the inflammatory 
lipid mediator in CC14-metabolizing rat liver. J Lipid Res. 42 587-596.
Marso PS & Stern MD 2003 Obesity. In Diabetes and cardiovascular disease, pp 199-218. Lippincott 
W illiams & Wilkins.
Massey JB, Gotto AM, Jr. & Pownall HJ 1981 Human plasma high density apolipoprotein A-I: effect 
of protein-protein interactions on the spontaneous formation of a lipid-protein recombinant. 
Biochem.Biophys.Res.Commun. 99 466-474.
Maugeais C, Uguerram K, Charbinnel B, Magot R, Maugere P & Krempf M 2001 Effect o f Low- 
Density Lipoprotein Apheresis on Kinetics o f Apolipoprotein B in Heterozygous Familial 
Hypercholesterolemia. The Journal o f  Clinical Endocrinology & Metabolism  8 6 .
Maugeais C, Tietge UJ, Broedl UC, Marchadier D, Cain W, McCoy MG, Lund-Katz S, Glick JM  & 
Rader DJ 2003 Dose-dependent acceleration of high-density lipoprotein catabolism by endothelial 
lipase. Circulation 108 2121-2126,
McCoy MG, Sun GS, Marchadier D, Maugeais C, Glick JM & Rader DJ 2002 Characterization of the 
lipolytic activity o f endothelial lipase J.Lipid Res. 43 921-929.
McIntyre N 1988 Familial LCAT deficiency and fish-eye disease J.Inherit.Metab Dis. 11 Suppl 1 
45-56.
M cLean J, W ion K, Drayna D, Fielding C & Lawn R 1986 Human lecithin-cholesterol acyltransferase 
gene: complete gene sequence and sites of expression Nucleic Acids Res. 14 9397-9406.
Meagher EA 2004 Addressing cardiovascular risk beyond low-density lipoprotein cholesterol: the 
high-density lipoprotein cholesterol story Curr.Cardiol.Rep. 6  457-463.
Mellon F  & Sandstrom B 1996 Stable Isotopes in Human Nutrition: Inorganic Nutrient Metabolism. 
Academic Press.
M iida T, Sakai K, Ozaki K, Nakamura Y, Yamaguchi T, Tsuda T, Kashiwa T, Murakami T, Inano K 
& Okada M  2000 Bezafibrate increases prebeta 1-HDL at the expense of HDL2b in 
hypertriglyceridemia. Arterioscler.Thromb.Vasc.Biol. 20 2428-2433.
Miida T, Yamaguchi T, Tsuda T  & Okada M  1998 High prebeta 1-HDL levels in 
hypercholesterolemia are maintained by probucol but reduced by a low-cholesterol diet 
Atherosclerosis 138 129-134.
Miyazaki O, Kobayashi J, Fukamachi I, Miida T, Bujo H & Saito Y 2000 A new sandwich enzyme 
immunoassay for measurement o f plasma pre-beta 1-HDL levels. J.Lipid Res. 41 2083-2088.
Moyad MA & Merrick GS 2007 Cholesterol, cholesterol-lowering agents/statins, and urologie 
disease; Part V I-T h e  recent rise and fall o f the HDL-boosting drug torceptrapib Urol.Nurs. 27 169- 
173.
Mukai, J, Yamaguchi N & M anabe T  2003 Two-dimensional separation of human plasma proteins 
using agarose gel isoelectric focusing followed by SDS capillary electrophoresis. Chromatography 24 
127-133.
164
Nanjee MN, Doran JE, Lerch PG & Miller ME 1999 Acute effects o f intravenous infusion of 
A poAl/phosphatidylchoiine discs on plasma lipoproteins in humans. Arterioscler.Thromb.Vasc.Biol. 
19 979-989.
Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW & P itas RE 1994 Differential effects 
of apolipoproteins E3 and E4 on neuronal growth in vitro 
19. Science 264 850-852.
Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, 
Hama S, Hough G, Kamranpour N, Berliner JA, Lusis AJ & Fogelman AM 2004 The oxidation 
hypothesis of atherogenesis: the role of oxidized phospholipids and HDL 
13. J.Lipid Res. 45 993-1007.
Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi 
W, W atson AD, Van Lenten BJ, Vora D & Fogelman AM 2001 HDL and the inflammatory response 
induced by LDL-derived oxidized phospholipids. Arterioscler.Thromb.Vasc.Biol. 21 481-488.
Nievelstein PF, Sixma JJ, Ottenhof-Rovers M, W ynne HJ, De Groot PG & Banga JD 1991 Platelet 
adhesion and aggregate formation in type I diabetes under flow conditions Diabetes 40 1410-1417.
Ooi EM, Watts GF, Farvid MS, Chan DC, Allen MC, Zilko SR & BaiTett PH 2006 High-density 
lipoprotein apolipoprotein A-I kinetics: comparison of radioactive and stable isotope studies. 
Eur.J.C lin.Invest36 626-632.
Panagotopulos SE, Horace EM, Maiorano JN  & Davidson WS 2001 Apolipoprotein A-I adopts a belt­
like orientation in reconstituted high density lipoproteins. J.BiolChem . 276 42965-42970.
Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A, Lewis SM & Najean Y 1995 
Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides 
o f the International Council for Standardization in Haematology. Br.J H aem atol 89 748-756.
Poison C, Sarkar P, Incledon B, Raguvaran V & Grant R 2003 Optimization of protein precipitation 
based upon effectiveness o f protein removal and ionization effect in liquid chromatography-tandem 
mass spectrometry J.Chromatogr.B Analyt.Technol.Biomed.Life S c l  785 263-275.
Porsch-Ozcurumez M, Westphal S & Luley C 2001 Measurement of low apolipoprotein 
concentrations by optimized immunoturbidimetric applications. Clin.Chem. 47 594-597.
Rao R, Albers JJ, W olfbauer G & Pownall HJ 1997 Molecular and macromolecular specificity of 
human plasma phospholipid transfer protein 
1. Biochemistry 36 3645-3653.
Rashid S, Patterson BW & Lewis GF 2006 Thematic review series: patient-oriented research. What 
have we learned about HDL metabolism from kinetics studies in humans? J.Lipid Res. 47 1631-1642.
Riddell DR, Graham A & Owen JS 1997 Apolipoprotein E  inhibits platelet aggregation through the 
L-arginine:nitric oxide pathway. Implications for vascular disease J.BiolChem . 272 89-95.
Rye KA & Barter PJ 2004 Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein 
A-I. Arterioscler.Thromb.Vasc.Biol 24 421-428.
Rye KA, Bright R, Psaltis M & Barter PJ 2006 Regulation of reconstituted high density lipoprotein 
structure and remodeling by apolipoprotein E. J.Lipid Res. 47 1025-1036.
Rye KA, Clay MA & Barter PJ 1999 Remodelling of high density lipoproteins by plasma factors. 
Atherosclerosis 145 227-238.
165
Sakai N, Yamashita S, Hirano K, Ishigam i M, Arai T, Kobayashi K, Funahashi T  & Matsuzawa Y 
1995 Decreased affinity o f low density lipoprotein (LDL) particles for LDL receptors in patients with 
cholesteryl ester transfer protein deficiency Eur.J,Clin.Invest 25 332-339.
Sambrook J, Fritsch EF & Maniatis T  1989 M olecular cloning : a laboratory manual. New York : 
Cold Spring Harbor Laboratory Press .
Schaefer JR, Rader DJ, Ikewaki K, Fairwell T, Zech LA, Kindt MR, Davignon J, Gregg RE & Brewer 
HB, Jr. 1992 In vivo metabolism o f apolipoprotein A-I in a patient with homozygous familial 
hypercholesterolemia. Arterioscler.Thromb. 12 843-848.
Segrest JP 1977 Amphipathic helixes and plasma lipoproteins; thermodynam ic and geometric 
considerations. Chem.Phys.Lipids 18 7-22.
Segrest JP, Jones MK, Klon AE, Sheldahl CJ, Hellinger M, De LH & Harvey SC 1999 A detailed 
molecular belt model for apolipoprotein A-I in discoidal high density lipoprotein. J.BiolChem . 274 
31755-31758.
Segrest JP, Li L, Anantharamaiah GM, Harvey SC, Liadaki KN & Zannis V 2000 Structure and 
function of apolipoprotein A-I and high-density lipoprotein. Curr.Opin.Lipidol 11 105-115.
Shah PK  & Chyu KY 2005 Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis 
management. Trends Cardiovasc.Med. 15 291-296.
Skupien J, Kepka G, Gorczynska-Kosiorz S, Gebska A, Klupa T, Wanic K, Nowak N, Borowiec M, 
Sieradzki J & Malecki MT 2007 Evaluation o f Apolipoprotein M  Serum Concentration as a 
Biomarker of HNF-1 alpha MODY. Rev.Diabet.Stud. 4 231-235.
Tailleux A, Duriez P, Fruchart JC & Clavey V 2002 Apolipoprotein A-II, HDL metabolism and 
atherosclerosis. Atherosclerosis 164 1-13.
Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E  & Rader DJ 1999 Regression of 
atherosclerosis induced by liver-directed gene transfer o f apolipoprotein A-I in mice. Circulation 100 
1816-1822.
Tosoh Bioscience LLC. Principles o f ion exchange chromatography. In tern e t. 2009. 10-12-0080.
R ef Type: Electr onic Citation
Toth PP 2005 Cardiology patient page. The "good cholesterol": high-density lipoprotein. Circulation 
lH e 8 9 -e 9 1 .
Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR & Holman RR 1998 Risk 
factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom 
Prospective Diabetes Study (UKPDS: 23). BM J 316 823-828.
Umpleby AM & Sonksen PH  1987 Measurement of the turnover o f substrates of carbohydrate and 
protein metabolism using radioactive isotopes. Baillieres Clin.EndocrinolM etab 1 773-796.
Valentin Fuster, R.W ayne Alexander, John Willis Hurst, Robert A.O'Rourke, Spencer B.King, Ira 
Nash & Eric N.Prystowsky 2004 Miscellaneous conditions and cardiovascular disease. In Hurst's the 
heart, edn 11, Eds Valentin Fuster & John Willis Hurst. McGraw-Hill Professional.
Van Lenten BJ, W agner AC, Nayak DP, Hama S, Navab M & Fogelman AM 2001 High-density 
lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation 103 
2283-2288.
Vance DE 1996 Biochemistiy o f  Lipids, : Lipoproteins and Membranes. New Comprehensive 
Biochemistry. Elsevier.
166
Velez-CaiTasco W, Lichtenstein AH, Barrett PH, Sun Z, Dolnikowski GG, W elty FK & Schaefer EJ 
1999 Human apolipoprotein A-I kinetics within triglyceride-rich lipoproteins and high density 
lipoproteins. J.Lipid Res. 40 1695-1700.
Vitello LB & Scanu AM 1976 Studies on human serum high density lipoproteins. Self-association of 
apolipoprotein A-I in aqueous solutions. J  BiolChem . 251 1131-1136.
Walsh BW, Li H  & Sacks FM  1994 Effects o f postmenopausal hormone replacement with oral and 
ti'ansdermal estrogen on high density lipoprotein metabolism. J  Lipid Res. 35 2083-2093.
Wang M & Briggs M R 2004 HDL: the metabolism, function, and therapeutic importance. Chem.Rev. 
104 119-137.
Wang N & Tall AR 2003 Regulation and mechanisms of ATP-binding cassette transporter A l- 
mediated cellular cholesterol efflux. Arterioscler.Thromb.Vasc.Biol 23 1178-1184.
Webb NR, de Beer MC, Asztalos BF, W hitaker N, van der Westhuyzen DR & de Beer FC 2004 
Remodeling of HDL remnants generated by scavenger receptor class B type I J.Lipid Res, 45 1666- 
1673.
Webb NR, de Beer MC, Yu J, Kindy MS, Daugherty A, van der W esthuyzen DR & de Beer FC 2002 
Overexpression of SR-BI by adenoviral vector promotes clearance of apoA-I, but not apoB, in human 
apoB transgenic mice. J.Lipid Res. 43 1421-1428.
Wolfrum C, Poy MN & Stoffel M 2005 Apolipoprotein M  is required for prebeta-HDL formation and 
cholesterol efflux to HDL and protects against atherosclerosis. Nat.Med. 11 418-422.
Xu N & Dahlback B 1999 A novel human apolipoprotein (apoM) J.B iol Chem. 274 31286-31290.
Xu Y, Fu M, Wu X & Ren Y 2001a Study on the content o f serum HDL subclasses in type 2 diabetic 
patients. Chinese Journal o f  Diabetes 9 160-162.
Xu Y & Fu M  2003 Alterations of HDL subclasses in hyperlipidemia. Clin. Chim. Acta  332 95-102.
Xu Y, Fu M, Xu Y & Liu B 2001b Study on the content of serum HDL subclasses in obese subjects. 
Hua X I Yi.Ke.Da.Xue.Xue.Bao. 32 509-512.
Yang Y, Yan B, Fu M, Xu Y & Tian Y 2005 Relationship between plasma lipid concentrations and 
HDL subclasses Clin.Chim.Acta 354 49-58.
Zannis VI, Chroni A & Krieger M 2006 Role of apoA-I, A BC A l, LCAT, and SR-BI in the biogenesis 
o f HDL. J.M olM ed. 84 276-294.
Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH & Rader DJ 2003 Overexpression of 
apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. 
Circulation 108 661-663.
167
Appendices
Appendix I: Preparation of solutions and experimental protocol
1. S epara tion  o f H D L by u ltracen trifuga tion
1,1 P rep ara tio n  of density solutions
1) Two solutions were required to prepare density solutions: Isotonic saline (1.006 g/ml), and 
saturated NaBr solution (1.51 g/ml). The density of saturated NaBr solution changed with 
temperature and needed to be checked every time before use.
2) The saturated NaBr solution density was checked with an accurate pipette (d=mass/volume), 
or using the specific gravity bottle to weight same volume o f water and saturated NaBr 
solution. The density of saturated NaBr equalled to the MNaBi/MH2 o (weight of NaBr/W eight 
of water)
3) All the other density solutions were prepared according to the formula:
Vd= Vi(dr d;)/(do-dp)
Vd= diluent’s volume added to Vi
Vi = initial volume
df = final density
d; = initial density
do = diluent’s density added to Vi
4) Densities of lipoproteins
VLDL (Very low density lipoprotein ): > 1.006 g/ml
IDL (Intermediate density lipoproteins): 1.006 g/ml < d < 1.019 g/ml
LDL (Low density lipoproteins): 1.019 g/ml < d < 1.063 g/ml
HDLz ( High density lipoprotein 2 ): 1.063 g/ml < d < 1.125 g/ml
HDLs (High density lipoprotein 2): 1.125 g/ml < d < 1 . 2 1 0 g/ml
HDL (high density lipoproteins); 1.063 g/ml < d < 1 . 2 1 0 g/ml
5) The following solution need to be prepared according to the formula in item 3).
1.006 g/ml isotonic saline solution used for VLDL separation
1.063 g/ml NaBr solution
1.125 g/ml NaBr solution
1.177 g/ml NaBr solution used for separation VLDL+IDL and LDL together
1.249 g/ml NaBr solution used for separation of HDL; from LDL
1.250 g/ml NaBr Solution
1.380 g/ml NaBr solution used for separation of HDL 3  from HDL%
1.504 g/ml NaBr solution used for separation HDL from LDL
Note: All solutions contained 0.1% NaiEDTA which was added at the end of preparation. 
Equipm ents used.
Beckman Coulter optima LE80-K ultracentrifuge (Beckman Instruments, Palo Alto, CA, USA) 
Centrifuge tube cutter (Beckman Instruments, Palo Alto, CA, USA)
Ultracenti'ifuge tubes and caps (Beckman Instruments, Palo Alto, CA, USA)
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2 ml m ini-volumetric flasks (Sigma-Aldrich Ltd, Gillingham, Dorset, UK)
4 ml mini-volumetric flasks (Sigma-Aldrich Ltd, Gillingham, Dorset, UK)
1.2 Surface M odification of ultraclear tubes using polyvinyl alcohol
1.2.1 Preparation of polyvinyl alcohol solution
1) Ten g polyvinyl alcohol was added into 250 ml H^O in a fume hood.
2) The mixture was heated (50 °C) and stirred with a heating block until the polyvinyl 
alcohol had dissolved.
3) Another 250 ml propan-2-ol was added into the hot solution and mixed well.
4) The solution was cooled down before use.
1.2.2 Coating the tubes
1) The ultracentrifuge tubes were filled with 2% polyvinyl alcohol solution.
2) The tubes were left upright for 25 minutes.
3) The polyvinyl solution was removed.
4) The tubes were filled with HgO and left upright overnight.
5) The H 2 O was removed and the tubes were washed with H 2 O twice.
6 ) The tubes were then placed upside down in a rack to dry.
1.3 Removed VLDL, IDL and LDL fraction at the same time
1) Tlnee ml plasma from each sample was put into labelled ultraclear ultracentrifugation 
tubes (U/C), which were precoated witli polyvinyl alcohol.
2) One point five (1.5) ml NaBr solution (1.177 g/ml) was added to samples to adjust the 
density to 1.063 g/ml with a total volume of 4.5 ml. In order to avoid the dent of U/C tube, 
200 p,l 1.063 g/ml solution was added to adjust volume to the upper line on the tube 
shoulder.
3) The U/C tubes were put into a black rack and caped. A black plastic cap sti ip was used to 
push the caps o f the U/C tubes down firmly. The samples were mixed well by inverting the 
tubes several times.
4) The tubes were carefully placed into a pre-chilled type 50.4 Ti rotor. The tubes were 
placed into appropriate slots so that the rotor was adequately balanced.
5) The yellow caps were pushed down onto the U/C tubes to hold them firmly in place using 
a small metal screw rod.
6 ) The samples were ultracenti ifuged at 37000 rpm (147425 x g) for at least 20 hours at 4°C.
7) After ultracentrifugation, approximately 1.2 ml VLDL, IDL and LDL was cut with a 
centrifuge tube cutter. VLDL, IDL and LDL were collected with 1ml plastic pipette, and 
the well o f cutter was washed with 1.006 g/ml saline containing 0 . 1  % Na2EDTA.
8 ) The final volume was made to be 2 ml using 2 ml mini-volumetric flask by adding 
1.006g/ml saline which contained 0.1% NagEDTA.
1.4 Separation of total HDL fraction
1) After cutting VLDL, IDL and LDL, the remainder of the sample in the bottom of the cut U/C
tube was transferred to a 4 ml volumetric flask. The tube was rinsed with 1.063 g/ml NaBr
solution and the washing solution was transfer to the volumetric flask. A final volume was
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made to be 4 ml by adding 1.063 g/ml NaBr solution. The solution was mixed well and thr ee 
ml was then transferred to a new U/C tube.
2) One point five ml NaBr solution (1.504 g/ml) was added to samples to adjust the density to
1.21 g/ml with a total volume of 4.5 ml. In order to avoid the dent o f U/C tube, 200p.l of 1.21 
g/ml solution was added to adjust volume to the upper line on the tube shoulder.
3) The U/C tubes were put into a black rack designed for U/C tubes and caped. A black plastic 
cap strip was used to push the caps of the U/C tubes down firmly. The samples were mixed 
well by inverting the tubes several times.
4) The tubes were carefully placed into a pre-chilled type 50.4 Ti rotor. The tubes were placed 
into appropriate slots so that the rotor was adequately balanced.
5) The yellow caps were pushed down onto the U/C tubes to hold them firmly in place using a 
small metal screw rod.
6 ) The samples were ultracentrifuged at 40000 rpm (172301 x g) for at least 24 hours at 4°C.
7) After ultracentrifugation, approximately 1.2 ml HDL were cut with a centrifuge tube cutter. 
HDL were collected with 1 ml plastic pipette, and the well o f cutter was washed with 1.006 
g/ml saline containing 0 . 1 % Na2 EDTA.
8 ) The final volume was made to be 2 ml by adding 1.006 g/ml saline which contained 0.1 % 
Na^EDTA. It was done with 2 ml mini-volumetric flask.
1.5 Separation of HDL; fraction
1) After cutting VLDL, IDL and LDL, the remainder of the sample in the bottom of the cut U/C
tube was transferred to a 4 ml volumetric flask. The tube was rinsed with 1.063 g/ml NaBr
solution and the washing solution was transfer to the volumetric flask. A final volume was 
made to be 4 ml by adding 1.063 g/ml NaBr solution. The solution was mixed well and three 
ml was then transferred to a new U/C tube.
2) One point five ml NaBr solution (1.249 g/ml) was added to samples to adjust the density to
1.125 g/ml with a total volume o f 4.5 ml. In order to avoid the dent o f U/C tube, 200|il of
1.125 g/ml solution was added to adjust volume to the upper line on the tube shoulder.
3) The U/C tubes were put into a black rack and caped. A black plastic cap strip was used to
push the caps of the U/C tubes down firmly. The samples were mixed well by inverting the
tubes several times.
4) The tubes were carefully placed into a pre-chilled type 50.4 Ti rotor. The tubes were placed 
into appropriate slots so that the rotor was adequately balanced.
5) The yellow caps were push down onto the U/C tubes to hold them firmly in place using the 
small metal screw rod.
6 ) The samples were ultracentrifuged at 40000 rpm (172301 x g) for at least 48 hours at 4°C.
7) After ultracentrifugation, approximately 1.2 ml HDLa fraction was cut with a centiifuge tube 
cutter. HDLz haction was collected with 1 ml plastic pipette, and the well o f cutter was 
washed with 1.006 g/ml saline containing 0.1% Na%EDTA.
8 ) The final volume was made to be 2 ml using 2 ml mini-volumetric flask by adding 1.006 
g/ml saline which contained 0.1% Na% EDTA.
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1.6 Separation of HDL3 fraction
1) After cutting HDL 2 , the remainder of the sample in the bottom of the cut U/C tube was 
transferred to a 4 ml volumetric flask. The tube was rinsed with 1.125 g/ml NaBr solution. A 
final volume was made to be 4 ml by adding 1.125 g/ml NaBr solution. The solution was 
mixed well and three ml was then transferred to a new U/C tube.
2) One point five ml NaBr solution (1.38 g/ml) was added to samples to adjust the density to
1.21 g/ml with a total volume of 4.5 ml. In order to avoid the dent of U/C tube, 200pl NaBr 
solution ( 1 . 2 1  g/ml) was added to adjust volume to the upper line on the tube shoulder.
3) The U/C tubes were put into a black rack and caped. A black plastic cap strip was used to 
push the caps o f the U/C tubes down firmly. The samples were mixed well by inverting the 
tubes several times,
4) The tubes were carefully placed into a pre-chilled type 50.4 Ti rotor. The tubes were placed 
into appropriate slots so that the rotor was adequately balanced.
5) The yellow caps were pushed down onto the U/C tubes to hold them firmly in place using 
the small metal screw rod.
6 ) The samples were ultracentrifuged at 40000 rpm (172301 x g) for at least 48 hours at 4°C.
7) After ultracentrifugation, approximately 1,2 ml HDL 3  fraction was cut with a centrifuge tube 
cutter. HDL 3  fraction was collected with 1 ml plastic pipette, and the well of cutter was 
washed with 1.006 g/ml saline containing 0 . 1 % Na2 EDTA.
8 ) The final volume was made to be 2 ml by adding 1.006 g/ml saline which contained 0.1% 
Na2 EDTA. It was done with 2 ml mini-volumetric flask.
2. Delipidation:
2.1 M ethanol and diethyl ether delipidation of HDL fraction separated by ultracentrifugation
1 ) Methanol and diethyl ether were precooled at 4 ”C for at least 30 minutes.
2) Four ml methanol was added into in a 10 ml round bottom glass tube.
3) Four hundred |ll HDL fraction was added to into methanol.
4) Four ml precooled diethyl ether was then added into the tubes and the samples were vortexed 
to ensure efficient delipidation.
5) The samples were centrifuged at 4000 rpm (3684 x g) for 30 minutes at 1°C and the solvent 
was gently poured off after centi ifugation.
6 ) Another 4 ml diethyl ether was added to the samples and vortexed.
7) The samples were centrifuged for 20 minutes under the same condition and the solvent was 
poured off gently after centrifugation.
8 ) The samples were left upside down at room temperature in a fume hood for 20 minutes.
9) The samples were then dissolved in 70 pi sample buffer (pH 6 .8 , see appendix 3.1.3) for 
SDS-PAGE.
10) The samples were stored at -20°C until use.
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2.2 E thano l p rec ip ita tion  an d  diethyl e th er delip idation  of (xHDL and  p repH D L  sep ara ted  by 2- 
DE
I ) Methanol and diethyl ether were precooled on ice.
2) Four ml ice cold ethanol was added to the tubes containing the HDL apolipoproteins extracted 
from agarose gel and the samples were mixed well.
3) The tubes were kept on ice for 1 hour.
4) The tubes were centrifuged at 4500 rpm (4662 x g) for 60 minutes at 1 °C. The blue supernatant, 
which contained almost all the coomassie blue, was gently decanted.
5) Four ml ice cold diethyl ether was added to each tube and they were centrifuged under the 
same conditions as described above. The clear supernatant was decanted gently without 
disturbing the precipitates.
6 ) The tubes were left to dry at room temperature in a fume hood for 20 minutes and 70 fxl sample 
buffer (pH 6 . 8  see appendix 3.1.3) for SDS-PAGE was added to dissolve the proteins.
7) Samples were stored at -20®C until use.
3. SDS-PAGE:
3.1 B uffer P re p a ra tio n
3.1.1 P re p a ra tio n  of sam ple bu ffe r fo r SDS-PA G E ( pH  6 .8 )
sodium phosphate 4.26 g 0.15M
glycerol 12.5 ml 12.50%
SDS 2 . 0  g 2 %
P-mercaptoethanol 5 ml 5%
bromophenol blue 0 . 0 0 1  g 0 .0 0 1 %
H 2 O 75 ml
Total 1 0 0  ml
The pH was adjusted by 12 M HCl. The buffer was stored at 4°C.
3.1.2 P re p a ra tio n  of bu ffe r A (pH  8 .8 )
SDS 2 . 0  g 0 .2 %
Tris base 90.855 g 0.75 M
H 2 O 800 ml
Total 1 0 0 0  ml
The pH was adjusted by 5 M  NaOH. The volume was adjusted to 1000 ml with nanopure H 2 O 
and stored at 4°C.
3.1.3 P re p a ra tio n  of bu ffer B (pH  6 .8 )
SDS 2.0 g 0.2%
Tris base 30.285g 0.25 M
H 2 O__________________________________ 900 ml______________________________
Total 1000 ml
The pH was adjusted by 12 M  HCl. The volume was adjusted to 1000 ml with nanopure H 2 O 
and stored at 4°C.
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3.1.4 Preparation of 10%SDS
SDS
H 2 O
1 0 . 0  g
90 ml
1 0 %
Total 1 0 0  ml
3.1.5 P re p a ra tio n  of 10% A m m onium  P ersu lphate  (APS)
APS
H 2 O
1 0 0  mg 
I ml
1 0 %
Total 1 ml
APS solution must be prepared daily and stored at 4°C to prevent 
3.1.6 P re p a ra tio n  of (5x) runn ing  buffer fo r SD S-PA G E
decomposition.
Glycine 
Tris base 
SDS(10%) 
H 2 O
94 g 
15.1 g 
50 ml 
800 mi
1.25 M 
0.125M 
0.5%
Total 1 0 0 0  ml
The volume was adjusted to IL. The buffer was stored at 4°C and diluted before use.
3.2 Resolving gel and  stacking gels p re p a re  form ula
Chemicals Resolving gel (10%) Stacking Gel (4%)
40% Acrylamide (ml)
Buffer A (ml)
Buffer B (ml) 
dd H 2 O (ml)
Ammonium persulphate (pi) 
TEM ED(pl)
Total (ml)
1 0  (2 x— 2 0 ) 
20.2 (2 x -^ 0 .4 )
1 0  (2 x -  2 0 )
200 pi (2 x -  400) 
1 1 2 (2 x -  224) 
40.5 (2X -91)
1.05 (2x—-2.1)
5.0 (2 x -  10)
3.9 (2 x -  7.8)
50 pi (2x— 100) 
2 0  (2x—40)
1 0  (2 x -  2 0 )
Table A1 C hem icals used fo r the gel p rep a ra tio n
The quoted amount was for making one gel and 2 x was for two gel.
3.3 Gel casting procedure
1) The glass plates were soaked in 3 M  HCL for 5 minutes and rinsed thoroughly in nanopure 
HjO before use.
2) The glass plates and the separators were cleaned with ethanol. The plates and separators were 
set up correctly. To avoid gel leaking, an airtight seal between the bottom of the plates and the 
cassette was essential and this could be achieved by wrapping round the plate bottom using 
double laryer parafilm.
3) The resolving gel was prepared by adding the components in the order of Table A l. 
Ammonium persulphate decomposes quickly and must be prepared within 1 hour of use. 
TEM ED was added immediately before use.
4) The gel solution was transferred into the space between the glass plates using a 10 ml syringe 
and up to 5cm below the upper edge.
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5) A thin layer o f isoamyl alcohol was loaded as an overlay. Gel was allows to stand for 15-20 
minutes and then poui- isoamyl alcohol off. Sample buffer was used to wash the top of gel and 
filter paper was used to remove tlie excess isoamyl alcohol.
6 ) Stacking gel was then prepared according to the order of reagents in Table A l. The stacking 
gel was poured on the remaining space using a syringe and the comb was gently inserted into 
the stacking gel to avoid any bubble. Bubbles could be removed by shaking the comb gently. 
The gel was allowed to set for 20-30 minutes.
7) Gel was set up at room temperature. It could be stored at 4°C until required up to 24 hours.
8 ) Protein samples in sample buffer (pH 6 .8 ) were heated for 5 minutes at 110°C and then cooled 
down immediately on ice. The samples were then centrifuged at 2500 rpm (1439 x g) for 30 
seconds to make condensed H^O down to the vial bottom.
9) W hen the samples were ready, the gel was installed to the electrode firmly. Running buffer ( 1 
X diluted from 3.1.6 ) was used to wash grave formed between two sets o f gels before use.
10) The comb was gently taken out and a pipette was used to blow each well to push any bubble 
out o f it.
11) One litre (I L) running buffer (1 x) was added to the electrode space and 3 cm the bottom of 
gel was soaked in running buffer.
12) Standard proteins (20 |0,1) with known molecular weight were loaded into the gel as markers.
13) Fifty |xl (depends on the concentration) sample was loaded into every other well.
14) Forty |0.1 sample buffer was loaded into the wells between those loaded with samples.
15) The gel was run at 80v for 16 hours.
4. A garose electrophoresis
4.1 P re p ara tio n  of buffer
4.1.1 P re p a ra tio n  of T ris-T ric ine B uffer (25mM , pH  8 .6 )
Tris base 3.03g 25 mM
Tricine 4.48 g 25mM
Calcium lactate 0.925g 3 mM
H 2 O 800 ml
Total 1 0 0 0  ml
The pH was adjusted using 5M  NaOH and volume was adjusted with nanopure H 2 O to 1000 ml
4.1.2 P re p a ra tio n  of T ris-tric ine  bu ffe r Sx (125mM , pH  8 .6 )
Tris base 15.15g 125mM
Tricine 22.4 g 125mM
Calcium lactate 4.65g 15 mM
H 2 O 800 ml
Total 1000 ml
The pH was adjusted using 5M NaOH and volume was adjusted with nanopure H 2 O to 1000 ml
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4.1.3 Preparation of 5x Tris-tricine sample buffer (125mM, pH 8.6)
Tris -Tricine buffer (5x) 50 ml
Glycerol 50 ml 50%
Bromophenol blue_____________________ 0.005 ml_______________0.005%______
Total 100 ml
4.1.4 Preparation of coomassie blue staining solution
Coomassie blue 1.25 g 0.125%
ethanol 500 ml 50%
Acetic acid 100 ml 10%
H^O___________________________________ 300 ml_____________________________
Total 1000 ml
The staining solution was filtered with No. 5 whatman filter paper to remove the undissolved 
sediment.
4.1.5 Preparation of Sudan Black B staining solution 1
Sudan Black B 0.2 mg 1 %
Ethanol 16 ml
Glycerol 4 ml
Total 20 ml
4.1.6 Preparation o f Sudan Black B staining solution 2
Sudan Black B 0.2 mg 1%
Ethylene glycol 20 ml
Total 20 ml
After Sudan black B was dissolved, the staining solution was filtered with whatman No.5 filter 
paper to remove the undissolved sediment.
4.2 Agarose electrophoresis procedure
1) Agarose gel (0.6%) was prepared with tris-tricine buffer using microwave
2) When the gel temperature was around 60°C, the gel was cast into a flat-bed gel cassette
3) Plasma (180 |il) was diluted with 5x tris-tricine sample buffer (4:1 v:v) to 225 |il and 200 \i\ 
samples (equal to 160 |xl plasma) was loaded into agarose gel
4) The gel was run at 170 V for 3 hours. The heat produced during electrophoresis was 
removed by using recirculating water.
5) Agarose gel was stained with 0.125% coomassie blue R250
4.3 PrepHDL and (xHDL extraction procedure
1) Three ml 1% SDS solution was used to incubate witli the freeze-dried gel for 2 hours at room 
temperature.
2) The supernatant was transferred with class pipette to a 10 ml round bottom class tube
3) Extraction was repeated by washing the gel with 3 ml 0.2% SDS twice for prePHDL three 
times for ocHDL.
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4) All the SDS extractions were put together in glasses vials and frozen at -20°C overnight. 
Samples were dried in a freeze dryer and stored at -20°C in freezer.
4.4 Sudan Black B prestained plasma separation on agarose gel
1) One ml plasma was diluted with Sudan Black B staining solution 1 or 2 by 5:1 (v:v) in a 1.5 
ml plastic vial and incubated at 37°C for 2 hours in an oven
2) The prestained plasma was centrifuged at 4000 rpm (2700 x g) for 5 minutes with a bench 
top centrifuge
3) The supernatant was transferred to a new 1.5 ml plastic vial
4) Fifty |il sample was loaded onto agarose gel.
5, W estern blotting:
5.1 Buffer Preparation
5.1.1 Preparation of Transfer buffer (pH 8.3)
Glycine 8.7 g 0.29%
Tris base 17.4 g 0.58%
SDS 1 . 1 1  ml 0.037%
Methanol 600 ml 2 0 %
H 2 O 2300 ml
Total 3000 ml
The pH was adjusted witli 5 M  NaOH and the volume was adjusted to 3L with nanopure H 2 O
5.1.2 Preparation of blocking buffer (pH 7.5)
Dried non-fat milk 25 g 5%
Tris base 0.605 g 10 mM
NaCl 2.922 g 0.05 M
Tween 20 2.5 ml 0.5%
H 2 O 400 ml
Total 500 ml
The pH was adjusted with 12 M  HCl and the volume was adjusted to 500 ml with nanopure 
H 2 O. The buffer was stored at 4°C
5.1.3 Preparation of PBST (PBS containing 0.05% Tween 20) (pH 7.4)
PBS (phosphate buffered saline) 1 Pack sigma
Tween 20 0.05%
H 2 O 990
Total 100 ml
The volume was adjusted to 500 ml with nanopme H 2 O. The buffer was stored at 4°C
5.1.4 AP (alkaline phosphatase) staining solution kit
AP color development buffer (25x) 2 ml
AP color reagent A 1 ml 2%
AP color reagent B 1 ml 2%
H 2 O 46 ml
Total 50 ml
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5.2 Electrophoretic transfer procedure
1) Two rectangular pieces of filter paper and one piece of 0.2 jtm nitrocellulose membrane were 
prepared at the same size with the SDS-PAG.
2) The membrane and filter paper were soaked together with the fibre pads in transfer buffer for 
1 0  minutes.
3) SDS-PAG was immersed in transfer buffer immediately after electrophoresis and removing 
the glass plates.
4) A piece of filter paper was first put on a fibre pad.
5) The gel was then gently placed onto that filter paper.
6) The wet nitrocellulose membrane was overlaid onto the gel and then was covered another 
piece of filter paper
7) A glass pipette was used to roll on the filter paper to get rid of air bubbles trapped between 
the layers.
8 ) Another fibre pad was put on top to complete the sandwich. The glass pipette was used to 
roll over on the fibre pad again
9) The sandwich was placed into a plastic sandwiching cassette which was fit into the mini­
transfer-blotting cell. The gel should be on negative polarity and the membrane on the
positive polarity.
10) The electrophoretic transfer was run at 30v for 24 hours at room tem perature..
Note: W estern blotting is a sensitive detection method and it is necessary to use a clean equipment 
and wear gloves throughout the procedure to avoid any contamination,
5.3 linm unolocalization procedure
1) After electrophoretic transfer, the membrane was taken out o f the sandwich and put into a 
clear plastic bag containing 100 ml of blocking buffer (see appendix 5.1.2), shaken for 1 
hour at room temperature.
2) The membrane was then transferred to a new plastic bag and washed with 100 ml PBST 
solution for 1 0  minutes tluee times to remove excess milk protein.
3) The membrane was incubated with a primary antibody (Goat anti-human apoA-I antibody 
Autogen Bioclear, Wiltshire, UK)) in 100 ml blocking buffer for 1 hour at room temperature.
4) The membrane was washed with 100 ml PBST solution for 10 minutes three times to remove 
excess primary antibody.
5) The membrane was incubated with a secondary antibody (Donkey polyclonal to goat IgG 
H&L, Autogen Bioclear, Caine, W iltshire, UK) in 100 ml blocking buffer for 1 hour at room 
temperature.
6 ) The membrane was washed with 100 ml PBST solution for 10 minutes three times to remove 
excess secondary antibody
7) The membrane was stained with 50 ml AP (alkaline phosphatise) staining reagent for 1 
minute. ApoA-I bands should appear after 30 to 90 seconds.
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8 ) The staining reaction was terminated by adding nanopure HgO.
6. Hydrolysis
6.1 Preparation o f 6M HCI solutions
HCl (12 M) 500 ml 6 M
H 2 O__________________________________ 450 ml_____________________________
Total 1000 ml
The total volume was adjusted to 1000 ml with nanopure H 2 O.
Note: 37% HCl (Fisher) D= 1.18 g/ml, Molecular weight=36.46 
Concentration o f HCl: 37% x 1000 x 1.18/36.46=12 M
6.2 Hydrolysis procedure
1) ApoA-1 bands excised from SDS-PAG were put into an oven proof glass tube.
2) One ml 6 M HCl was added into each tube. The tubes were capped firmly and vortexed.
3) The tubes were heated at 120°C for 24 hours.
4) Five ml nanopm-e H 2 O was added to the protein hydrosylate solution and vortexed. The protein 
hydrosylate solution was then transferred into a prewashed cation exchange chromatography 
column (see Appendix 7).
5) Another 4  ml nanopure H 2 O were then added into the hydrolysis tubes and vortexed. The 
washing solutions were transferred to the lEC columns.
7. Ion exchange chromatography (lEC)
7.1 Preparation o f solutions
7.1.1 Preparation of 4M HCI
HCl (12M) 333.3 ml 4 M
H 2 O 600 ml
Total 1000 ml
The total volume was adjusted to 1000 ml with nanopure H 2 O.
7.1.2 Preparation of 4M NH4OH
NH 3  (18M) 222.2 ml 4 M
H 2 O 650 ml
Total 1000 ml
The total volume was adjusted to 1000 ml with nanopure H 2 O .
Note: 35% NH 3  (Fisher) D= 0.88g/ml. M olecular weight= 17.03 
Concentration of NH 4 OH: 35% x 1000 x 0.88/17.03=18 M
7.2 Cation exchange chromatography procedure
1) Resin (50W-X8) was weighted and washed with 200 ml nanopure H 2 O for five times,
2) The resin was filled into tlie column (1 g/column).
3) The column was washed with 5 ml 4 M  NH 4 OH for four times.
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4) The column was washed with nanopure 5 ml HgO for four times.
5) The column was washed with 5 ml 4 M  HCl for four times.
6 ) The column was washed with 5 ml nanopure H^O for four times.
7) Te apolipoprotein hydrolysates samples were eluted through the columns.
8 ) The column was washed with nanopure H 2 O till pH was around 6.5.
9) The amino acid was washed out with 3 ml 4 M NH 4 OH.
10) The samples were collected with 2 dram vials.
11) The samples were frozen at -20 °C over night and freeze dried.
8. Derivatisation :
1) The freeze dried samples were mixed with lOOpl trifluoroacetic acid (TFA)/ trifluoroacetic 
anhydride (TFAA) (1:1, v;v) mixture.
2) The mixture was heated at 110°C for 5 minutes.
3) Five hundred pi benzene and 1 ml nanopure H^O were added to samples and vortexed.
4) The samples was briefly centrifuged (2500 rpm = 1439 x g) for 10 minutes to separate into two
phases. The toluene layer was removed with a glass pipette and transferred into GC vial for 
GC-MS analysis.
9. GC-MS set up (Agilent Technologies 6890N GC System, 5973 M ass Selective Detector)
9.1 GC oven conditions:
Initial temperature: 50°C for 1 minute
Ramp: 11°C /minute to 110°C, 30°C /minute to 280°C
Run time: 12.12 minutes
9.2 Inlet
1:5 Split injection 
Initial temperature: 250°C 
Pressure: 4.06 psi 
Split flow: 3.4 ml/minute 
Gas flow: 40
9.3 M S Conditions
MS in the negative chemical ionization (NCI) mode 
Selected Ion M ode (SIM)
Ions: 209.0 (m) and 210 (m+1)
Solvent delay: 5.0 minutes 
MS Quad: 150°C.
MS source: 200°C
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Appendix II: Individual HDL subclass kinetic data from subjects in chapter 6 
1. The isotopic enrichment of leucine in apoA-I from pre|3HDL and aH D L
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Figure A l The isotopic enrichment o f leucine in apoA-1 from prePHDL and aH D L from subject 
APE: Atom percent excess. Pink diamond (♦ ) aH D L; Blue squire(«): prepHDL
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Figure A2 The isotopic enrichment o f leucine in apoA-I from prePHDL and aH D L from subject 2 
APE: Atom percent excess. Pink diamond (♦ ) aH D L; Blue squire(a): prePHDL
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Figure A3 The isotopic enrichment o f leucine in apoA-I from prePHDL and aH D L from subject 3 
APE: Atom percent excess. Pink diamond (♦) aH D L; Blue squire(m): prePHDL
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Figure A4 The isotopic enrichment o f leucine in apoA-I from prePHDL and aH D L from subject 4 
APE: Atom percent excess. Pink diamond (♦): aH D L; Blue squire(m): prePHDL
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2. The isotopic enrichm ent o f leucine in apoA-1 from  H D L; and H D L 3  
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Figure A5 The isotopic enrichment o f leucine in apoA-I from HDL] and HDL 3 from subject 1 
Green triangle (A ); HDL]; light blue cross (%): HDL3; APE: atom percent excess.
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Figure A 6  The isotopic enrichment o f leucine in apoA-I from HDL] and HDL3 from subject 2 
Green triangle (A ): HDL]; light blue cross (%): HDL3; APE: atom percent excess.
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Figure A7 The isotopic enrichment o f leucine in apoA-I from HDLz and HDL 3 from subject 3 
Green triangle (A ): HDL 2 ; light blue cross (%): HDL 3 ; APE: atom percent excess.
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Figure A 8  The isotopic enrichment o f leucine in apoA-I from HDL2  and HDL 3 from subject 4 
Green triangle (A ): HDL 2 ; light blue cross (x): HDL 3 ; APE: atom percent excess.
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